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ABSTRACT
Thymidine phosphorylase (TP) is identical to platelet-derived endothelial cell growth 
factor (PD-ECGF) and was originally isolated from platelets as the sole moiety with 
endothelial cell mitogenic activity. TP activity is increased in a number of tumour types 
compared with adjacent normal tissues including colon, stomach and breast cancer. TP 
has a role in tumour angiogenesis and increased activity in tumours confers a more 
aggressive tumour phenotype. TP also has a role in the activation of the 
fluoropyrimidine 5-fluorouracil (5-FU) to 5-fluorodeoxyuridine (5FdUrd). Intratumoural 
expression of TP is heterogeneous and may explain why only a proportion of patients 
respond to therapy with 5-FU. Modulation of 5-FU with interferon-a (IFN-a) increases 
the cytotoxicity of 5-FU in colon cancer cell lines. This is thought to occur through an 
increase in the activity of TP leading to greater formation of 5’-fluorodeoxyuridine 
monophosphate (FdUMP) and increased inhibition of thymidylate synthase (TS). HT-29 
colon adenocarcinoma cell lines were transfected with TP cDNA and a novel TP activity 
assay demonstrated a 5-fold increase in TP activity in HT-29(TP) cells compared with 
the parental cells and the vector alone transfected controls, HT-29(V). 5-FU cytotoxicity 
was increased 1.6-fold in HT-29(TP) cells compared with HT-29(V) cells (pcO.OOl, 
Students’ t-test). There was no significant difference in cytotoxicity between HT-29(TP) 
and HT-29 parental cells (p>0.1, Students’ t-test). Transfection alone without TP cDNA 
increased the resistance of HT-29 cells to 5-FU. The apparent increase in 5-FU 
cytotoxicity in HT-29(TP) cells was not enhanced by Leucovorin (LCV) or 
Deoxyinosine and cytotoxicity was not significantly reversed by exogenous thymidine, 
although a small increase in 5-FU IC50 was observed in the controls. Inhibition of TS by 
FdUMP was observed in these cells; .however it does not appear to be the critical 
mechanism of action of 5-FU. The data from this thesis suggest that an increase in the
activity of TP alone (5-fold) is not sufficient to significantly increase 5-FU cytotoxicity. 
Confirmation was obtained when TP activity and 5-FU cytotoxicity were measured in a 
number of cell lines from several tumour types. TP activity alone did not determine the 
sensitivity of the cell lines to 5-FU. Despite disappointing results with respect to 5-FU, a 
greater and more significant effect may be observed with 5-FU pro-drugs such as 5- 
dFUrd and Tegafur, which require activation by TP. The application of TP as a 
candidate gene for gene-directed/fluoropyrimidine pro-drug therapy is therefore 
promising as a means of improving the current lack of effective treatment for colon 
cancer and requires further investigation.
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CHAPTER 1
1. Introduction
1.1 Recent Cancer Statistics
Over recent years there have been reductions in mortality from some cancers 
including Hodgkins's disease, Burkitt's lymphoma and testicular cancer. The American 
Cancer Society reports that since 1960 the death rate from cancer in children has 
decreased 62 percent (Rennie and Rusting, 1996). The three leading causes of cancer 
death are lung, breast and colorectal cancers and mortality from these cancers has started 
to decrease. Lung cancer mortality rates decreased by 3% between 1990 and 1992, partly 
due to a decrease in smoking. This disease is largely preventable. Mortality rates in 
women with breast cancer decreased by 5% between 1989 and 1993, stemming from 
improvements in treatment available as well as early detection. Finally, death from 
colorectal cancer fell by 17% between 1973 and 1992 again influenced by early 
detection. Colon cancer is however relatively resistant to treatment with systemic 
chemotherapy. The fluoropyrimidine 5-fluorouracil (5-FU) is the mainstay of treatment 
and improvement of the efficacy of this agent is an ongoing concern.
1.2 Colon cancer
Cancer of the colon is thought to develop through the acquisition of a sequence 
of genetic mutations (Boland, 1993). The primary carcinogens responsible for these 
mutations are not known. There are many carcinogens present in food and mutagenic 
compounds have been identified in the stool. These compounds are however, found not 
only in patients with colon cancer but also in control subjects.
Carcinogenesis of the colon can be divided into a series of pathological stages. 
In the normal colon, proliferation occurs in the lower two thirds of the colonic crypt.
Cells migrate up the crypt and upon arrival at the luminal surface they differentiate in 
order to function. At a later stage apoptosis occurs and the cells are sloughed into the 
lumen. A balance is therefore present between the generation of new cells, migration up 
the crypt and the subsequent loss of differentiated cells. Cells at the base of the colonic 
crypt are protected from damage from environmental carcinogens. The differentiated 
cells, however, are exposed to these carcinogens and it is vital that programmed cell 
death occurs in these cells in order that damage may not be replicated.
The initial stage of carcinogenesis occurs when there is a shift in the zone of 
proliferation to the upper third of the colonic crypt. This results in a failure of the 
proliferating epithelial cells to differentiate and then apoptose. Cells accumulate and 
form an adenomatous polyp which constitutes the second stage of neoplastic 
development. Interestingly, cells in the first two stages of neoplasia have the ability to 
spontaneously regress. They are benign since they do not have the ability to invade or 
metastasise. They can, however, grow and develop higher grades of epithelial dysplasia. 
Mutations in the Ki-ras proto-oncogene may play a role in this development although 
not all colorectal neoplasms show this lesion (Vogelstein, 1988). It is hypothesised that 
the tumour becomes malignant, as a result of the accumulation of mutations and other 
genetic instabilities which do not allow cell death to occur. Instead the cell continues to 
proliferate thus creating greater genetic instability, such as chromosome deletions, 
duplications and rearrangements. In particular, in 75% of colon tumours one copy of the 
gene for p53 (on chromosome 17p) has been lost and in most cases the remaining allele 
is mutated (Vogelstein, 1989). If the function of the p53 gene is lost, there is no cell 
cycle arrest in which repair of DNA damage can occur and less programmed cell death, 
leading ultimately to greater loss of heterozygosity and genetic instability. When the 
normal copy of p53 is restored, the cells lose their tumourigenic properties (Baker,
1990).
2
A deletion on chromosome 18q has also been demonstrated in 80% of colorectal 
tumours resulting in the loss of another tumour suppressor gene (Fearon, 1990). The 
resultant loss of heterozygosity is reported only in malignant lesions and is thought to be 
of importance in the progression from a benign lesion to malignant neoplastic tissue.
In time, a fraction of cells develop a combination of genetic instabilities which 
gives them the ability to digest the extracellular matrix, invade through adjacent tissues, 
infiltrate the bloodstream and create metastatic tumours at sites distant from the primary 
tumour. This metastatic disease is the main cause of cancer death in patients.
The main risk factor associated with colorectal cancer is a family history of 
colon cancer, polyps or inflammatory bowel disease. Exposure to pollutants through 
living in industrial or urban areas and high fat and low fibre diets are also thought to be 
contributory factors (Boland, 1993).
Much is known, therefore, about the biology of this disease in terms of the 
various stages of carcinogenesis. Colon cancer is however, relatively resistant to 
treatment with systemic chemotherapy. 5-FU has been the mainstay of treatment since 
the mid-1950's. However, the efficacy of this agent, is limited in a substantial number of 
patients with a response rate of 10-20% (defined as a 50% reduction in tumour 
dimensions) as a single agent for standard bolus administration (Grem and Fischer, 
1989, Sotos, 1994 and Abbruzzese, 1989).
Most patients with colon cancer present with disease limited to a local site 
although some present with unresectable or metastatic disease. Those with resectable 
disease will be treated with surgery to remove all visible disease and are thus potentially 
curable at this stage (August, 1984). In certain cases surgery is combined with 
chemotherapy (Rennie, 1986). Despite surgery many patients relapse months or years 
later due to the presence of occult metastases which were present but undetected at 
surgery (Saltz, 1997). Adjuvant chemotherapy based on 5-FU reduces the risk of relapse
in certain groups of patients. Treatment for advanced or metastatic disease is usually 
palliative rather than curative and based around chemotherapy, again with 5-FU as the 
single most important agent.
1.3 5-Fluorouracil
The 5-fluorinated pyrimidines were designed and synthesised following the 
observation that rat hepatomas utilised radiolabeled uracil to a greater degree than 
normal liver (Rutman, 1954; Heidelberger, 1957). This suggested that the enzymatic 
pathways for the utilisation of uracil were upregulated in tumour cells compared to 
normal tissues and therefore could be a potential target for chemotherapeutic agents.
5-FU is an analogue of uracil with a fluorine molecule substituted at the carbon 5 
position of the pyrimidine ring in place of hydrogen (Figure 1.1). It is used in the 
treatment of solid tumours such as breast, head and neck and gastrointestinal cancers. In 
order to exert it's cytotoxic effects, 5-FU requires anabolism to cytotoxic nucleotides. 
Despite the fact that fluorine is larger than hydrogen, this does not hinder it's anabolism 
to nucleotides.
5-FU rapidly enters the cell via the same facilitated transport mechanism as 
uracil, adenine and hypoxanthine (Domin, 1993). Phosphorylation of 5-FU rather than 
intracellular entry, appears to be the rate-limiting factor in the formation of cytotoxic 
nucleotides (Wohlhueter, 1980 and Bowen, 1979).
1.3.1 Anabolism of 5-FU
The cellular anabolism of 5-FU and the interaction of it’s active products with 
intracellular targets have been intensively investigated. Three pathways of anabolism 
have been identified (Figure 1.1).
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Figure 
1.1 
5-FU 
anabolic 
pathw
ays.
Firstly, 5-FU can be converted to fluorodeoxyuridine (FdUrd) in the presence of 
deoxyribose-1-phosphate (dR-l-P) by thymidine phosphorylase (TP) followed by 
phosphorylation to fluorodeoxyuridine monophosphate (5-FdUMP) by thymidine 
kinase. 5-FdUMP can also be formed indirectly as a consequence of the conversion of 
fluorouridine diphosphate (FUDP) by ribonucleotide reductase to FdUDP and 
subsequent dephosphorylation. The cytotoxic nucleotide 5-FdUMP inhibits thymidylate 
synthase. Secondly, 5-FdUMP can be further phosphorylated by pyrimidine 
monophosphate kinase to FdUDP and then by pyrimidine diphosphate kinase to the 
cytotoxic nucleotide FdUTP. This nucleotide can compete with dUTP for DNA 
polymerase and become incorporated into DNA. Finally, 5-FU can be anabolised to 
fluorouridine monophosphate (FUMP) either through direct conversion by orotic acid 
phosphoribosyltransferase (ORTPase) in the presence of 5-phosphoribosyl-l- 
pyrophosphate (PRPP) or through the sequential action of uridine phosphorylase 
(forming fluorouridine, FdUrd) and uridine kinase. FUMP may be further 
phosphorylated to the cytotoxic nucleotide fluorouridine triphosphate (FUTP) which can 
compete with UTP for RNA polymerase and become incorporated into RNA.
1.3.2 Catabolism of 5-FU and it's nucleotide derivatives
In humans, approximately 90% of administered 5-FU is degraded through a 
catabolic pathway (Heggie, 1987). The pyrimidine ring is firstly reduced by 
dihydropyrimidine dehydrogenase (DPD) as shown in Figure 1.2, to form the 
dihydropyrimidine dihydrofluorouracil (DHFU) in the presence of nicotinamide adenine 
dinucleotide phosphate (NADPH). This is the first and rate-limiting step in the 
catabolism of 5-FU which regulates the availability of 5-FU for anabolism.
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Dihydropyrimidase converts DHFU to a-fluoroureidopropionic acid (FUPA) which is 
then irreversibly converted to fluoro-|3-alanine (FBAL) ammonia and carbon dioxide by 
|3-alanine synthase. FBAL and FUPA are excreted in the urine with FBAL being the 
principle urinary metabolite. Pharmacokinetic studies show that approximately 90% of 
the administered dose of 5-FU is eliminated by this pathway. Naguib et al (1985) 
measured DPD activity in several normal and neoplastic tissues and found the highest 
DPD activity in liver and lymphocytes in comparison to lower activities in the pancreas, 
lung and intestinal mucosa.
Catabolism of the nucleotide derivatives of 5-FU also occurs. Acid and alkaline 
phosphatases are capable of converting nucleotides to nucleosides. For example, 5- 
FdUMP can be converted to FdUrd by 5'-nucleotidases. In addition, the pyrimidine 
phosphorylases responsible for the phosphorylation of pyrimidine bases to nucleoside 
are reversible (Figure 1.1).
1.3.3 Modes o f Action
Three known mechanisms of action of 5-FU have been elucidated at three 
different cellular targets: TS, RNA and DNA.
1.3.3.1 Inhibition o f thymidylate synthase
One site of 5-FU cytotoxicity is the enzyme thymidylate synthase (TS), which is 
discussed in detail in section 1.4. TS catalyses the methylation of deoxyuridine 
monophosphate (dUMP) to thymidylate (dTMP) and is responsible for the only de novo 
source of dTMP. dTMP is the precursor for one of the four deoxyribonucleotides 
required for synthesis of DNA. The cytotoxic nucleotide 5-FdUMP competes with 
dUMP for the active site on TS (Figure 1.3). 5-FdUMP binds covalently to TS in the 
presence of reduced folates to form a covalent reversible ternary complex. This results
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in the depletion of dTMP necessary for DNA synthesis. An accumulation of dUMP also 
occurs resulting in the formation of dUTP which may become incorporated into DNA.
1.3.3.2 RNA Cytotoxicity
Secondly, FUTP formed by the ribonucleotide pathway competes with UTP for 
RNA polymerase. FUTP is incorporated into both nuclear and cytoplasmic RNA 
altering it's processing and function in human colon cell lines in culture (Greenhalgh 
and Parish 1990). This has been shown to be the growth-limiting mechanism of action 
of 5-FU in MCF-7 breast carcinoma cells, where incorporation of 5-FU into total RNA 
correlates with loss of clonogenic survival (Kufe and Major, 1981). The specific 
mechanism whereby incorporation of 5-FU into RNA leads to cytotoxicity is unclear. A 
study of Friend erythroleukemia cells demonstrated that cytotoxicity related to 
incorporation into pre-ribosomal RNA resulting in an inhibition of maturation to 
cytoplasmic rRNA species (Herrick, 1984) and this has also been demonstrated in HT- 
29 colon carcinoma cells (Greenhalgh and Parish, 1990).
5-FU exposure may also result in changes in mRNA processing and translation, 
for example, polyadenylation of mRNA is inhibited by low concentrations of 5-FU 
resulting in increased instability (Carrico, 1979). Some specific species of mRNA and 
their respective proteins are altered following exposure to 5-FU. A dose-dependent 
increase in dihydrofolate reductase (DHFR) mRNA was reported in cells resistant to 
Methotrexate (Dolnick, 1985). In addition, the gene product had a reduced affinity for 
it's substrate. An increase in thymidylate synthase mRNA (one of the principle targets of 
5-FU cytotoxicity) and a reduced affinity for it's substrate 5-FdUMP was observed in 
cells resistant to 5-FU (Washtein, 1983; Berger, 1984).
The ribonucleotide route of anabolism appears to be the principle pathway for 
anabolism of 5-FU in normal tissues since inhibition studies with a nucleotide
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metabolite of allopurinol (which blocks 5-FU activation by OPRTase) demonstrated a 
reduction in toxicity to the gastrointestinal mucosa and bone marrow (Schwartz, 1979 
and 1980, Houghton, 1980 and 1983).
1.3.3.3 DNA cytotoxicity
The third site of 5-FU cytotoxicity is DNA. FdUTP and dUTP compete with 
dTTP for DNA polymerase and subsequent incorporation into DNA. FdUTP 
incorporation into DNA contributes to 5-FU cytotoxicity in cell lines in vitro (Lonn, 
1984 and 1986; Cheng, 1983; Major, 1982) and into marrow and tumour cell DNA in 
vivo (Sawyer, 1984). FdUrd exposure can result in the formation of large (1-5 
megabase) DNA fragments as a result of double strand DNA breaks. The time course 
and extent of DNA megabase fragmentation was shown to correlate with loss of 
clonogenicity in HT-29 cells (Dusenbury, 1991). In addition, a depletion of thymidine 
monophosphate (dTMP), due to inhibition of TS by 5-FdUMP, results in the 
incorporation of dUTP into DNA in place of dTTP.
Two mechanisms prevent the incorporation of false nucleotides into DNA. 
dUTP hydrolase cleaves dUTP and FdUTP to dUMP and 5-FdUMP respectively 
(Ingraham, 1980 and Mauro, 1993). Uracil-DNA-glycosylase catalyses the hydrolysis of 
the 5-fluorouracil- and uracil-deoxyribose glycosyl bond of 5-FdUMP and dUMP 
residues present in DNA (Ingraham, 1980 and Mauro, 1993). Further endonucleolytic 
cleavage of the remaining deoxyribose sites results in a strand break which is 
subsequently repaired. Increased activity of dUTP hydrolase and Uracil DNA 
glycosylase contributes to resistance to 5-FU in KB cells (Cardonna and Cheng, 1980) 
and in resistant PE04 ovarian cells (Chu, 1990a).
Alterations in DNA stability have been demonstrated following depletion of 
dTTP and FdUTP incorporation (Yin, 1991, Lonn, 1986 and Lonn 1988). 5-FU
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treatment results in inhibition of DNA elongation and causes a reduction in the average 
DNA chain length (Schuetz, 1985). DNA strand breakage also takes place although the 
exact mechanism through which this occurs is unclear. The inability of cells to excise or 
repair nucleotides from DNA may contribute to strand breakage, since dTTP depletion 
means that there are insufficient amounts of nucleotides for replacement (Yoshioka, 
1987). In turn, more dUTP may become falsely incorporated and so the process of 
excision and repair continues.
Factors downstream of damage also influence drug sensitivity e.g. p53 and bcl-2. 
The tumour suppressor gene p53 is known to play a vital role in the repair of DNA 
damage. Following DNA damage, expression and stability of p53 is induced (Kastan,
1991) and either cell cycle arrest occurs allowing repair of DNA damage (Mcllwrath,
1994) or apoptosis occurs (Clark, 1993, Lowe, 1993). Normal p53 function can become 
disrupted by mutation of the gene, causing cells to continue proliferating despite DNA 
damage. Apoptosis is a key event in the killing of human tumour cells growing as 
xenografts in nude mice in vivo (Inada, 1997)
The means by which 5-FU exerts it's cytotoxic effects are many and varied. 
Which cytotoxic mechanism(s) predominates is thought to depend on the patterns of 
intracellular 5-FU metabolism which can vary among different normal tissues and 
tumour types and with drug concentration and duration of exposure.
1.4 TS Inhibition
It has long been recognised that inhibition of TS by 5-FdUMP is one of the 
principle mechanisms underlying 5-FU action. The kinetics of this reaction have been 
extensively studied (Danenberg, 1979). 5-FdUMP binds to a specific site on TS 
exposing a second site for the binding of 5,10-CH2THF the reduced folate necessary for 
the stabilisation and retention of the ternary complex (Santi, 1987). TS inhibition is
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therefore determined by a number of variables, including the levels of TS, the amount of 
5-FdUMP present and it's rate of breakdown, the concentrations of dUMP which 
compete with 5-FdUMP and finally the levels of reduced folates and the extent of their 
polyglutamation (Figure 1.3).
The covalent ternary complex between 5-FdUMP and TS is reversible and 
persistence of the complex correlates with cytotoxicity. This is determined by the levels 
of free 5-FdUMP and reduced folates and also by the levels of dUMP. High levels of 
dUMP can aid in restoration of TS activity (Myers, 1975).
TS inhibition correlates with response to 5-FU in patients with colon and breast 
adenocarcinomas (Spears, 1984). Tumours from 3 patients who benefited from 
treatment with 5-FU demonstrated greater TS inhibition than the tumours from non­
responding patients.
Overexpression of TS in tumours from patients with colorectal and gastric 
tumours correlates with resistance to 5-FU based therapies (Johnston, 1995) and this has 
also been demonstrated in cells in culture (Johnston, 1992). On the other hand, a 
retrospective study of rectal cancer patients demonstrated that increased TS levels at the 
time of surgery had prognostic significance (Johnston, 1994). Patients with Duke's B 
and C rectal cancer with high intrinsic TS levels derived the greatest benefit from 
adjuvant chemotherapy (Semustine, Vincristine (Oncovin®) and 5-FU, known as 
MOF). Adjuvant chemotherapy seemed to be of no added benefit in patients with low 
TS levels. The explanation for this unexpected result is uncertain. Patients with low TS 
levels may not have demonstrated survival benefit from chemotherapy because of the 
relatively non-vascularised nature of their tumours. In addition, the other drugs given in 
combination with 5-FU may have contributed to their response.
Alterations in the TS gene have been correlated with resistance to 
fluoropyrimidines, both intrinsic and acquired. Two point mutations have been reported
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in a colon cell line insensitive to 5FdUrd (Barbour, 1990). This caused structural 
changes in TS leading to reduced affinity for both 5-FdUMP and 5,10-CH2THF. 
Amplification of the TS gene resulting in increased enzyme levels has also been found 
in cell lines resistant to 5-FU and FdUrd (Berger, 1985 and Clark, 1987).
The inhibition of TS by 5-FdUMP can be reversed by exogenous thymidine, 
which is routinely used to determine the relative importance of this mechanism of action 
of 5-FU in studies in vitro (Murgo, 1980). Exogenous thymidine is not always 
successful in completely reversing 5-FU cytotoxicity. This suggests that in some cases 
other mechanisms exist alone or in addition to TS inhibition. For example, TS inhibition 
was the principle mechanism of action of 5-FU at lower concentrations (5-20pM) in 
mouse sarcoma 180 cells since thymidine reversed toxicity (Evans, 1980). At higher 
concentrations, however, thymidine was unable to reverse toxicity suggesting an 
alternative mechanism of cytotoxicity. Studies in vivo have demonstrated that when 
thymidine is administered with 5-FU incorporation into DNA is inhibited (Nayak,
1992). This also results in increased toxicity of 5-FU to normal tissues in various animal 
models by increasing incorporation into RNA (Speigelman, 1980 and Santelli, 1978).
1.5 TS Regulation
TS is therefore widely regarded as an important target for the anti-tumour 
activity of 5-FU. It's activity is more pronounced in tissues which are rapidly 
proliferating due to it's role in the synthesis of DNA (Conrad and Ruddle, 1972 and 
Johnson, 1984).
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TS activity increases as cells enter S-phase of the cell cycle suggesting that TS 
levels are associated with cellular proliferation and DNA synthesis (Pestalozzi, 1995). In 
addition it’s activity increases in response to 5-FU exposure, a resistance mechanism in 
tumour cells in vitro and in vivo that is discussed in more detail in chapter 4.
Regulation of TS occurs at the translational level with levels of mRNA 
remaining unchanged. TS mRNA translation is inhibited by the presence of TS protein 
(Chu, 1991). TS protein binds to specific regions on it's mRNA and mutations in these 
regions hinder TS binding (Chu, 1993).
1.6 Resistance
Resistance to 5-FU can occur as a result of alterations at many stages of the 
anabolic and catabolic pathways. For example, correlations between enzyme activity 
and sensitivity to 5-FU have been made for OPRTase (Piper and Fox, 1982), uridine 
phosphorylase (Peters, 1986) uridine and thymidine kinase (Bresnick, 1965 and Hande 
1978) and TP (El-Assouli, 1985 and Piper, 1982). In addition, the availability of the co­
factors for these activating enzymes is also of importance and may alter the anabolism 
and therefore response to fluoropyrimidines (Cory, 1979, Cadman, 1979 and Washtein, 
1984). Increased activity of the target enzyme TS following exposure to 5-FU or 
elevated levels of the nucleotide dUMP can result in reduced 5-FU cytotoxicity. 
Depleted levels of reduced folates necessary for stabilisation of the inhibitory ternary 
complex with 5-FdUMP will also alter response to 5-FU. Finally, as discussed 
previously, increased activity of enzymes responsible for the excision and repair of 
DNA damage (Cardonna & Cheng, 1980) and the cellular response to DNA damage 
(e.g. p53) may reduce 5-FU cytotoxicity.
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1.7 Modulation of 5-FU
5-FU is an attractive target for biochemical modulation due to the complexity of 
it’s anabolic pathways and it’s multiple sites of action. A number of strategies have been 
explored in order to increase the efficacy of 5-FU. These include attempts to enhance 
it’s binding to TS, increase incorporation into DNA or RNA, decrease the catabolism of 
5-FU and it’s metabolites or increase the conversion of 5-FU to it’s active metabolites.
1.7.1 Leucovorin and 5-FU
One such strategy to enhance the cytotoxicity of 5-FU has been the co­
administration of Leucovorin (LCV). Leucovorin (5-formyl-H4PteGlu, folinic acid) is a 
reduced folate which is metabolised intracellularly to 5,10-methylene-H4PteGlu (Figure
1.3). This results in expansion of the intracellular reduced folate pools and permits 
maximal ternary complex formation with TS and the 5-FU metabolite 5-FdUMP 
(Wright, 1989).
The stability and increased retention of the ternary complex between 5-FdUMP, 
TS and 5,10-CH2-FH4 is an important determinant of 5-FU cytotoxicity. High 
concentrations of reduced folates are required for optimal binding and stabilisation of 
the ternary complex (Santi, 1974). Prolonged inhibition of TS results in greater 
depletion of dTTP, greater inhibition of DNA synthesis and ultimately an increased 
cytotoxicity (Pinedo, 1988). Resistance to 5-FU has been associated with insufficient 
concentrations of intracellular reduced folates (Houghton, 1981).
LCV is a chemically synthesised compound which must be metabolised 
intracellularly to exert it's effects on 5-FU (Boarman, 1992). It is transported across the 
cell membrane by a saturable reduced-folate carrier prior to metabolism and 
polyglutamation. Variations in the polyglutamation of reduced folates determine the 
extent of modulation by Leucovorin, therefore prolonged exposure to LCV is more
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beneficial. Important aspects of resistance to modulation by LCV include impaired 
transport, metabolism and polyglutamation.
This combination has been extensively investigated in the clinic (Machover, 
1986 and Poon, 1991). Phase III trials have shown an advantage of the combination in 
terms of response rate and time to disease progression (Poon, 1989 and Piedbois, 1992). 
A meta-analysis of nine randomised trials of 5-FU/LCV in patients with advanced 
colorectal cancer compared to 5-FU alone, demonstrated that 5-FU/LCV was 
significantly more beneficial than 5-FU alone in terms of tumour response rate (23% 
versus 11%, Piedbois, 1992). There was no advantage with respect to overall survival 
however. In the adjuvant setting, a trial of patients with Dukes stage B and C colon 
cancer demonstrated that 5-FU/LCV did result in a survival advantage over MOF 
(Wolmark, 1993).
1.7.2 Interferon and 5-FU
1.7.2.1 INF and 5-FU in colon cell lines in vitro
Interferons (IFNs) are involved in the regulation of a broad range of cell 
functions and modulate responses to infection and malignancy. IFN-a, -|3 and -y bind to 
high affinity cell receptors activating a signalling pathway which leads to changes in 
gene expression, protein expression, enzyme activities, cell cycle distribution and 
nucleotide pools (Goldstein, 1986).
A number of studies in colon tumour cell lines have investigated the 
combination of 5-FU and IFNs. These studies have demonstrated that the IFNs can 
synergistically enhance the cytotoxicity of 5-FU in human (Wadler, 1990; Chu, 1990; 
Schwartz, 1992; Tevaearai, 1992; Eda, 1992; Houghton, 1993) and murine (Elias, 1988) 
cell lines.
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The mechanism by which IFNs exert their effect on 5-FU cytotoxicity in vitro 
has been evaluated and a number of explanations given. IFN-y abrogated the 5-FU 
induced increase in TS expression in H630 colon carcinoma cells, resulting in greater 
TS inhibition and 5-FU cytotoxicity (Chu, 1990). The interaction between 5-FU and 
IFN-a in these cells was at the level of DNA damage and the key factor appeared to be 
an increase in TP activity resulting in increased concentrations of 5-FdUMP via FdUrd, 
consequently greater TS inhibition and 5-FU cytotoxicity. Houghton and colleagues 
reported that the level of DNA single and double strand breaks were increased by IFN-a 
in GC3/CI colon adenocarcinoma cells (Houghton, 1993). There was further potentiation 
by the addition of exogenous LCV resulting from inhibition of TS and thymineless 
stress.
Schwartz demonstrated that IFN-a enhanced 5-FU cytotoxicity in HT-29 cells 
through an increased formation of 5-FdUMP (Schwartz, 1992). No change in the levels 
of 5-FdUMP, FUDP and FUTP was detected. There was no increase in intracellular 5- 
FU concentrations and no measurable change in incorporation of 5-FU into DNA or 
RNA, suggesting TS inhibition as the cytotoxic mechanism in these cells. In addition, an 
increase in the enzyme activity of thymidine phosphorylase, one of the first enzymes 
involved in the activation of 5-FU to cytotoxic nucleotides was demonstrated. These 
particular studies were the inspiration for the present study and are discussed in chapter 
4. Schwartz later showed that this modulation could be further enhanced by the addition 
of the co-substrate for TP, dR-l-P, which appeared to be rate-limiting (Schwartz, 1994).
7.7.2.2 IFN and 5-FU, Clinical, Phase I
Of the three separate classes of IFNs (a, p, y), IFN-a’s have been most widely 
used clinically and the sub-type IFN-a2a has been most frequently utilised in clinical 
trials combined with 5-FU.
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The early in vitro studies persuaded Wadler and colleagues to conduct a Phase I 
clinical study in patients with advanced colorectal cancer (Wadler, 1989). Patients were 
treated with 5-FU 750mg/m2 i.v. continuous infusion daily for 5 days followed by a one 
week rest period, then weekly bolus therapy at 750mg/m2 and IFN-a 9mU administered 
sub-cutaneously 3 times weekly starting on day 1. Thirty evaluable patients were 
included, 17 previously untreated with chemotherapy. Thirteen of the 17 previously 
untreated patients responded to the treatment regime. Toxicity was significant and one 
toxic death was reported. A clinical series update from 1990 (Wadler, 1990) 
demonstrated that of the 32 previously untreated patients there were 20 partial responses 
corresponding to a 63% response rate. Three toxic deaths occurred in the expanded 
series.
1.7.2.3 IFN and 5-FU, Clinical, Phase II
Following this promising study, a number of Phase II studies were conducted 
over the next few years. Twelve studies have been published over the period 1990-94 on 
a total of 548 patients 509 of whom were evaluable (Wrighely, 1992; Wadler, 1990; 
Pazdur, 1990; Weh, 1992; Rubio, 1992; Pazdur 1993; John, 1993; Finlay, 1994). A 
response rate of 28% was observed (142 recorded responses out of 509 patients) and 15 
complete responses (3%). Eight toxic deaths (2%) were also reported. These studies 
were unable to confirm the impressive activity of this treatment regime originally 
reported by Wadler. A 28% response rate with 2% toxic deaths is no improvement from 
the results obtained with 5-FU and Leucovorin and appears more toxic.
1.7.2.4 IFN and 5-FU in vivo, phase III
A number of randomised Phase III studies were also initiated to confirm the
results of Wadler and to investigate any impact on patient survival. As expected, the
comparative arms in the studies used different 5-FU regimens. Four studies used the
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Wadler schedule of 5-FU and IFN-a (York, 1993, The Corfu-A Study Group, 1995, 
Dofour, 1994 and Hill 1995). Two studies used a modified dose of 5-FU and/or IFN-a 
(Kohne, 1995 and Kreuser, 1995). One study combined 5-FU and IFN-a with 
hydroxyurea (Di Constanzo, 1995) and another used protracted i.v. 5-FU infusion over 
10 weeks. There was also one double modulation study using both Leucovorin and IFN- 
a  (Seymour, 1994).
A total of 1727 patients have been included in these Phase III studies. Only one 
study (Dufour, 1994) describes a significant difference in response between 5-FU alone 
and 5-FU and IFN-a (27% versus 10% for 5-FU alone). Survival was 12.3 months for 
the combination compared with 10.1 months for 5-FU alone. The remaining studies 
either demonstrate no difference (York, 1995, The Corfu-A Study group, 1995, Di 
Constanzo, 1995, Seymour, 1994, Hill, 1994 and 1995) or even a significant difference 
in favour of 5-FU without IFN (Kohne, 1995 and Kreuser, 1995). Most studies report 
significant increases in toxicities in the IFN-containing groups.
Results therefore suggest that there is no advantage in using the 5-FU/IFN-a 
combination together in place of 5-FU alone. In fact, the disadvantage of this regime is 
clearly the pronounced toxicity observed including abdominal pain, constipation, 
diarrhoea, fatigue, fever, influenza-like symptoms, nausea/vomiting, shivering, 
somnolence and stomatitis (Corfu-A Study Group, 1995). Focus has been especially on 
a toxicity syndrome characterised by watery diarrhoea followed by life threatening 
sepsis (Van Hoff, 1991).
1.7.2.5 IFN and 5-FU Summary
In summary, IFN-a potentiates the anti-tumour activity of 5-FU in colon cancer 
in vitro. A likely mechanism for this action is the induction of TP, resulting in increased 
formation of the nucleotide 5-FdUMP (presumably through the sequential actions of TP
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and thymidine kinase on 5-FU) and greater inhibition of TS. This modulation can be 
further enhanced by the addition of the co-substrate for TP, dR-l-P. The results of 
clinical studies were initially very promising however have not been achievable in later 
studies. This combination gives no greater a response rate than 5-FU and Leucovorin, is 
costly, and toxic.
Since IFN-a acts, in part, through the elevation of TP activity, the current study 
will explore the hypothesis that colon cancer cells transfected with the gene for TP in 
vitro will be more sensitive to the effects of 5-FU. If so, this system could be exploited 
through the application of gene therapy techniques directing tissue specific expression 
of TP in a transient fashion, rendering tumour cells more sensitive to fluoropyrimidines 
such as 5-FU and avoiding the unnecessary side effects of INF-a.
1.8 Thymidine phosphorylase
The characteristic role for TP in cells is in thymidine metabolism and 
homeostasis. TP catalyses the reversible synthesis of thymidine and inorganic phosphate 
from thymine, using deoxyribose-1-phosphate as a co-substrate (Reaction (1), Figure
1.4). TP also catalyses a deoxyribosyltransfer from one deoxynucleotide to another base, 
to form a second deoxynucleoside (Reaction (2), Figure 1.4).
Reaction 1: Thymidine + Phosphate; ^  * Thymine + dR-l-P
Reaction 2: Thymine* + Thymidine Thymidine* + Thymine
Figure 1.4 The enzymatic reactions of thymidine phosphorylase
TP is highly expressed in the liver, lung, spleen, lymph nodes and peripheral 
lymphocytes (Yoshimura, 1990). Western immunoblotting has revealed that TP consists 
of 2 identical sub-units; the molecular weight of each sub-unit is approximately 45kDa
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in bacteria and 55kDa in mammals. Human TP has been reported to be identical to the 
angiogenic factor platelet-derived endothelial cell growth factor (PD-ECGF), both being 
products of the same gene (Moghaddam and Bicknell, 1992; Furukawa, 1992 and 
Sumizawa, 1993). Recombinant PD-ECGF has TP activity (Sumizawa, 1993). PD- 
ECGF was originally isolated as the sole moiety with endothelial cell mitogenic activity 
in platelets (Miyazono and Heldin, 1989). The TP activity of PD-ECGF promotes 
endothelial cell proliferation by reducing thymidine levels (Finnis, 1993) and is thought 
to be important in tumour angiogenesis in breast cancer (Fox, 1993; Miyazono, 1987 
and Yonenga, 1998). It is a non-glycosylated intracellular protein which lacks a 
secretion signal peptide (Ishikawa, 1989 and Relf, 1997). PD-ECGF is also chemotactic 
for endothelial cells in vitro. There is a high expression of TP in macrophages in many 
tissues (Yoshimura, 1990 and Fox, 1995). Zimmerman and colleagues first reported that 
several human tumours, such as kidney, stomach and lung cancers have relatively high 
TP activity compared with normal tissues (Zimmerman, 1964). Yoshimura and 
colleagues also showed by Western immunoblotting that TP expression was higher in 
tumours of the stomach, colon and ovary, compared to the non-cancerous region of the 
same surgical sample (Yoshimura, 1990). Western blot analysis of TP in breast tumour 
tissue demonstrated overexpression in breast carcinomas compared to normal breast 
tissue, p<0.001 (Moghaddam, 1995). Therefore, these data are consistent with a role for 
TP in tumour proliferation. In addition, studies have shown that TP activity is elevated 
in the plasma of tumour bearing animals and in the plasma of patients with uncontrolled 
neoplastic disease compared to that of normal subjects (Pauly, 1977 & 1978).
Studies in vitro have shown that TP has angiogenic activity in vivo (Ishikawa, 
1989) and in vitro (Moghaddam, 1995 and Miyadera, 1995). The catalytic activity of TP 
is essential for it’s angiogenic activity, as shown using active site-directed mutants that 
maintained their secondary structure but had reduced TP activity (Moghaddam, 1995).
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The mutants did not exhibit angiogenic activity in the rat sponge model. In addition, 
over-expression of TP by gene transfer in MCF-7 cells has no effect on breast carcinoma 
cell growth in vitro. It did however confer a growth advantage to these cells when grown 
as a xenograft in nude mice. This growth advantage could be as a result of an angiogenic 
advantage, although this remains to be proven.
In patients with breast cancer, a study of 100 invasive-ductal-carcinoma tissue 
samples, showed 39% to be positive for TP expression by immunohistochemistry (Toi,
1995). The expression was significantly associated with microvessel density, a marker 
for angiogenesis. This was also demonstrated in malignant ovarian tumours (Hata, 
1998), endometrial cancer (Fijiwaki, 1998) and squamous cell carcinoma (Igarashi, 
1998). This suggests that TP expression plays an important role in the 
neovascularisation of human breast cancer. In benign and malignant human TP 
expression also correlates with areas of high blood velocity (Toi, 1995 and Reynolds, 
1994). The mechanism by which TP elicits growth of new blood vessels is as yet 
unknown. The realisation that PD-ECGF and TP are identical and that they have no 
classic growth-stimulatory activity indicates that they are indirectly angiogenic. It may 
be that modulation of nucleotide metabolism in the tumour environment could have a 
true effect on endothelial cell growth and angiogenesis.
1.9 Hypothesis
The hypothesis of this thesis is that the genetic transfer of the gene for TP will 
increase the sensitivity of colon cancer cells to the cytotoxic effects of the 
fluoropyrimidine 5-FU.
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1.10 Objectives
The primary objective of this thesis was to gain a further understanding of the 
enzymes involved in 5-FU metabolism in colon cancer, in order that new therapies 
might be designed which would improve the therapeutic index of this agent. Recent 
literature concerning the modulatory effects of IFN-a on 5-FU highlights the potential 
importance of the enzyme TP in the activation of 5-FU. The definitive test would 
therefore be to genetically transfer the gene for TP into colon cancer cells in vitro and 
using cytotoxicity experiments to analyse the cells for increased sensitivity to 5-FU. 
This strategy could then be further evaluated as a potential gene therapy approach in 
human colon cancer patients.
The individual aims of the study were to characterise 5 colon carcinoma cell 
lines with respect to growth kinetics, sensitivity to 5-FU, protein expression of the 
enzymes TP and TS and TP activity. In addition, TP protein expression and activity 
would be measured in human colon tumour and normal biopsy pairs. Following 
characterisation of the cell lines, the aim was to transfect the cells with the gene for 
thymidine phosphorylase and assess mechanisms for increasing sensitivity to 5-FU.
Whilst these studies were being undertaken, Schwartz and colleagues carried out 
similar experiments in HT-29 colon adenocarcinoma cells (Schwartz, 1995). They 
showed that HT-29 cells transfected with TP had increased TP activity and were more 
sensitive to 5-FU. However in the same year a similar study in MCF-7 breast cancer 
cells failed to demonstrate a correlation between increased TP activity and sensitivity to 
5-FU (Patterson, 1995). Because of the contradictory data, the present study went on to 
further clarify the role of TP in 5-FU cytotoxicity in colon cancer cells lines.
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CHAPTER 2 
2. Characterisation of Colon Cancer Cell Lines
2.1 Introduction
Colon cancer has been chosen as the model for these studies and a panel of colon 
adenocarcinoma cell lines were characterised. A number factors thought to influence the 
sensitivity of these cells to the chemotherapeutic agent 5-FU were also evaluated. This 
study was used as a starting point preceding the transfection studies.
Firstly, the growth kinetics of the cell lines was evaluated. Following sub­
culture, cells progress through a characteristic pattern of growth consisting of a lag 
phase (an adaptation period), followed by a log phase (a period of exponential growth) 
and finally a stationary or plateau phase (confluence; growth fraction falls between 0 
and 10%), (Freshney, 1987). These phases provide information about a cell line, such as 
the population doubling time. In addition, measurement of these phases of growth can 
be used to quantify the response of the cells to inhibitory or stimulatory culture 
conditions. For example variations in nutrient concentration, hormonal effects or toxic 
drugs. In the current study, the population doubling times of a panel of colon 
adenocarcinoma cell lines were measured.
Secondly, the expression of enzymes thought to be important in the activation 
and cytotoxicity of 5-FU was evaluated. As discussed earlier, TP is the first enzyme 
involved in a series of reactions resulting in the activation of 5-FU to 5-FdUMP, the 
cytotoxic nucleotide which inhibits TS, Figure 1.1. The expression of these two 
enzymes was therefore measured by Western Immunoblotting. Antibodies raised against 
TP and TS were made available by Dr Roy Bicknell and Prof. Patrick Johnston 
respectively.
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Thirdly, following evaluation of the five colon cell lines for TP and TS protein 
expression, the cells were characterised for their sensitivity to 5-FU. There are a number 
of methods that can be employed for measuring the cytotoxic potential of anti-cancer 
drugs. Two such methods are the clonogenic assay and the growth inhibition assay (or 
MTT assay). Both methods are widely used, although protocols may differ from one 
laboratory to another.
The clonogenic assay (Puck, 1955) measures the ability of cells to proliferate 
and form colonies following exposure to the drug under test and has been used 
extensively in the assessment of tumour cell lines (Hill, 1983) and freshly biopsied 
tumour tissue (Hamburger, 1977 and Courtenay, 1978). The cytotoxic potential of anti­
cancer drugs is therefore measured as an anti-proliferative effect. Cytotoxicity is 
measured as a percentage of the number of colonies formed in comparison to untreated 
cells.
The MTT growth inhibition assay measures the respiration of cells as a function 
of the ability of mitochondria to reduce a tetrazolium-based compound (3-(4,5- 
dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide; MTT) to a blue formazan 
product (Mosmann, 1983 and Alley, 1988). This product absorbs light at a wavelength 
of 570nm and can be quantitated using a spectrophotometer, in the form of a 96 well 
plate-reader. Cytotoxicity is measured against untreated control cells. This method 
(Plumb, 1989) is an adaptation of the tetrazolium dye-based micro titration assay 
described previously (Carmichael, 1987).
For both the clonogenic and MTT assays, cytotoxicity is quantified in the form 
of an IC50 value; the concentration of drug, which results in a 50% cell kill. This 
represents a 50% reduction in colony number compared to control untreated cells for the 
clonogenic assay and a 50% reduction in optical density at 570nm compared to that of 
cells in the control untreated wells for the MTT assay. Finally, following analysis of
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these factors, possible correlations between levels of enzyme expression and 5-FU 
cytotoxicity could be investigated.
2.2 Materials and Methods
2.2.1 Cell Lines
2.2.1.1 Source and characteristics
Analysis of the proteins regulating 5-FU cytotoxicity was performed on 5 human
colon adenocarcinoma cell lines.
CELL
LINE
CHARACTERISTICS SOURCE REFERENCE
DLD-1 Human Colon 
Adenocarcinoma ATCC, CCL221 Dexter, 1979
BE Human Colon 
Adenocarcinoma
Dr Jane Plumb 
Department of Medical 
Oncology,
University of Glasgow
Seigel, 1990
HT-29 Human Colon 
Adenocarcinoma ATCC, HTB 38 Fogh, 1975
CACO-2 Human Colon 
Adenocarcinoma ATCC, HTB 37 Fogh, 1970
LOVO Human Colon 
Adenocarcinoma ATCC, CCL 229 Drewinko, 1976
Table 2.1 Source and characteristics of the five colon cell lines used in this study.
2.2.1.2 Chemicals and reagents
DMEM, sodium bicarbonate, L-glutamine, foetal calf serum, penicillin and 
streptomycin and Trypsin were obtained from Gibco BRL (Paisley, UK). Ham's F10 
medium was from SIGMA (Poole, UK), and diaminoethanetetra-acetic acid, disodium 
salt (EDTA) was obtained from Fisons Scientific Equipment (Loughborough, UK).
2.2.1.3 Routine cell maintenance
All cell lines were maintained in a combined Ham's F10 and DMEM medium
supplemented by sodium bicarbonate (0.075%), L-glutamine (2mM), foetal calf serum
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(10%, v/v), penicillin (50 U/mL) and streptomycin (50mg/mL). Cells were sub-cultured 
at weekly intervals at a 1:50 dilution and medium was replenished every 48 hours. All
cell lines were incubated at 37°C in an atmosphere of 2% CO2 in air.
Cells were sub-cultured by removal of all medium from the 75cm flask and 
subsequent addition of 2.5 mLs of phosphate buffered saline (PBS) containing EDTA 
(ImM) and trypsin (0.25%) to the flask. Cells were incubated with the trypsin solution 
for 5-10 minutes, depending on the cell line, to allow dissociation of the cells in the 
monolayer. Trypsin was inactivated when the cells were resuspended in 7.5 mLs of 10% 
serum-containing medium. This suspension was diluted to the appropriate seeding 
concentration in new sterile tissue culture flasks.
2.2.1.4 Mycoplasma testing
All cell lines were free of mycoplasma as confirmed by monthly screening. Cells 
were fixed with ice-cold glacial acetic acid (25%, v/v) in methanol and stained with the 
fluorescent DNA stain Hoescht 3328 (SIGMA Chemical Company, Poole, UK) at a 
concentration of 100 ng/mL for 15 minutes at room temperature (Chen, 1977). Plates 
were then examined under a fluorescent microscope (Polyvar Microscope, Reichert, 
Leica Ltd, Milton Keynes, UK) for visible evidence of infection, i.e. characterised by 
extra-nuclear staining.
2.2.2 Growth kinetics
2.2.2.1 Chemicals and reagents 
See section 2.2.1.2
2.2.2.2 Estimation o f cell doubling times
The doubling time of each cell line was measured by counting the number of 
cells in the wells of a 24-well plate (Corning). Adherent cells were detached from
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routine culture flasks using 0.05% trypsin-EDTA as described in section 2.2.1.3. Micro- 
titre plates (24-well) were seeded at a density of 2xl04cells/mL, with lmL per well. 
After allowing cell attachment and growth to proceed for 24 hours in a humidified 
atmosphere (2% CO2), cells in three wells were counted using a Coulter counter. 
Medium was replenished in the remaining wells daily to maintain optimal growth 
conditions. Sampling was continued at daily intervals for 11 days.
The pattern of cell growth was visualised by plotting log cell number against 
time. The population doubling time was then measured as the rate of growth in the 
linear section of the growth curve, corresponding to the exponential growth phase.
2.2.3 Polyacrylamide Gel Electrophoresis and Western Blot Analysis
This assay involves the solubilisation of cells using sodium dodecyl sulphate 
(SDS), followed by electrophoresis through a polyacrylamide gel, where proteins are 
separated on the basis of molecular size, a method developed by Laemmli (1970). The 
resolved proteins on the gel are transferred (by electroblotting) to a nitrocellulose 
membrane. Immobilised proteins are then visualised by reaction with antibodies specific 
to the protein of interest. The method of detection of these complexes is enhanced 
chemiluminescence (ECL). ECL is achieved by performing the oxidation of luminol by 
the Horse-radish Peroxidase (HRP) in the presence of chemical enhancers such as 
phenols (Whitehead, 1979). Immediately following oxidation, the luminol is in an 
excited state which then decays to ground state via a light emitting pathway. This can be 
detected by a short exposure to light sensitive autoradiography film.
2.2.3.1 Chemicals and Reagents
Triton X-100, sodium deoxycholate, phenylmethylsulfonylfluoride (PMSF), 
sodium orthovanadate, p-mercaptoethanol, bovine albumin, and Tween 20 (Polythylene- 
sorbitan mono laurate) were purchased from SIGMA (Poole, UK). Sodium chloride
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(NaCl), sodium dodecyl sulphate (SDS), dithiothreitol were obtained from BDH 
Laboratory Supplies (Poole, UK). Bio-Rad protein dye was purchased from Bio-Rad 
Laboratories GmbH (Hertfordshire, UK) and the Perkin-Elmer Lambda 2 UV/Vis 
spectrometer was purchased from Perkin Elmer (Buckinghamshire, UK). Tris was 
obtained from GIBCO (Paisley, UK) and hydrochloric acid (HC1), glycerol, glycine and 
diaminoethanetetra-acetic acid, disodium salt (EDTA) were purchased from Fisons 
(Loughborough, UK). Immobilon-P nitrocellulose transfer membrane and a Milliblot™ 
graphite electroblotter were purchased from Millipore (Watford, UK) and Marvel™ was 
obtained from Premiere Beverages (Stafford, UK). The Enhanced Chemiluminescence 
(ECL) kit was obtained from Amersham (Buckinghamshire, UK). XR medical film was 
obtained from Fuji (Tokyo, Japan) and the KODAK X-OMAT 480 RA Processor was 
obtained from KODAK Ltd. (Hemel Hempstead, UK) and the Molecular Dynamics 
Laser Densitometer was purchased from Protein Databases Inc. (New York, USA). P- 
GF.44c, a mouse anti-TP monoclonal antibody raised against human TP was supplied 
by Dr Roy Bicknell, Molecular Angiogenesis Group, ICRF Clinical Oncology Unit, 
University of Oxford. The TS106 mouse anti-TS antibody raised against human TS was 
supplied by Prof. Patrick Johnston, Queens University of Belfast, Northern Ireland. An 
anti-mouse secondary antibody was obtained from Amersham (Buckinghamshire, UK).
2.23.2 Cell Lysate Preparation
Cells were dissociated from routine culture flasks using 0.05% trypsin-EDTA, as 
described in section 2.2.1.3. Cells were seeded in 25cm2 culture flasks at a density of 
2xl04 cells/mL in a volume of 5mLs of 10% serum containing medium. The cells were 
allowed to attach and grow for approximately 48 hours, until 70% confluence was 
reached. Cells were rinsed three times with ice-cold phosphate-buffered saline (PBS) 
and lysed by incubation with a buffer containing tris (25mM), NaCl (150mM), pH 7.5,
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Triton X-100 (1%), sodium deoxycholate (1%), SDS (0.1%), dithiothreitol (ImM), 
sodium orthovanadate (lOOmM) and PMSF (lOmM), for 20 minutes on a rocking table 
at 4°C. Cells were then removed from the tissue culture flasks using a cell scraper. 
Following centrifugation at 10,000g for 20 minutes in a refrigerated microcentrifuge, 
cytoplasmic protein concentration was quantified using the Bio-Rad protein assay 
(section 2.3.2.3) and aliquots stored at -70°C until required.
2.23.3 Measurement o f protein content
The Bio-Rad protein assay was used to determine protein content in each cell 
lysate preparation. This assay is a colourimetric assay for the measurement of total 
protein concentration. The principle of the assay being that Coomassie brilliant blue G- 
250 dye will undergo a concentration dependant colour change in response to different 
concentrations of protein (by binding to basic and aromatic amino acid residues).
A series of known concentrations of bovine albumin standards were prepared (0- 
25pg/mL) in 800pL of water and 200pL of Bio-Rad dye. These were transferred to 
1.5mL cuvettes and the optical density was measured at 595nm on a spectrophotometer. 
Test samples (supernatants from the crude cell lysate preparations), were diluted as 
appropriate and lOpL of each sample was added to 790pT of water and 200p,L of Bio- 
Rad dye. A plot of protein concentration versus optical density at 595nm defined the 
standard curve from which the protein concentration of the unknown samples could be 
determined.
2.23.4 Electrophoresis
One hundred micrograms of crude cell lysate was size-fractionated by SDS-
PAGE in a 6.5% acrylamide (30% w/v acrylamide, Bis Acrylamide Ratio 19:1) gel
containing tris base (300mM), SDS (3mM), pH 8.9 with HC1. The stacking gel
contained 4% acrylamide in tris (170mM) and SDS (5mM) pH 6.7 with HC1. Samples
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were diluted 1:2 (v/v) in loading buffer; SDS (4%), tris (250mM), EDTA (0.05M), 
glycerol (20%), |3-mercaptoethanol (5%) and bromophenol blue. Samples were then 
boiled for 3 minutes prior to electrophoresis. Electrophoresis of proteins was carried out 
at 60mA, 300V for 1 hour, followed by 5-10mA, 300V overnight, in electrode buffer; 
tris (lOOmM), glycine (lOOmM) and SDS (3.5mM).
2.23.5 Immunoblotting
A semi-dry graphite electroblotter was used to transfer the proteins from the gel 
onto a nitrocellulose membrane in a buffer consisting of tris (48mM), glycine (39mM) 
and SDS (0.037%). In order to block non-specific binding of the antibodies, the 
membranes were incubated in 5% Marvel™ (condensed milk) for 1 hour at room 
temperature. Membranes were washed in freshly prepared tris buffered saline containing 
tris base (lOmM) and NaCl (150mM) pH 7.4 and 0.025-0.05% Tween 20 (TBST). 
Following washing, the membrane was incubated with the primary antibody diluted 
appropriately in blocking solution, for the appropriate time period. For example, TP 
antibody (P-GF.44c) was diluted 1:1000 (v/v) in blocking solution and incubated 
overnight at 4°C whereas the TS antibody (TS106) was diluted 1:500 in blocking 
solution and incubated for 1 hour at room temperature. The membrane was then washed 
3 times (5 minutes each) in TBST prior to incubation with the secondary antibody 
linked to horseradish-peroxidase. This antibody was diluted 1:5000 (v/v) in blocking 
solution and incubated for 1 hour at room temperature. Following a final wash with 
TBST, the antibody/protein complex was visualised using an Enhanced 
Chemiluminescence kit (ECL™) and exposed to X-ray film. The film was processed 
using a KODAK X-OMAT 480 RA Processor. The density of the bands representing the 
protein of interest were quantified using a Molecular Dynamics Laser Densitometer with 
Image Analysis Software.
2.2.4 Cytotoxicity Assays
2.2.4.1 Chemicals and reagents
5-FU and MTT were purchased from SIGMA (Poole, UK). Dimethylsulphoxide 
(DMSO), was obtained from Fisons Scientific Equipment (Loughborough, UK) and 
Gram's crystal violet solution was from BDH Laboratory Supplies (Poole, UK). 96 well
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microtitre plates and 25cm culture flasks were obtained from Bibby Sterilin (Stone, 
Staffordshire). A Precision Microplate Reader was purchased from Molecular Devices 
Corporation (West Sussex, U.K.). An Artex colony counter was purchased from Artex 
Systems Corporation.
2.2.4.2 Growth inhibition assay (MTT assay)
Cells were dissociated from routine culture flasks using 0.05% trypsin-EDTA as 
described in section 2.2.1.3. Cells were seeded in 96 well microtitre plates in a volume 
of 200pL per well, at a density of 2.5x10 cells/mL. Two hundred microlitres of 
complete medium was added to cell-free wells as controls. After allowing cell 
attachment and growth to proceed for 48 hours in a humidified atmosphere of 2% CO2 
in air, concentrations of 5-FU from 2.5xl0'7 to 5xlO'5M were added in a volume of 
200pL. The drug was replenished daily when incubation times were greater than 24 
hours. At the end of the drug treatment period the medium was replaced with drug-free 
medium and the cells were allowed to grow for a further 72 hours with daily 
replenishment of medium. After 72 hours the cells were assayed for growth inhibition. 
MTT at a concentration of 0.5mg/mL was added to the medium in the wells and the 
plates were incubated in the dark at 37°C in the same humidified atmosphere. After 4 
hours the MTT/medium was removed from the wells and the MTT-formazan crystals 
were dissolved in 200pL of DMSO, followed by 25pL of glycine buffer (0.1M glycine, 
0.1M NaCl, pH 10.5). The optical density of the blue formazan product was measured
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on a Precision Microplate Reader at a wavelength of 570nm and dose-response curves 
and ICso's were calculated using the SOFTmax 2.32 programme. ICso's were calculated 
as the concentration of drug required to inhibit cell growth by 50% compared to the 
controls, visualised as a 50% reduction in optical density at 570nm. A typical dose- 
response curve consisted of 8 drug concentrations with 8 wells per concentration and 3 
plates were analysed within each experiment.
2.2.4.3 Clonogenic assay
Cells were seeded in 25cm2 tissue culture flasks (Corning) in 5mLs of medium, 
at a density of 7.75xl04cells/mL. After allowing cell attachment and growth to proceed 
for 48 hours, concentrations of 5-FU were added from 2.5xl0"7 to 5xlO"5M in 5mLs of 
medium. A control flask with drug-free medium was also included. The drug was 
replenished daily where incubation times were greater than 24 hours. At the end of this 
period, the cells in the control flask were removed by treatment with trypsin (0.05%) 
and counted. A total of 103 cells were subsequently seeded into four 60x15mm petri- 
dishes in a volume of 5mLs. The drug-treated flasks were processed in the same manner 
as the controls and colonies were allowed to grow for an additional 10 days under 
conditions of temperature and CO2 previously described, at which point they were fixed 
with methanol and stained with 0.1% crystal violet. Following counting of the colonies 
on an Artex colony counter, a graph was plotted of drug concentration against colony 
number represented as a percentage of the control number. ICso's were calculated as the 
concentration of drug, which resulted in a 50% reduction in colony number compared 
with the controls.
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2.3 Results
2.3.1 Growth Kinetics
The estimated population doubling times of the 5 cell lines, taken from a single 
experiment, are outlined in Table 2.2 and growth curves are shown in Figure 2.1. A 1.7- 
fold range in population doubling times was observed among the 5 cell lines.
Cell line Estimated Population 
Doubling Time (hrs)
BE 36.0
HT-29 38.4
LOVO 28.8
DLD-1 40.8
CACO-2 50.4
Table 2.2 Estimated population doubling times of the 5 colon adenocarcinoma cell 
lines. Cells were counted daily for 11 days as described in section 2.2.22.
2.3.2 TP protein expression
TP enzyme was detected in only LOVO cells (lane 6) with a band corresponding 
to a protein of 55kDa in size, consistent with the band for human recombinant TP in 
lanes 1-3, Figure 2.2. TP protein was not detected in CACO-2, DLD-1, LOVO and HT- 
29 cells.
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Figure 2.1 Cell growth curves for colon adenocarcinoma cell lines; 
BE, HT-29, LOVO, DLD-1 and CACO-2. Values are means and 
standard deviations of 3 counts per day.
55kD a -►
V
u T'r* os ^  ® 32hrTP 2  » © r  h
2 o  *® © • & K» H - S©© c-1© ©
3 3 3
crq ore crq
Figure 2.2 Western immunohlot of human recombinant TP (1(H), 
10 and lng), BE, CACO-2, LOVO, DLD-1 and HT-29 cells with 
PGF.44c anti-TP antibody. For analysis of TP protein levels, cells 
were lysed and cytosols prepared by centrifugation at 10,000g. lOOfig 
of cytosol was size-fractionated by SDS-polyacrylamide gel 
electrophoresis. Proteins were electroblotted onto nitrocellulose 
membranes and incubated with PGF.44c, a mouse monoclonal 
antibody raised against human TP, followed by an anti-mouse 
secondary antibody linked to HRP. Protein-antibody complexes were 
visualised using enhanced chemiluminescence.
2.3.3 TS protein expression
TS protein was detected in all five cell lines with varying degrees of expression, 
Figure 2.3. TS protein (as a positive control) is not available commercially, however the 
bands corresponded to a protein approximately 36kDa in size; the molecular weight of 
TS (Johnston, 1991). A 13.1-fold range in TS protein expression was observed, as 
outlined in Table 2.3. There was no correlation between TS expression and population 
doubling time(r=0.4, Figure 2.4).
Cell Line Relative TS 
expression
HT-29 4.7
CACO-2 1
DLD-1 9.0
LOVO 5.3
BE 13.1
Table 2.3 TS protein expression in colon cell lines relative to CACO-2 from a 
single Western immunoblot experiment. TS protein expression was evaluated by 
immunoblotting with TS106 antibody. Antibody/protein complex was visualised using 
enhanced chemiluminescence as illustrated in Figure 2.3. These results are based on a 
single experiment.
2.3.4 5-FU Cytotoxicity
5-FU IC50 data (for 24 hour drug exposure) obtained using both the clonogenic 
and the MTT assays are outlined in Table 2.4. Representative dose-response curves are 
shown in Figure 2.5, with (A) and (B) portraying the clonogenic and MTT assays 
respectively.
From Table 2.4 it can be seen that there is a 3.3-fold range in sensitivity of the 
colon cells to 5-FU as measured by the MTT assay and a 4.1-fold range for the 
clonogenic assay. All IC50 values are in the lower micromolar range (8-36pM). To 
confirm whether the observed range of 5-FU sensitivities measured by both assays 
correlated, the two sets of data were compared (Figure 2.6). Chemosensitivity measured 
by the two assays was strongly correlative (r=0.89).
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Figure 2.3 Western immunoblot of BE, CACO-2, LOVO, DLD- 
1 and HT-29 cells (lanes 1-5 respectively) with TS106 anti-TS 
antibody. For analysis of TS protein, cells were lysed and cytosols 
prepared by centrifugation at 10,000g. 1 OOpg of cytosol was size- 
fractionated by SDS-polyacrylamide gel electrophoresis. Proteins 
were electroblotted onto nitrocellulose membranes and incubated 
with TS106, a mouse monoclonal antibody raised against human TS, 
followed by an anti-mouse secondary antibody linked to HR P. 
Protein-antibody complexes were visualised using enhanced 
chemiluminescence.
Likewise when ranked in order of sensitivity (most sensitive to least sensitive), 
the same ranking was shown for both assays, except for HT-29 and CACO-2 where 
ICso's were very similar (Table 2.4).
To determine whether TS enzyme expression correlates with 5-FU sensitivity, 
relative protein expression (Table 2.2) was compared with 5-FU IC50S obtained using 
the MTT assay (Table 2.4). The level of TS protein expression was found to correlate 
with 5-FU sensitivity (r=0.87), Figure 2.7.
CELL
LINE
IC 5o([xM ) (Rank)
Clonogenic
Assay
Growth 
Inhibition (MTT) 
Assay
DLD-1 23(4) 30.3±12.1 (4)
BE 36(5) 30.4±3.7 (5)
H T-29 12.5 (2 ) 9.2±3.4 (1)
CACO-2 8.8 (1) 11.2±3.2 (2)
LOVO 17(3) 20.3±8.1 (3)
Table 2.4 5-FU IC50 measurements in colon cell lines, measured by the growth 
inhibition (MTT) assay and the clonogenic assay. Representative 5-FU IC50 values 
obtained from dose-response curves pictured in Figure 2.5. MTT IC50 values are means 
and standard errors of three 96-well plates, 8  wells per plate.
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Figure 2.4 TS protein expression versus population doubling time. Linear 
regression analysis (y=mx+c); TS expression = -0.3 (Doubling time) + 16.9, r=0.4.
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Figure 2.6 MTT Assay versus Clonogenic Assay. Plot of 5-FU IC50 as measured by 
the MTT assay versus the Clonogenic Assay. Linear Regression Analysis (y=mx+c); 
MTT IC50 = 0.83 (Clonogenic IC50) + 4.11, r=0.88.
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Figure 2.7 TS expression versus 5-FU IC5o. Plot of 5-FU IC50 (from MTT Assay, 
Table 2.4) versus TS protein expression (from Western blot analysis, Figure 2.3, 
Table 2.3) in colon adenocarcinoma cell lines BE, HT-29, LOVO, DLD-1 and CACO- 
2. Linear regression analysis (y=mx + c); 5-FU IC50 = 1.92 (TS expression) + 7.56, 
r=0.87.
2.4 Discussion
Five colon adenocarcinoma cell lines have been characterised for their growth 
patterns and the expression of two important enzymes responsible, in part, for the 
cytotoxicity of the pyrimidine analogue 5-FU. This study was carried out to consider the 
importance of these characteristics in relation to the intrinsic sensitivity of colon cancer 
cell lines to 5-FU.
2.4.1 Population Doubling Times
There was only a 1.7-fold range in population doubling times (29-50hrs) within 
the five cell lines. LOVO cells were the fastest growing and also the only cell line in 
which TP protein expression could be detected by Western immunoblotting. In addition, 
a 30 minute exposure of the x-ray film did result in a faint band at approximately 55kDa 
in HT-29 cells.
2.4.2 TP
No correlations could be made with respect to TP expression and other 
characteristics such as 5-FU cytotoxicity, due to the lack of detection of TP by Western 
immunoblotting (later in this study a more sensitive method for measuring TP activity 
was developed, see chapter 5).
Interestingly, TP protein was detected in DLD-1 cell lines earlier in the study, 
however it was discovered at a later mycoplasma test that the cells were mycoplasma 
positive. The presence of TP protein could be attributable to the mycoplasma infection 
itself since it is known to have high TP activity (Levine, 1972).
A narrow range in sensitivities to 5-FU was observed. Cytotoxicity measured by 
the MTT assay was, in general, in concordance with that measurable by the clonogenic 
assay method. There was no apparent relationship between 5-FU IC50 and TP protein
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expression measured by Western immunoblotting. LOVO cells, despite being the only 
cell line with detectable levels of TP protein, were not the most sensitive to 5-FU. 5-FU 
has multiple routes of anabolism to cytotoxic nucleotides. TP may not, therefore, be the 
rate-limiting step for the intrinsic sensitivity to 5-FU in this particular cell line. In cell 
lines such as CACO-2, where TP was not detected yet 5-FU sensitivity was relatively 
high, other enzymes or anabolic pathways must predominate.
TS protein was detected in all five cell lines, with a 5.9-fold range in expression. 
LOVO cells, which were the fastest growing and the only cells to have detectable levels 
of TP protein, had a high expression of TS protein in relation to the other cell lines. 
There was no correlation between TS expression and population doubling time (r=0.4).
There was a correlation (r=0.87) between TS protein expression and sensitivity 
to 5-FU. Other studies have demonstrated a similar relationship between TS protein 
levels and response to 5-FU in cell lines (Washtein 1984 and Johnston, 1992), 
experimental tumours (Spears, 1982) and in the clinical setting (Swain, 1989). Johnston 
et al demonstrated that the levels of TS enzyme measured using the same TS antibody 
(TS 106), were higher in 5-FU insensitive cell lines.
These data have been confirmed clinically where response to 5-FU-based 
therapy significantly correlates with TS protein levels and mRNA in the primary tumour 
from colorectal and gastric cancer patients (Johnston, 1995 and Lenz, 1993). Those 
colorectal and gastric patients who responded to treatment had a low mean TS protein 
level whereas those who did not respond had high TS expression. More recently, studies 
with colon and breast tumour biopsy specimens demonstrated that TS-positive colon 
specimens, from previously untreated patients showed a 30% reduction in response to 5- 
FU.
In the following chapter TP expression was measured in human tissue to determine 
whether the cell line data reflects the clinical situation. In addition, it may be that TP
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activity is more relevant than protein expression, therefore a method was developed to 
measure enzyme activity in cell lines and human tissues.
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CHAPTER 3
3. TP Protein Expression in Human Colon Tumour and 
Normal Tissue
3.1 Introduction
Thymidine phosphorylase (TP) has diverse roles within cells. These include 
maintaining steady-state levels of thymidine, which is required for DNA synthesis and 
mediating physiological and pathological angiogenesis. TP also catalyses the conversion 
of 5-FU to the active metabolite 5-FdUrd which in turn is converted to 5-FdUMP 
resulting in inhibition of the enzyme TS.
TP (originally known as PD-ECGF) was first isolated from platelets (Miyazono, 
1987) and has since been demonstrated in placenta (Usuki 1990), spleen, peripheral 
lymphocytes, lymph nodes and macrophages in liver and lung tissues (Yoshimura, 
1990).
TP has a role in cancer cell proliferation with increased expression found in 
many tumours compared to adjacent normal tissues including carcinomas of the colon, 
stomach and ovaries (Yoshimura, 1990). Elevation of TP has been demonstrated by both 
the ribonuclease protection assay (RPA) and immunohistochemistry in breast tumours 
(Fox, 1996). Increased TP protein expression is found in invasive ductal breast 
carcinoma tissue compared to normal ducts of the same carcinoma tissue and benign 
lesions including fibrocystic disease and fibroadenomas (Toi, 1995). In patients with 
gastric carcinomas who have received no chemotherapy or radiation therapy prior to 
surgery, TP is detectable in tumours but not in normal gastric mucosa (Maeda, 1996).
Studies measuring TP mRNA expression found a similar trend as that seen with 
protein expression. In ovarian cancer there is a significant elevation in TP mRNA in 
malignant tumours compared to benign tumours (Reynolds, 1994). In 45 primary
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bladder tumours and eight normal bladders evaluated by O'Brien and colleagues (1995), 
the invasive tumours had 33-fold greater TP mRNA than superficial tumours and 260- 
fold greater TP mRNA than normal bladder. TP enzymatic activity has also been 
measured in tumours and this will be discussed in more detail in chapter 5. To 
summarise some of these studies however, TP activity is higher in gastric, colorectal, 
cervical, breast and liver tumours than normal tissues (Luccioni, 1994; Miwa, 1986; 
Zimmerman and Seidenberg, 1964).
In the current chapter, human colon tumour and normal tissues were evaluated 
for TP protein expression by Western immunoblotting with the P-GF.44c monoclonal 
antibody raised against human TP protein used in chapter 2. This allowed comparison of 
human tumours with cell lines since TP protein expression was previously evaluated in 
5 human colon adenocarcinoma cell lines (section 2.3.2) and was detected in only one of 
them (LOVO). In chapter 5 TP activity is measured in human tumour cell lines and a 
different panel of 10 human colon tumour and normal tissues.
3.2 Materials and Method
3.2.1 Chemicals and reagents
See Section 2.2.3.1
3.2.2 Preparation o f tissue samples
Nine human colon tumour/normal biopsy pairs were obtained from Dr. Richard 
Lamb (Beatson Institute for Cancer Research, Glasgow). Patients had received no 
chemotherapy or radiation therapy prior to surgery. Information such as grade, size and 
malignancy was not available and therefore a correlation between TP expression and 
these factors could not be assessed.
Tissue samples were weighed and homogenised in 5w/v of lysis buffer (see 
section 2.2.3.2). Homogenates were centrifuged at 10,000g at 4°C for 20 minutes and
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supernatants were stored at -70°C until required. The protein concentration of the 
supernatant was measured using the Bio-Rad assay method outlined in section 2.2.33.
3.2.2.1 Western blotting
Western Blot analysis was carried out using the P-GF.44c antibody as described in 
section 2.2.3.4-2.2.3.5. The results were quantified by densitometric scanning.
3.3 Results
TP protein was detected in all tumour and normal colon biopsy tissues analysed. 
A representative Western immunoblot is shown in Figure 3.1. Densitometry of the 
Western immunoblots for all colon pairs is illustrated in Figure 3.2. TP protein is 
consistently higher in tumours when compared with patient matched normal colon 
mucosa (1.2- to 8.7-fold). Heterogeneity of TP protein expression was demonstrated 
with a 14.5-fold range in expression between normal colon mucosas and a 4.7-fold 
range in expression in between the tumours.
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Figure 3.1 Representative western immunoblot of 
three human colon normal/tumour (N/T) biopsy 
pairs with PGF.44c anti-TP antibody. For analysis 
of TP protein levels, biopsies were homogenised and 
cytosols were prepared by centrifugation at I00,000g. 
For analysis of TP protein levels, cells were lysed and 
cytosols prepared by centrifugation at 10,000g. lOOpg 
of cytosol was size-fractionated by SDS- 
polyacrylamide gel electrophoresis. Proteins were 
electroblotted onto nitrocellulose membranes and 
incubated with PGF.44c, a mouse monoclonal 
antibody raised against human TP, followed by an 
anti-mouse secondary antibody linked to HRP. 
Protein-antibody complexes were visualised using 
enhanced chemiluminescence.
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Figure 3.2 TP Expression in tumour/normal biopsy pairs. Plot of relative TP 
protein expression in colon normal and tumour biopsy pairs.
3.4 Discussion
TP expression is elevated in many tumour types compared to adjacent normal 
tissue. TP protein expression was measured in nine human colon tumour/normal mucosa 
biopsy pairs and was higher in all tumours tissues compared to their normal tissue 
counterparts. The current study is consistent with current literature on TP mRNA and 
activity.
Studies have correlated TP expression in tumours with other factors such as 
vascularity, response to chemotherapy and overall survival. In a study of 100 invasive 
ductal breast carcinoma tissues, TP expression correlated with microvessel density, a 
marker for angiogenesis (Toi, 1995). Fox et al also found that strong TP staining was 
prominent at the tumour periphery where angiogenesis is most active (Fox, 1996). The 
ovary is one of the few sites where physiological angiogenesis occurs and an increase in 
TP mRNA was demonstrated in sections of malignant ovarian tumours compared with 
benign ovarian tumours (Reynolds, 1994). Microvessel density was also significantly 
higher in TP positive tumours compared with TP negative gastric tumours (Maeda, 
1996). These data emphasise the involvement of TP in the process of angiogenesis 
which in turn has prognostic significance. Patients with TP positive gastric tumours are 
more likely to develop hepatic metastasis (Maeda, 1996) and have a shorter survival 
than those with TP negative tumours. Likewise, a worse prognosis was also described 
for patients with TP positive lung tumours (Koukourakis, 1997).
A study of TP expression in 91 curative resected primary colorectal carcinomas 
demonstrated that tumours where more than 5% of carcinoma cells stained positive with 
TP antibody, had an increased depth of invasion, increased number of metastatic lymph 
nodes, greater vessel invasion, more advanced Duke’s stage and higher incidence of 
recurrence. Patients with Duke’s C stage tumours which were TP-positive, demonstrated
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shorter survival time, compared with TP-negative tumours of the same stage (P<0.05). It 
would appear therefore that up-regulation of TP defines a more aggressive tumour 
phenotype.
A study of 240 primary breast carcinomas examined the relationship between TP 
protein and mRNA, and correlations between TP protein and other variables such as 
tumour grade, size and prognosis (Fox, 1996). In those women with node positive 
disease and TP-positive tumours, relapse free survival was better than in other patient 
groups thus contradicting the results obtained for lung cancer. This difference may be 
related to the different agents used in their treatment. Breast cancer is usually treated 
with fluoropyrimidine-based therapy and TP is an important activating enzyme. Lung 
cancer is rarely treated with fluoropyrimidines therefore increased TP may not provide 
any therapeutic benefit. A pilot study of 328 invasive breast carcinomas has indeed 
shown that there is a correlation between TP levels and response to treatment with 
Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF). This resulted in a 
significant survival advantage (relapse-free and overall survival) following treatment 
with CMF (Fox, 1997).
As can be seen in Figure 3.2, there is interpatient heterogeneity of expression of 
TP in the normal colon. In a recent immunohistochemical study, Fox and colleagues 
also demonstrated heterogeneous TP staining in different human tissues and also 
between adjacent cells in the same tissue (Fox, 1996). The same heterogeneity of TP 
expression was observed in tumour tissue in the current study. This is consistent with 
studies of other tumour types including breast, lung, ovarian, colorectal, gastric and 
bladder tumours (Toi, 1995; Fox, 1996; Heldin, 1993; Reynolds, 1994; Luccioni, 1994; 
Maeda, 1996; O'Brien, 1995). Intra-tumoural heterogeneity of TP expression may be 
explained by the fact that tumours include stroma, inflammatory infiltrate and 
inflammatory cells such as macrophages which have high TP expression (Fox, 1996).
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Heterogeneity between tumours may be explained by the grade or vascularity of the 
tumour. In breast cancer TP expression inversely correlates with size and grade of the 
tumour suggesting that TP plays an important role in the initial stages of angiogenesis in 
these tumours (Fox, 1996). In malignant ovarian tumours TP is expressed at a 
significantly higher level compared with benign tumours (Reynolds, 1994).
These data differ from that obtained from human tumour cell lines (section 2.3.2, 
Figure 2.2) where TP was detected in only 1 out of 5 colon tumour cell lines. Luccioni 
and colleagues evaluated various pyrimidine nucleotide metabolising enzymes for their 
relative activity in normal tissues, primary tumours and xenografts. TP activity was 
lower in xenografts than in the primary tumours from which they were derived 
(Luccioni, 1994). TP activity was also greater in tumours and xenografts than in colon 
cell lines (including HT-29 and CACO-2), which is similar to the findings described in 
section 2.3.2. One possible explanation is that there is down-regulation of TP in vitro. 
This reduction in TP activity may be due to an adaptation of the tumour cells to 
alternative growth conditions in vitro. For example, there may be an increased 
requirement for thymidine due to an increased growth rate or lower availability of 
thymidine. Another explanation is that TP protein detected in tumours could be derived 
from cells other than neoplastic cells such as macrophages or endothelial. Alternatively, 
it may be that the principle role of TP in tumours is in the process of angiogenesis, a 
process no longer required nor driven in culture.
Colon cell lines therefore, may not be representative of colon tumours when 
evaluating 5-FU cytotoxicity since TP appears to be down-regulated when tumour cells 
are introduced into culture. For the purposes of this thesis however, comparisons will be 
made between cells in which TP activity/expression has been increased by DNA 
transfection. This provides a controlled environment in which to evaluate the impact of 
TP on 5-FU activity.
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The current study has shown that colon cancer behaves in the same manner as 
gastric, ovarian and breast cancers in that the tumours express higher levels of TP 
compared with their normal tissue counterparts. Interpatient tumour TP expression is 
heterogeneous as is expression in normal colon mucosa. The current data on the 
prognostic impact of TP staining suggests a correlation between TP and response to 
CMF in breast cancer (Fox, 1997). It may be of therapeutic benefit in colon cancer 
therefore to select patients with low intra-tumoural levels of TP and use gene therapy to 
transiently increase the expression of TP. This may sensitise the tumour cells to the 
effects of fluoropyrimidines and transient gene expression may avoid the development 
of a more aggressive phenotype. This could be of significant benefit in colon cancer due 
to its inherent resistance to treatment. This hypothesis was explored in a colon tumour 
cell line and is described in the following chapters.
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CHAPTER 4
4. Characterisation of colon cells transfected with TP cDNA
4.1 Introduction
The aim of this study was to transfect colon cells in vitro with the gene encoding 
TP, confirm it's expression and assess it’s contribution to 5-FU cytotoxicity.
4.1.1 IFN-a and 5-FU
The mechanism by which the IFN-a exerts it’s effect on 5-FU cytotoxicity in
vitro has been evaluated. IFN-a treatment leads to increased cytotoxicity of 5-FU and 
some studies have demonstrated that this is at the level of TS (Elias, 1988, Schwartz, 
1992, Chu, 1990 and Houghton, 1991). In a number of studies an increase in the activity 
of TP has been observed following exposure to IFN-a (Eda, 1993, Tevaearai, 1992 and 
Schwartz, 1992). The subsequent increase in 5-FU cytotoxicity was circumvented by 
exogenous thymidine, confirming that inhibition of thymidylate synthase occurred 
(Wadler, 1990; Elias, 1988 and Houghton, 1991).
Patient studies using this combination were initially promising (Wadler, 1989) 
however many groups have been unable to repeat Wadlers work (Pazdur, 1990; 
Kemeny, 1990; Huberman, 1991; Weh, 1992 and Martoni, 1995). There was a high 
incidence of side-effects particularly leucopenia, diarrhoea, mucositis and neurotoxicity. 
The most frequent side-effect was a flu-like syndrome induced by IFN.
The current study sought to evaluate whether an increase in the expression of TP 
alone, by DNA transfection, could enhance 5-FU cytotoxicity in colon cell lines in vitro. 
The cell line chosen for these studies was HT-29, a cell line in which the effects of IFN- 
a  and 5-FU have previously been studied (Schwartz, 1992 and Tevaearai, 1992). HT-29 
cells have also been evaluated earlier in the present study and were found to have no 
detectable levels of TP protein by Western blotting. The role of TP can therefore be
57
assessed in transfected cells compared with parental cells with no or very low TP 
activity. Colon cancer was chosen as the model for these studies since it is commonly 
treated with 5-FU and other fluoropyrimidines although response rates are 
disappointing.
If transfection of colon cells (HT-29) with TP cDNA confers increased 
sensitivity to 5-FU, this will provide direct evidence of the pharmacological interaction 
between 5-FU and IFN-a. More importantly, this pathway could also be exploited 
through the application of gene therapy techniques directing tissue-specific expression 
of TP in a transient fashion, rendering cells more sensitive to fluoropyrimidines such as 
5-FU. As a consequence, the toxicity associated with the biochemical modulator IFN-a 
may be avoided.
4.1.2 DNA transfection
DNA transfection required first a decision regarding which method to use. There 
are four commonly used methods for the transfection of mammalian cells; calcium 
phosphate (Ca2P0 4 ) precipitation, DEAE-Dextran-mediated gene transfer, 
electroporation and liposomal-mediated gene transfer.
Ca2P0 4  precipitation is one of the most widely used techniques and involves the 
introduction of DNA to monolayer cultures via a precipitate which adheres to the cell 
surface. DNA is then taken up by the cells via endocytosis (Graham, 1973).
DEAE-Dextran works by a similar method to Ca2PC>4 precipitation, in that it 
forms complexes with DNA which are incubated with cells in culture. The complexes 
are thought to stick to the cell surface and as before DNA enters the cells by endocytosis 
(McCutchan, 1968 and Kawai, 1984). This is the preferred method for transient 
expression of genes and therefore is not appropriate for the study at hand which required 
stable transfection of the TP gene for subsequent characterisation.
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Electroporation involves the use of high-voltage electric shocks to introduce 
DNA into cells (Neumann, 1982). Cells are placed in suspension in an appropriate 
electroporation cuvette. DNA is added and the cells are subjected to a high voltage 
electrical pulse of defined magnitude and length. The cells are then allowed to recover 
briefly before they are placed in normal growth medium. This is the method of choice 
for suspension cultures, as cells must be transferred into cuvettes for transfection.
Liposomal-mediated transfer involves the mixing of DNA with a liposomal 
suspension comprising cationic lipids and then applying to monolayer cell cultures. 
Negatively charged phosphate groups on DNA bind to the positively charged surface of 
the liposome. The residual positive charge is thought to mediate binding to the cell 
surface (Feigner, 1987) and again DNA enters the cell by endocytosis. This method 
results in higher efficiency and greater reproducibility than other transfection methods 
and was the method of choice for the current study.
There are several commercially available liposomal preparations. One such 
product is the cationic lipid DOTAP (N-[l-(2,3-Dioleoyloxy)propyl]-N,N,N- 
trimethylammonium methylsulfate) produced by Boehringer Mannheim (Leventis and 
Silvius, 1990).
The following chapter describes the transfection of HT-29 colon carcinoma cell 
lines with TP cDNA inserted into the pcDNA-l-Neo plasmid vector and the control 
transfections with the vector alone. Subsequent assessment of the cells is described to 
determine whether increased expression of TP results in alterations in growth kinetics, 
enzyme expression and most importantly sensitivity to 5-FU.
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4.2 Materials and Methods
Firstly, stable HT-29 transfectants were evaluated for their growth kinetics to 
determine whether transfection with TP would alter the population doubling time of the 
cells. In addition, the vector alone controls were also assessed to evaluate any effect of 
transfection alone on growth kinetics.
Secondly, TP protein expression was measured to assess whether the TP 
transfected cells were expressing increased levels of TP protein compared to the 
controls. The levels of TS protein were also evaluated by Western immunoblotting. If 
TS levels were to increase following transfection this may affect 5-FU cytotoxicity and 
counteract any effects of increased TP.
Thirdly, the MTT growth inhibition assay and the clonogenic assay were used to 
determine whether increased TP conferred an increased sensitivity to 5-FU in vitro with 
24 and 72 hours drug exposure times.
Finally, in addition to measuring 5-FU cytotoxicity, inhibition of TS was also 
quantitated by Western immunoblot analysis. In general, TS inhibition is measured as 
the amount of 3H-5-FdUMP bound to TS (Moran, 1979 and Priest, 1980). Here an 
alternative method employs the TS106 monoclonal antibody raised against human TS 
in a Western immunoblotting assay which distinguishes free TS from that bound in a 
ternary complex (Drake, 1993). This allows evaluation of TS inhibition in HT-29 
transfected cells compared with the vector alone transfected cells and the parental cells.
4.2.1 Geneticin Concentration
Analysis of the role of TP requires cells that contain the TP gene in a stable 
integrated form. Less than one in every 104 cells in a transfection experiment will stably 
integrate DNA surface (Current Protocols in Molecular Biology, 1997). A dominant 
selection marker on the plasmid vector is used to isolate stable transfectants. All
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plasmid vectors used in the current study contain the Neomycin resistance gene for this 
purpose. This gene codes for the enzyme aminoglycoside phosphotransferase which 
detoxifies Neomycin and it's analogues, including Geneticin, that would otherwise 
inhibit protein synthesis in mammalian cells by interfering with ribosomal function 
leading to cell death.
Studies were carried out prior to the transfection experiments to determine the 
appropriate concentration of Geneticin to use for selection. Cells growing in the 
presence of lethal doses of Geneticin will continue to proliferate through 1-2 growth 
cycles. As a result, the effects of the drug take several days to manifest themselves 
(Southern and Berg, 1982).
4.2.1.1 Chemicals and Reagents
DMEM, sodium bicarbonate, L-glutamine, foetal calf serum, penicillin and 
streptomycin and Trypsin were obtained from Gibco BRL (Paisley, UK). Ham's F10 
medium was from SIGMA (Poole, UK), and diaminoethanetetra-acetic acid, disodium 
salt (EDTA) was obtained from Fisons Scientific Equipment (Loughborough, UK). 
Geneticin was purchased from SIGMA (Poole, UK).
4.2.1.2 Method
Cells were dissociated from routine culture flasks as described in section 2.2.1.3 
and seeded in 100mm petri-dishes at a density of 105 cells/mL in lOmLs of 10% serum- 
containing medium with a range of concentrations of Geneticin from 0.6-1.4mg/mL. 
Cells incubated in drug-free medium were used as a control. Cells were allowed to grow 
for 7 days in a humidified atmosphere (2% C 02 in air) and observed for toxicity.
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4.2.2 Transfection of HT-29 cells
4.2.2.1 Chemicals and Reagents
DOTAP Transfection Reagent, N-[l-(2,3-Dioleoyloxy) propyl]-N,N,N- 
trimethylammonium methylsulfate, was purchased from Boehringer Mannheim 
(Germany). pcDNA-I-Neo eukaryotic expression vector was purchased from R & D 
Systems (Abingdon, UK) and the pCMV-TP-Neo vector shown in Figure 4.1 was donated 
by Dr Roy Bicknell (Molecular Angiogenesis Group, University of Oxford, UK). 
Plasmid vector pHSG272, was used as a positive control for transfection and was 
supplied by Dr R. Brown (Department of Medical Oncology, University of Glasgow).
4.2.2.2 Method
HT-29 colon adenocarcinoma cells were dissociated from routine tissue culture 
flasks as described in section 2.2.I.3. Cells were seeded in 100mm petri dishes at a 
density of 105 cells/mL. After allowing cell attachment and growth to proceed for 24 
hours in a humidified atmosphere (2% CO2  in air), the cells were transfected with the
DNA vectors. Three vectors were used: pCMV-TP-Neo containing TP cDNA; pcDNA-I- 
Neo the vector alone control and pHSG272 as a positive control for transfection, which 
is known to successfully transfect cells and expresses the G418 resistance gene.
5p,g of DNA was diluted in HEPES buffer (20mM) to a final concentration of 
O.lpg/mL. In a separate sterile reaction tube, 30p,L of the DOTAP preparation was 
mixed with 7(VL of HEPES buffer (20mM). The DNA was then combined with the 
DOTAP and allowed to stand at room temperature. After 10-15 minutes, the 
DOTAP/DNA mixture was added to lOmLs of 10% serum-containing medium and the 
cells were incubated for 16 hours in a humidified atmosphere (2% CO2  in air). After
incubation the medium in the petri dishes was replaced with lOmLs of 10% medium
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containing Geneticin (lmg/mL). Cells were then incubated for up to 14 days until 
colonies started to appear. Selection medium was replenished as required.
4.2.3 Evaluation of effects of transfection
The growth kinetics, TP and TS protein expression and 5-FU sensitivity by MTT 
and clonogenic assays (sections 2.2.2.2-2.2.43) were evaluated in HT-29, HT-29(V) 
and HT-29(TP) cells to determine the effects of DNA transfection. The cells transfected 
with pHSG272 were evaluated for growth kinetics and TP expression only, since they 
were purely a control for transfection.
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4.2.4 Measurement of TS inhibition
4.2.4.1 Introduction
TS inhibition is routinely measured as the amount of 3H-5-FdUMP bound to TS 
(Moran, 1979). Here an alternative method was employed using the TS106 monoclonal 
antibody raised against human TS. This is a simple method which does not require the 
use of radioactivity. Free TS and TS bound to FDUP in a ternary complex present in cell 
lysates are separated by gel electrophoresis, the free TS having a size of 36kDa and TS 
in the ternary complex having a size of 38.5kDa. Immunoblotting with the TS106 
antibody detects both bound and free enzyme (Drake, 1993) and the ratio can be 
quantified by densitometric scanning.
4.2.4.2 Chemicals and Reagents 
See section 2.2.3.1
4.2.4.3 Treatment with 5-FU
Cells were dissociated from routine culture flasks as described in section 2.2.1.3 and 
seeded in 25cm2 tissue culture flasks at a density of 2xl05 cells/mL in 5mLs of 10% 
serum-containing medium. After allowing cell attachment and growth to proceed for 24 
hours in a humidified atmosphere (2% CO2  in air) the cells were treated with 5-FU at
IC10 and IC50 concentrations (5 and lOpM respectively) for 1 and 24 hours. Drug-free 
control flasks were also set up and lysates prepared at identical time points as described 
above.
4.2.4.4 Cell lysate preparation 
See section 23.2.2
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4.2.4.5 Electrophoresis 
See section 2.3.2.4
4.2.4.6 Immunoblotting 
See section 2.3.2.5
The ratio of bound to free TS was quantitated by densitometric scanning of the film.
4.2.5 Statistical Analysis
Analysis of Variance (the F test) was used to identify differences in the 
sensitivities of HT-29, HT-29(V) and HT-29(TP) cell lines to 5-FU. Students’ t-tests 
were used to determine the significance of the difference identified.
4.3 Results
4.3.1 Determination of G418 concentration
The concentration of the selection agent G418 used for transfection experiments 
was determined as the minimum concentration required to effect 1 0 0 % cell kill as 
determined visually by a reduction in colony numbers in 7 days and was lmg/ml.
4.3.2 Transfection using DOTAP
HT-29 cells were transfected with the vectors pcDNA-I-Neo, pCMV-TP-Neo and 
pHSG272 using the cationic liposomes DOTAP. Cells were grown in selection medium 
containing G418 (lmg/mL). A minimum of 50 surviving colonies were pooled from 
each transfection experiment.
4.3.3 Growth Kinetics
The growth kinetics of the HT-29(TP), the HT-29(V) cells and the parental cells, 
HT-29, were assessed. Growth curves are illustrated in Figure 4.2 and the population
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doubling times are shown in Table 4.1. The population doubling time was not altered in 
the HT-29(TP) cells compared with the HT-29(V) and the parental cells.
4.3.4 TP protein expression
TP protein expression was evaluated by Western immunoblot analysis, in order 
to verify that the HT-29(TP) cells express an increased level of TP protein compared to 
the controls. The Western immunoblot is shown in Figure 4.3. As described in section 
2.3.2, TP protein was not detected in the HT-29 parental cells. TP protein was also 
undetected in the vector alone controls and the cells transfected with the control vector 
pHSG272. TP protein was however detected in the cells transfected with 5pg of TP 
cDNA, and to a lesser extent in those transfected with lOpg of TP cDNA. The 
transfection experiments were therefore successful, resulting in increased expression of 
TP protein in HT-29(TP) cells.
4.3.5 TS Protein Expression
TS protein expression was evaluated in the HT-29(TP), HT-29(V) and HT-29 
parental cells by Western immunoblot analysis with the TS106 antibody. As can be seen 
in Figure 4.4 there was no change in TS protein expression in the three cell lines. 
Transfection with TP cDNA or transfection alone did not, therefore, alter the expression 
of one of the target enzymes for 5-FU.
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4•   H T-29
+----  H T-29(V )
« ----  HT-29(TP)
0 50 100 150 200
Time (Hrs)
Figure 4.2 Growth curves of HT-29, HT-29(V) and HT-29(TP) cell lines. Points are 
means and standard deviations of 3 counts carried out daily.
Cell Line Population Doubling
Time(Hrs)
HT-29 3 0
HT-29(V) 3 0
HT-29(TP) 3 0 . 5
Table 4.1 Population doubling times of HT-29 parental cells, the vector alone controls; 
HT-29(V) and the TP transfected cells; HT-29(TP)
55kDa
Figure 4.3 TP Western immunoblot using PGF.44c anti-TP antibody. 
From left to right, human recombinant TP protein (hrTP), HT-29 parental 
cells, HT-29 cells transfected with pHSG272, pcDNA-I-Neo and pCMV-TP- 
Neo (pcDNA-I-Neo containing TP cDNA) 5 and lOpg. For analysis of TP 
protein levels, cells were lysed and cytosols prepared by centrifugation at 
10,0Q0g. lOOpg of cytosol was size-fractionated by SDS-polyacrylamide gel 
elctrophoresis. Proteins were electroblotted onto nitrocellulose membranes and 
incubated with PGF.44c, a mouse monoclonal antibody raised against human 
TP, followed by an anti-mouse secondary antibody linked to HRP. Protein- 
antibody complexes were visualised using enhanced chemiluminescence (see 
secions 2.2.3.2-2.2.3.5).
36 kDa
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Figure 4.4 TS Western immunoblot using TS 106 anti-TS 
monoclonal antibody. HT-29 parental cells, HT-29 cells 
transfected with the vector alone, HT-29(V) HT-29 transfected 
with TP, HT-29(TP). Transfected cells were selected by long-term 
incubation with Geneticin. For analysis of TS protein levels, cells 
were lysed and cytosols prepared by centrifugation at 10,000g. 
lOOpg of cytosol was size-fractionated by SDS-polyacrylamide gel 
electrophoresis. Proteins were electroblotted onto nitrocellulose 
membranes and incubated with TS 106, a mouse monoclonal 
antibody raised against human TS, followed by an anti-mouse 
secondary antibody linked to HRP. Protein-antibody complexes were 
visualised using enhanced chemiluminescence.
4.3.6 5-FU Cytotoxicity
The transfected cells were assessed for their sensitivity to 5-FU using the growth 
inhibition assay and the clonogenic assay. Cells were exposed to 5-FU for 24 and 72 
hours. Representative dose response curves for both the MTT and clonogenic assays are 
shown in Figures 4.5 and 4.6 respectively. The corresponding 5-FU IC50 values are 
outlined in Table 4.2.
5-FU IC50 (m.M)
Cell Line Growth Inhibition (MTT) Assay Clonogenic Assay
24 hours 72 hours 24 hours
(n=30) (n=6) (n=3)
HT-29 9.8±5.8 3.9±0.3 17.7±8.1
HT-29(V) 14.5±2.0 3.9±0.9 20.3±19.4
HT-29 (TP) 8 .8 ±0 . 6 4.5±0.2 13.5±6.7
Table 4.2 Mean 5-FU ICso's ± standard errors (SE) determined by the Growth 
Inhibition(MTT) Assay and the Clonogenic Assay in HT-29, HT-29(V) and HT- 
29(TP) cells.
4.3.7 Statistical Analysis
There was an 8.7-fold range in 5-FU IC50 (3.3-28.8p,M) obtained for HT-29 cells as 
measured by the MTT assay (n=30) following a 24 hour exposure to 5-FU (CV=42.5%). 
A single cytotoxicity experiment involved triplicate plates for each cell line with at least
4-8 wells within each plate for each drug concentration. Analysis of Variance of the 
ICso's obtained for HT-29, HT-29(V) and HT-29(TP) demonstrated that, despite the 
apparent variability in IC50S from one week to another, none of the experiments gave 
significantly different results (F =1.184, p>0.05, n=90). In other words the difference in 
sensitivities observed was between cell lines and not between experiments, since the 
same order of sensitivity was observed from one experiment to another.
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When comparing 5-FU cytotoxicity between HT-29, HT-29(V) and HT-29(TP) 
cell lines using Analysis of Variance, a significant difference in their sensitivity was 
observed (F= 6.432, p<0.005, n=30). On further analysis HT-29(TP) cells were shown 
to be significantly more sensitive to 5-FU than the HT-29(V) cells (p<0.005, Students’ 
t-test). This is demonstrated by a 1.7-fold decrease in 5-FU IC5 0 . There was however no 
significant difference between HT-29(TP) and HT-29 cells (p>0.01, Students’ t-test). 
The results obtained from the clonogenic assay were more variable than the MTT assay 
with larger standard errors. There is, however, a trend for HT-29(TP) cells to be more 
sensitive than HT-39(V).
4.3.8 TS Inhibition
Inhibition of TS was assessed by Western immunoblot analysis of HT-29(TP), 
HT-29(V) and HT-29 cells treated with 5-FU at IC10 and IC50 concentrations for one and 
24 hours. Drug-free controls were also assessed at 1 and 24 hours. Immunoblots are 
illustrated in Figures 4.7 and 4.8, representing cells treated with 5-FU IC10 and IC50 
concentrations respectively.
As can be seen in both Figures 4.7 and 4.8 there was no ternary complex 
(38kDa) detected following 1 hour treatment with 5-FU in HT-29, HT-29(V) and HT- 
29(TP) cells (lanes 2, 6 and 10 respectively). After 24 hours in the presence of drug, an 
additional band was apparent, approximately 38kDa in size (lanes 4, 8 and 12) which 
was not present in the drug-free controls. This corresponds to TS bound in a covalent 
ternary complex with 5-FdUMP and reduced folates (Johnston, 1991). Densitometric 
scanning of these bands showed that levels of bound TS were higher in HT-29(V) and 
HT-29(TP) cells than in the HT-29 controls (Tables 4.3 and 4.4). Free TS (36kDa) 
levels were unchanged following 1 hour drug treatment compared with the drug-free 
controls for each cell line (comparing lanes 2, 6 and 10 with 1, 5 and 9 respectively).
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However, free TS was also increased after 24 hours exposure in HT-29(V) and HT- 
29(TP) cells, thus the ratio of bound to free TS was unchanged, as shown in Tables 4.3 
and 4.4.
Cell Line OD x mm
5-FU (5pM) / 24 hours
Free TS Bound TS 
(Ternary complex)
TS Ratio 
Bound: Free
HT-29 0.6 0.8 1.3
HT-29 (V) 2.2 2.6 1.2
HT-29 (TP) 1.8 3.7 1.7
Table 4.3 (OD x mm) measurements of Western immunoblot of HT-29, HT-29(V) 
and HT-29(TP) cell lines following treatment with 5uM 5-FU (Figure 4.7).
Cell Line OD x mm
5-FU (lOpM) / 24 hours
Free TS Bound TS 
(Ternary complex)
TS Ratio 
Bound: Free
HT-29 0.7 0.9 1.2
HT-29 (V) 1.5 1.8 1.2
HT-29 (TP) 1.1 1.5 1.4
Table 4.4 (OD x mm) measurements of Western immunoblot of HT-29, HT-29(V) 
and HT-29(TP) cell lines following treatment with lOuM 5-FU (Figure 4.8).
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72kDa — ►
38.5 kDa 
36 kDa
1 2  3  4  5  6  7  8  9  1 0  1 1  1 2
Cell line HT-29 HT-29(V) HT-29(TP)
5-FU - + - + + - + + - +
Duration 1 1  24 24 1 1 24 24 1 1 24 24
Figure 4.7 TS Western immunoblot of HT-29, HT-29(V) and HT- 
29(TP) cells following treatment with 5-FU (5jjM) for 1 and 24 
hours. Cells were lysed and cytosols prepared by centrifugation at 
10,000g. TS bound in a ternary complex with FdUMP and reduced 
folates was distinguished from free TS by size, 38.5 and 36kDa 
respectively. lOOpg of cytosol was size-fractionated by SDS- 
polyacrylamide gel electrophoresis. Proteins were electroblotted onto 
nitrocellulose membranes and incubated with TS 106, a mouse 
monoclonal antibody raised against human TS, followed by an anti­
mouse secondary antibody linked to HRP. Protein-antibody 
complexes were visualised using enhanced chemiluminescenc.
38.5kDa  
36kDa
Cell line HT-29 HT-29(V) HT-29(TP)
5-FU - + - + - + - + + - +
Duration 1 1 24 24 1 1 24 24 1 1 24 24
Figure 4.8 TS Western immunoblot of HT-29, HT-29(V) and HT- 
29(TP) cells following treatment with 5-FU (IOjxM) for 1 and 24 
hours. Cells were lysed and cytosols prepared by centrifugation at 
10,000g. TS bound in a ternary complex with FdUMP and reduced folates 
was distinguished from free TS by size, 38.5 and 36kDa respectively. 
lOOjag of cytosol was size-fractionated by SDS-polyacrylamide gel 
electrophoresis. Proteins were electroblotted onto nitrocellulose 
membranes and incubated with TS 106, a mouse monoclonal antibody 
raised against human TS, followed by an anti-mouse secondary antibody 
linked to HRP. Protein-antibody complexes were visualised using 
enhanced ehemiluminescence.
4.4 Discussion
The aim of this study was to transfect HT-29 human colon carcinoma cells with 
the gene encoding TP and to assess it's contribution to 5-FU cytotoxicity and potential 
gene therapies. In order to assess this effect it was first necessary to confirm that 
transfection had occurred and then to establish whether this altered the growth kinetics 
of the cells or the expression of the target enzyme.
4.4.1 DNA Transfection
Cells were successfully transfected with TP cDNA. This was confirmed by an 
increase in TP protein expression detected by Western immunoblotting. Two 
concentrations of DNA were used in the transfection experiments (5 and lOpg). The 
levels of TP protein detected in transfections using lOpg of pCMV-TP-Neo, although 
greater than the parental cells, were less than the transfections using 5pg of DNA. This 
may be related to the mechanism by which cationic liposomes carry DNA and allow it's 
entrance into the cell. The increased quantity of DNA in the lOpg transfection 
experiments may have resulted in saturation of the positive charges on the cationic 
liposomes, leaving no or few residual positive charges for binding to the negatively 
charged sialic acid residues on the cell surface (Current Protocols in Molecular Biology, 
1997). Since the 5pg transfection was more successful, these cells were used for 
subsequent experiments.
Transfection with TP had no effect on the growth characteristics of the cells and 
there was no difference in the basal levels of the target enzyme TS compared to the 
pcDNA-l-Neo transfectants and parental cells. Therefore, any changes in the sensitivity 
of the cells to 5-FU cannot be attributed to these factors.
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4.4.2 Cell Sensitivity to 5-FU
Having established an increase in TP protein expression in the HT-29(TP) cells, 
together with unaltered growth kinetics and TS levels, the potential contribution to 5-FU 
sensitivity was assessed using MTT and clonogenic cytotoxicity assays. There was a 
striking 8.7-fold variation in 5-FU ICso's obtained for HT-29 cells alone after multiple 
experiments (range 3.3-28.8pM, CV=42.5%) when measured by the MTT assay 
following a 24 hour exposure to 5-FU. Each cytotoxicity experiment involved triplicate 
plates with at least 4 wells within each plate for each drug concentration. It may be that 
the variability is due to factors such as pipetting, culture media and drug concentration. 
For example, new drug stock was weighed and dissolved in PBS for each experiment. 
Drug solutions were then filter sterilised and non-specific binding to the filters may have 
varied from one experiment to another. For the purposes of this study, however, it is of 
more value to consider the relative difference in 5-FU IC50 between cell lines within 
each experiment.
In comparing 5-FU cytotoxicity (using a 24 hour exposure time) between cell 
lines using the MTT assay, there is a small increase (1.6-fold) in the sensitivity of HT- 
29(TP) cells to 5-FU compared to the vector only controls. Although this increase is 
small there is a significant difference (p<0.001, Students’ t-test) in the mean IC50S 
between these cell lines following 24 hour treatment. There is however no difference in 
5-FU IC50 between the parental and HT-29(TP) cells (p>0.1, Students’ t-test). The 
clonogenic assay confirmed that there was no difference between the parental cells and 
the HT-29(TP) line. It was not possible to confirm the increased sensitivity of the HT- 
29(TP) cells compared to the HT-29(V) cells using the clonogenic assay since there was 
a larger variation in the ICso’s obtained for the HT-29(V) cells.
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It would appear, therefore, that the presence of the TP gene does increase the 
sensitivity of the cells to 5-FU. The presence of the vector alone appears to have resulted 
in increased resistance to 5-FU following 24-hour treatment and this cannot be 
attributed to altered basal levels of TS. The further inclusion of the gene encoding TP 
may have resulted in sensitisation of the cells to a similar level as that of the parental 
cells. It is important to note that both HT-29(V) and HT-29(TP) cell lines are pools of 
transfected cells and therefore the apparent differences in 5-FU sensitivity are not due to 
clonal variations.
4.4.3 TS Inhibition
Resistance to 5-FU can be attributed to increased levels of TS (Berger, 1987 and 
Clark, 1987) and this may mask the effects of any increase in TP activity. In contrast, 
decreased TS levels may exaggerate any effects caused by increased TP activity. Indeed, 
the present study has shown that TS protein expression does correlate with 5-FU IC50 in 
a number of colon cell lines (Figure 2.7). In the current study, however, transfection of 
TP did not lead to altered basal levels of TS or growth kinetics (Figures 4.4 and 4.2 
respectively). Therefore, any change in sensitivity of the transfected cells to 5-FU could 
not be explained by either of these factors.
Inhibition of the target enzyme TS was investigated in the HT-29, HT-29(V) and 
HT-29(TP) cells following treatment with 5 and lOpM 5-FU. There was no measurable 
change in the level of TS inhibition in the 3 cell lines. Basal levels of TS increased with 
time in culture from 1 to 24 hours in all cells analysed. This is due to cell proliferation 
and an increased requirement for DNA synthesis (Heidelberger, 1975, Conrad and 
Ruddle, 1972 and Pestalozzi, 1995).
5-FU treatment resulted in an increase in total TS levels following exposure to 5 
and lOpM 5-FU in all cell lines compared with drug-free controls. This is thought to be
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a protective mechanism of cells in response to cytotoxic stress, especially from agents 
which bind to TS and result in changes in the metabolite pools, most significantly the 
depletion of thymidylate (Pestalozzi, 1995 and Washtein, 1983). Interestingly, total TS 
protein levels (bound and free) were higher in both the HT-29(V) and HT-29(TP) cells 
compared to the parental cells following exposure to 5-FU for 24 hours. The reason for 
this is unclear. It does however, confirm that transfection alone has resulted in 
biochemical alterations in cells as seen with the cytotoxicity studies where HT-29(V) 
cells were more resistant to 5-FU compared to the parental cells. As a result of the effect 
of time and 5-FU treatment on TS, interaction between drug and target enzyme is best 
evaluated by studying the free/bound drug ratio.
There was no measurable change in the ratio of bound to free TS in the 3 cell 
lines, however the increase in sensitivity of the HT-29(TP) cells compared to the HT- 
29(V) was small (1.6-fold) and it may be that this small difference could not be detected 
by Western blot analysis.
Although it is clear that TS inhibition is occurring in these cells, it is not 
apparent whether this is the principle mechanism of action of 5-FU. It may be that 
incorporation into RNA or DNA is also important. Spears and colleagues reported that 
tumour sensitivity in murine tumour models is associated with complete inhibition of 
TS activity (Spears, 1982). This was not achieved in the current study at the time points 
analysed, which may suggest that TS inhibition is not the principle mechanism of action. 
However, further experiments with a wider range of time-points would be required to 
draw any conclusions as to the role of TS inhibition.
In summary, this study has demonstrated that HT-29 colon cancer cell lines can 
be transfected with TP without altering growth kinetics or basal expression of TS. HT- 
29(TP) cells were more sensitive to 5-FU than the vector alone controls suggesting that 
TP plays a role in 5-FU cytotoxicity. There was however no difference in sensitivity of
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TP transfected and parental cells nor any evidence of altered TS inhibition. The effect of 
TP on sensitivity to 5-FU may, therefore, be mediated by mechanisms other than TS.
4.4.4 Increased TP activity in other cell lines
Other groups have sought to determine the role of an increase in TP activity in 
colon and other tumour cell lines using DNA transfection techniques. The first study 
was carried out by Haraguchi et al who transfected human KB epidermal carcinoma 
cells with TP resulting in a clone with high TP activity (KPE-3) compared to the 
parental cells (KB) which have no endogenous TP activity (Haraguchi, 1993). There 
was no significant difference in the sensitivity of the KPE-3 cells to 5-FU compared to 
the parental cells. The effects of 5-FU were not reversed by thymidine, indicating that 
TS inhibition is not the principle mechanism of action of 5-FU in these cells and 
therefore these cells were not a good model for this investigation. KPE-3 cells were 
however more sensitive to the 5-FU pro-drugs 5'-DFUR (19-fold) and Tegafur (2.3-fold) 
than 5-FU. Despite this, overall growth inhibition was no greater with 5'-DFUR than 
with 5-FU alone (IC50 13.3±2.8 and 7.0±1.0 respectively). Increased TP activity had 
therefore resulted only in an increased capacity of the cells to convert 5'-DFUR to 5-FU.
In another study, MCF-7 breast adenocarcinoma cells with low basal levels of 
TP activity were transfected with TP (Patterson, 1995). Two clones were subsequently 
characterised, one with 100-fold increased TP activity (TP4) and the other with a 7-fold 
increase (TP7). There was no difference in the sensitivity of TP4 or TP7 cells to 5-FU 
compared to the MCF-7 parental cells. Exogenously added thymidine did not reverse 5'- 
DFUR cytotoxicity in the parental MCF-7 cells suggesting that in this cell line 5-FU 
cytotoxicity is not TS related. Cytotoxicity was partially reversed by thymidine in the 
clone with 100-fold increased TP activity suggesting the emergence of a minor role for 
TS inhibition in the cells. Increased TP activity enhanced the sensitivity of TP4 and TP7
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cells to 5 ’-D F U R  compared with the controls (ICso's 0.104, 7.1 and 17.33pM 
respectively). However, with a 4-fold increase in TP in the TP4 clone, these cells were 
still less sensitive to 5 ’-D F U R  than 5-FU . Only when TP was increased 100-fold (TP7 
cells) was 5'-D FU R more cytotoxic than 5-F U  (ICso's of 1.44±0.96pM and 7.1±1.7pM 
for 5'-D FU R  and 5-F U  respectively). Again increased TP activity had resulted only in an 
increased capacity of the cells to convert 5'-D FU R  to 5-FU  and had no effect on 5-FU  
cytotoxicity itself.
Transfection of PC-9 lung adenocarcinoma cells with TP resulted in cells with 
50-fold greater TP activity (PC9-DPE2) compared with vector alone controls and 
parental cells (Kato, 1997). PC-9-DPE2 cells were 8-fold more sensitive to 5-FU than 
controls. They were also more sensitive to the 5-FU pro-drugs Tegafur and 5'-DFUR 
(26- and 167-fold decrease in IC50 respectively). Reversal of TS inhibition with 
thymidine was not investigated nor were the levels of 5-FU nucleotide anabolites or 
incorporation into RNA or DNA. It is therefore not possible to postulate the mechanism 
of action of 5-FU in these cells.
These experiments cast doubt on the importance of TP in relation to 5-FU 
cytotoxicity. The best evidence for a role of TP in 5-FU cytotoxicity came from 
Schwartz et al who demonstrated that IFN-a enhanced the cytotoxicity of 5-FU through 
an increase in TP activity, in HT-29 cells (Schwartz, 1992). Transfection studies with 
TP cDNA resulted in 5 clones with 1.8- to 5.4-fold greater TP activity than the parental 
cells which were characterised for their relative sensitivity to the fluoropyrimidine 5-FU 
(Schwartz, 1995). All clones demonstrated greater sensitivity to 5-FU than the parental 
cells, ranging from a 2- to 5-fold decrease in 5-FU IC50  in four clones and a 19-fold 
decrease in IC50  was observed in the clone with a 5.4-fold greater TP activity.
In these experiments by Schwartz et al there was a significant correlation (r=0.9)
between the relative increase in TP activity and the relative decrease in 5-F U  IC5 0 . There
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was also an associated increase in 5-FdUMP levels in the transfected cells following 5- 
FU exposure. Schwartz et al compared the results from the IFN-a studies with that of 
the DNA transfection studies and found that in both cases increased TP activity 
correlated with increased levels of 5-FdUMP and most importantly increased sensitivity 
to 5-FU. TS activity decreased following transfection compared with the parental cells. 
This reduction in target enzyme activity may have contributed in part to the increase in 
sensitivity to 5-FU.
The present study used the same DNA construct and HT-29 colon 
adenocarcinoma cells as that used by Schwartz et al. The impact of increased TP 
expression on 5-FU cytotoxicity differed however between the two studies. The IC50 of 
5-FU in Schwartz’s HT-29 cells was 2.53±0.74pM following treatment with 5-FU for 
seven days compared with 9.9±5.8p,M and 3.9±0.3pM for cells treated with 5-FU for 24 
and 72 hours in the current study. It is not possible to compare 5-FU cytotoxicity in 
Schwartz’s HT-29 cells and the cells used in the present study since drug exposure times 
were different. There are however several differences in the methods employed by 
Schwartz compared with the present study. Schwartz dosed cells for 7 days in the same 
drug/medium solution. By contrast in the current study, cells were dosed with 5-FU for 
either 24 hours followed by 72 hours of daily replenishment of medium or 72 hours with 
daily dosing of drug and a similar recovery period.
Another factor which might explain, in part, the difference in results is the
methods employed for measuring 5-FU cytotoxicity. The cytotoxicity assay used by
Schwartz and colleagues measured total protein concentration by Sulforhodamine B
(SRB) staining of cells treated with 5-FU compared with untreated cells to determine
growth inhibition. It does not distinguish between living and dead cells or proliferating
and non-proliferating cells. The methods used in the present study evaluated alternative
functions of the cell as a measure of cytotoxicity. The MTT assay is similar to the SRB
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assay but can distinguish between living and dead cells. The clonogenic assay measures 
the ability of individual cells to proliferate after drug exposure. In addition, drug 
treatment in the SRB assay differed from the MTT assay used as described above. 
Although these differences may lead to differences in ICso's, the relative sensitivity 
between transfected and parental cells should be consistent if increased TP expression 
did confer greater sensitivity to 5-FU. Therefore these differences remain unexplained.
4.4.5 Summary
There is considerable variation in the effects of TP transfection on 5-FU 
sensitivity in different cell lines. It is worth noting that in those studies in which no 
increase in sensitivity to 5-FU was reported there was no reversal of 5-FU cytotoxicity 
by thymidine in the parental cells. This suggests that TS inhibition is not the principle 
mechanism of action of 5-FU in these cells and increasing TP activity has no impact. 
These cells may utilise other routes of 5-FU cytotoxicity. For example Kufe and 
colleagues showed that RNA toxicity is the principle mechanism of action of 5-FU in 
MCF-7 cells (Kufe, 1981). By contrast, Schwartz et al showed that TP transfection did 
confer sensitivity to 5-FU in a cell line where TS expression was reduced (Schwartz, 
1995). Schwartz and colleagues demonstrated that TS inhibition was an important 
mechanism of cytotoxicity for HT-29 cells, illustrated by an increased inhibition 
following transfection with TP. Kato and colleagues demonstrated increased 5-FU 
sensitivity in TP transfected cells but reversal by thymidine was not investigated 
therefore no comment can be made regarding the principle mechanism of cytotoxicity 
(Kato, 1997).
In the present study, TS inhibition has been observed, however it's contribution 
to the overall cytotoxicity of 5-FU is not certain. If screening of cell lines for thymidine-
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mediated reversal of 5-FU cytotoxicity had been included in the characterisation of cell 
lines, selection of a more relevant model to test the hypothesis may have been ensured.
This study has demonstrated an increase in TP protein expression and 5-FU 
cytotoxicity in HT-29 colon carcinoma cells transfected with TP cDNA compared to 
vector alone controls. No change in 5-FU cytotoxicity was observed between HT-29 and 
HT-29(TP) cells however. This increase in TP expression did appear to contribute to 5- 
FU sensitivity when measured using the growth inhibition (MTT) assay, following 24 
hour drug exposure. No difference was observed following 72-hour treatment. There 
was little change in the ratio of TS bound in a ternary complex to free TS enzyme 
between HT-29, HT-29(V) and HT-29(TP) cells as measured by Western 
immunoblotting following treatment of cells with IQo and IC50 concentrations of 5-FU.
It may be that there are other rate-limiting factors which when addressed may 
result in a greater increase in sensitivity of the HT-29(TP) cells to 5-FU. For example, 
reduced folate concentrations may be limiting TS activity/inhibition. This will be 
addressed in Chapter 6 along with other potentially rate-limiting factors such as 
deoxyribose-1-phosphate (the co-substrate for TP). The ability of thymidine to rescue 
HT-29(TP) cells from 5-FU will also be assessed in this chapter to assess whether the 
inhibition of TS is important for 5-FU cytotoxicity in HT-29 cells. Finally, despite an 
increase in TP protein expression, in the transfected cells an increase in TP activity must 
be confirmed. This is discussed in the next chapter.
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CHAPTER 5
5. TP Activity Assay
5.1 Introduction
Having established increased TP protein expression in the HT-29(TP) cells 
which resulted in a small increase in 5-FU cytotoxicity compared with the vector alone 
controls, the primary purpose of this study was to ensure that the observed increase in 
TP protein reflected an increase in enzyme activity. An enzyme assay was therefore 
developed to measure the activity of thymidine phosphorylase (TP) in vitro. This assay 
was subsequently used to place TP activity in HT-29 cells in context with other colon 
carcinoma cell lines and also cell lines derived from other tumour types. Enzyme 
activity in cell lines was then compared to that of normal colon mucosal tissue and 
colon tumours.
TP catalyses the reversible phosphorolysis of thymidine, deoxyuridine and it's 
analogues to their respective bases and deoxyribose-1-phosphate, Reaction 1 below 
(Zimmerman and Seidenberg, 1964; Krenitsky, 1967; 1981 and Schwartz, 1971). TP 
also catalyses a deoxyribosyl transfer from one deoxynucleotide to another base to form 
a second deoxynucleotide, Reaction 2 below (Zimmerman, 1964; Zimmerman and 
Seidenberg, 1964; Gallo, 1967 and Krenitsky, 1967)
Reaction 1: Thymidine + Phosphatej ^  * Thymine + dR-l-P
Reaction 2: Thymine* + Thymidine Thymidine* + Thymine
Many currently used methods for the measurement of TP activity utilise the 
former reaction i.e., thymidine to thymine (Schwartz, 1971 and Iltzsch, 1985). For the 
purposes of this study however, a method has been developed to measure the reverse of 
this reaction and uses 5-FU in place of thymine as the substrate. TP catalyses the 
conversion of 5-FU to 5-FdUrd and this reaction is the focus of the study.
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Two enzyme assay methods have been previously described: a
spectrophotometric method and a thin layer chromatography (TLC) method. The 
spectrophotometric assay is a modification of the method developed by Friedkin and 
Roberts (1953) and has been used in a number of studies (Moghaddam, 1992; Heldin, 
1993; Miyadera, 1995; Patterson, 1995; Sumizawa, 1993; Haraguchi, 1993 and 
Yoshimura, 1990). This assay is based on the difference in molar extinction co­
efficients between thymidine and thymine at alkaline pH. Thymidine is incubated with 
enzyme preparation (e.g. purified enzyme or crude cell lysate) and tris buffer, pH 7.5 at 
37°C. The formation of thymine can then be measured at 300nm on a 
spectrophotometer. One measurement is made at a fixed time point of 90 minutes 
(Friedkin and Roberts, 1953) or at 16 hours (Patterson, 1995). This assay appears not to 
be fully validated. In few studies has the linearity of the assay with respect to time, 
protein or substrate concentration been evaluated. In addition, contaminating substances 
in crude enzyme preparations interfere with this assay, making it difficult to determine 
TP's activity. An improvement in the assay is observed after purification of the enzyme.
The second method is based on both thin-layer chromatography and radiometric 
analysis. This method was developed by Gan (1981) and was developed further by 
Yoshimura and colleagues (1990) and involves the use of [14C]-labelled thymidine or 
thymine. This assay has been used in a number of studies (Kouni, 1993; Kato, 1997 and 
Miwa, 1986). TP activity can be assayed either by the conversion of [14C]-thymidine to 
[14C]-thymine or vice versa. Incubations contain substrate (radiolabeled thymine or 
thymidine), buffer, enzyme preparation/cell lysate and sodium phosphate or 2- 
deoxyribose-l-phosphate respectively depending on the substrate used. After 15-45 
minutes the reaction is terminated by boiling and samples are spotted onto 
chromatography paper or plates and developed by ascending chromatography. Bands 
corresponding to thymidine and thymine are detected using an ultra-violet (UV) lamp
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and cut out of the chromatography paper or scraped off the plates and the radioactivity is 
quantified using a scintillation counter. This assay is linear with respect to time and 
protein concentration (Gan, 1981). The main disadvantage is the limitation of the 
number of samples which can be analysed at one time, due to the capacity of the 
chromatography equipment.
As a result of the disadvantages of currently available methods described above, 
a new sensitive assay for the measurement of TP activity was developed which allows 
the processing of multiple samples simultaneously. This method exploits the ability of 
TP to convert 5-FU to 5-FdUrd in the presence of dR-l-P, which is more appropriate for 
the purposes of the current study than the conversion of thymine to thymidine. It was 
based on a combination of two methods. Firstly, Peters (1986) describes methods for 
measuring the activity of enzymes capable of catalysing 5-FU metabolism. Enzyme 
activities were measured in extracts prepared from freshly isolated cells or from cell 
pellets frozen at -70°C and enzymes were selected by the inclusion of the relevant co­
substrate into the assay mixture. Substrates were then separated from products by TLC. 
The second method is a solid-phase extraction (SPE) method used for the purification of
5-FU and it’s anabolites, followed by HPLC analysis. This method was originally 
developed by R. Blackie, Department of Medical Oncology, University of Glasgow for 
the purification and quantitation of 5-FU and 5-FdUrd from human plasma for 
pharmacokinetic analysis.
A new assay was designed whereby cell extracts were incubated with 5-FU in 
the presence of the co-substrate dR-l-P. Samples were processed via the solid-phase 
extraction method (to remove interfering substances present in cell extracts) and 
substrate and product were detected using the HPLC method described by R. Blackie.
The following chapter describes the enzyme assay method in detail and the 
validation steps taken to ensure optimal conditions of TP activity evaluation. Linearity
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with time, protein and substrate concentration was ensured when measuring TP activity 
in cell lines with both high and low enzyme activities. The assay was subsequently used 
to measure TP activity in HT-29(TP) cells and other colon tumour cell lines. TP activity 
in colon cell lines was then compared with cell lines derived from other tumour types. 
Finally TP activity in cell lines was compared with that of human colon mucosal tissue 
and colon tumours.
5.2 Materials and Methods
5.2.1 Chemicals and reagents
Diaminoethanetetra-acetic acid disodium salt (EDTA), isopropanol, acetone, 
methanol, potassium hydroxide were purchased from Fisons (Loughborough, UK). 5- 
FU, Iodouracil, 5-FdUrd and bovine albumin were purchased from SIGMA (Poole, 
UK). Deoxyribose-1-phosphate (dR-l-P) was obtained from Fluka Chemicals (Dorset, 
UK). Potassium dihydrogen orthophosphate (KH2PO4), tetrabutylammonium phosphate 
and sucrose were obtained from BDH laboratory supplies (Poole, UK). Bio-Rad protein 
dye was purchased from Bio-Rad Laboratories GmbH (Hertfordshire, UK) Isolute NH2 
(aminopropyl) cartridges were purchased from International Sorbent Technology Ltd. 
(Mid Glamorgan, UK).
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5.3 Cell Lines
The following cell lines were chosen to reflect a broad range of tumour types
within which to assess the activity of TP.
CELL
LINE
CHARACTERSITICS SOURCE REFERENCE
MCF-7 Metastatic breast 
carcinoma
ATCC 
(HTB 22)
Soule, 1973
ZR-75 Breast carcinoma 
(malignant ascitic effusion)
ATCC
(CRL-1500)
Engel, 1978
W IL NSCLC Ludwig Institute, Sri-
(Bronchial) Sutton, UK Pathmanathan,
1994
A549 NSCLC ATCC 
(CCL 185)
Giard, 1973
H125 NSCLC NCI,
USA
Gazdar, 1980 
Carney, 1985
LDAN NSCLC Jane Plumb, 
University of Glasgow
Not published
CALU-1 NSCLC 
(Metastasis to pleura)
ATCC
(HTB-54)
Fogh, 1975
SKMES NSCLC 
(Pleural effusion)
ATCC
(HTB-73)
Fogh, 1975
OVCAR Ovarian
Adenocarcinoma
ATCC 
HTB 161
Hamilton, 1983
OVIP Ovarian
Adenocarcinoma
Jane Plumb 
University of Glasgow
Bernard, 1985
POV Ovarian Jane Plumb 
University of Glasgow
Not published
A2780 Ovarian Fox Chase Cancer 
Centre, Philadelphia
Eva, 1982
A375 Human malignant 
melanoma
ECACC 
CRL 1619
Giard, 1973
C32 Human metastatic 
melanoma
ATCC Chen, 1978
HS852T Melanoma 
Primary tumour
Dept, of Dermatology, 
Uni. Of Glasgow
Creasey, 1979
C8161 Melanoma 
(Abdominal wall metastasis)
Dept, of Dermatology, 
Uni. Of Glasgow
Welch, 1991
HS294T Melanoma 
(Lymph node metastasis)
ATCC 
HTB 140
Creasey, 1979
G361 Malignant Melanoma ATCC 
(CRL 1424)
Peebles, 1978
Table 5.1 Table outlining sources and characteristics of cell lines.
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5.4 Methods
5.4.1 Preparation of cell pellets
Cells were dissociated from routine culture flasks as described in section 22.13 . 
After dilution in 8mLs of 10% serum-containing medium the cell suspension was 
centrifuged at lOOOg for 5 minutes at 4°C. The cell pellet was washed three times in ice- 
cold phosphate-buffered saline (PBS). The final pellet was snap frozen and stored at - 
70°C until required.
5.4.2 Preparation of cell extracts
TP activity was measured in .extracts prepared from cells frozen at -70°C. 
Extracts were prepared by suspending the cell pellet in 200pL of 50mM Tris-HCl buffer 
containing ImM EDTA (pH 7.4). The suspension was sonicated for 3 cycles of 5 
seconds at maximal output with intervals of 10 seconds (during sonication the sample 
tube was cooled on ice). A 10,000xg supernatant (30 minutes, 4°C) was prepared and 
used as the source of enzyme. Protein concentration was determined by the Bio-Rad 
protein assay (section 2.2.33).
5.4.3 Enzyme assay conditions
The incubation consisted of 2.5mM dR-l-P, 0.5mM 5-FU, 2mg/mL of cell lysate 
and 50mM Tris-HCl, ImM EDTA (pH 7.4). The assay was performed at 37°C in a 
water bath. dR-l-P, cell lysate and buffer were combined and pre-incubated at 37°C for 
5 minutes and the reaction was started by the addition of the substrate, 5-FU. 50|iL 
samples were removed at 15 minute intervals up to 1 hour and added to 200pJL of 
isopropanol and 50pL of internal standard (Iodouracil, 50pg/mL) on ice. The samples 
were vortex mixed for 5 seconds. The isopropanol samples were centrifuged at 550g for 
15 minutes at 4°C, the supernatants transferred to glass centrifuge tubes and evaporated
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to dryness in a Haake-Bucchler vortex evaporator for approximately 20 minutes. The 
resultant residues were reconstituted in lOOpL of 0.1M KH2P 0 4, pH 5.5 and vortex 
mixed twice for 10 seconds to ensure that all the material was in suspension. To this 
suspension was added 400pL of ice-cold acetone, followed by a vortex mix for 10 
seconds. Samples were transferred to clean eppendorfs and centrifuged at 550g for 5 
minutes at 4°C.
5.4.4 Solid-phase extraction method
Isolute NH2 (aminopropyl) cartridges were conditioned with 1 mL of acetone 
and the supernatants were loaded onto the cartridges and the eluent collected. This was 
followed by a wash step with 2 mLs of methanol. Eluates were evaporated to dryness in 
the Haake-Bucchler vortex evaporator for 25-30 minutes. The final residue was 
reconstituted in 200pL of mobile-phase and 150 pL were injected onto the HPLC 
column, section 5.4.5.
5.4.5 HPLC method
The HPLC system consisted of a Waters WISP auto-sampler, Waters 600E 
pump, Waters 600E controller and Waters Photodiode array detector. Two 5mM 
Spherisorb (ODS-1) HPLC columns were used in series (150 X 4.6 mm followed by 250 
X 4.6 mm (Crawford Scientific/Jones Chromatography).
The mobile-phase consisted of 0.02M KH 2PO 4 and 10'4M tetrabutylammonium 
phosphate, pH 5.5 with 2M potassium hydroxide (K O H ). The mobile-phase was 
pumped at a flow-rate of lmL/minute and the detection wavelength was 270nm. The 
run-time was 30 minutes and the approximate retention times of the compounds of 
interest are as follows: 5-FU 8 minutes, 5-FdUrd 16 minutes and 5-IU 19 minutes 
(internal standard) Figure 5.1.
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5-FU 270nm
_ CNCL
5-FdUrd
5-IU
Time (min)
Figure 5.1 Representative HPLC chromatogram showing 5-
Fluorouracil (5-FU), 5-Fluorodeoxyuridine (5-FdUrd) and 5- 
Iodouracil (5-IU), retention times 8, 16 and 19 minutes respectively.
O 
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5.4.6 Method Validation
5.4.6.1 Standard Curves
A range of standard samples of the analytes 5-FU and 5FdUrd were evaluated 
(0.05 to lOpg/mL) to define the standard curves. Analytes were serially diluted in 
mobile phase and 50pL injected onto the HPLC column. A plot of peak area versus 
concentration was created.
5.4.6.2 Accuracy
The accuracy and precision with which known concentrations of analyte could 
be determined was demonstrated by extraction of replicate sets of analyte samples of 
known concentration ranging from 0.156 to 5p,g/mL. The analytes were combined with 
2mg/mL of cellular protein and Iodouracil (50jig/mL). Replicates were extracted using 
the procedure outlined in section 5.4.4 and analysed by HPLC, section 5.4.5. 
Efficiencies were calculated as the percentage of the peak area of unextracted analyte. 
Where internal standard was included in the calculation, the ratio of the peak area of 
unextracted to extracted internal standard from each sample was used to correct for 5- 
FU and 5-FdUrd in each sample.
5.4.6.3 Co-efficients o f Variation
Within- and between-day accuracy was calculated by analysis of TP activity in 
replicate LOVO cell pellets. Three pellets were analysed on the same day and 3 on 
separate days. Incubations containing dR-l-P (2.5mM), 5-FU (0.5mM), cell lysate 
(2mg/mL) and Tris-HCl (50mM), EDTA (ImM), pH 7.4 were assayed as described in 
sections 5.4.2-5.4.5.
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5A.6.4 Linearity with cellular protein concentration
Fixed concentrations of substrate (0.25mM) and co-substrate (25mM) were 
incubated at 37°C with a range of cellular protein concentrations (0.5-5mg/mL). Both 
LOVO and HT-29 cells were evaluated since they represent high and low TP enzyme 
expression respectively, Figure 2.2. As before, 50pL samples were removed at 15- 
minute intervals up to 1 hour and processed as described in section 5.4.4-5.4.5. A graph 
was plotted of nmoles FdUrd/min versus cellular protein concentration.
5.4.6.5 Linearity with substrate concentration
Fixed concentrations of cellular protein (2mg/mL) and co-substrate (2.5mM) 
were incubated at 37°C with increasing concentrations of 5-FU (0.13-lmM). As before, 
50pL samples were removed at 15-minute intervals up to 1 hour and processed as 
described in section 5.4.4-5.4.5. A graph was plotted of nmoles FdUrd/min versus 
substrate concentration. HT-29 and LOVO cells were evaluated.
5.4.6.6 Linearity with time
A fixed concentration of cellular protein (2mg/mL), co-substrate (2.5mM) and 
substrate (0.25mM) were incubated at 37°C. As before, 50pL samples were removed at 
15 minute intervals up to 1 hour and processed as described in 5.4.4-5.4.5. A graph was 
plotted of nmoles FdUrd/min versus time. HT-29 and LOVO cells were evaluated.
5.4.7 TP Activity in HT-29 cells transfected with TP cDNA and LOVO cells
HT-29, HT-29(V), HT-29(TP) and LOVO cells were evaluated for TP activity. 
Cell pellets were processed as described in section 5.4.2 and TP activity was measured 
under conditions of dR-l-P (2.5mM), 5-FU (0.5mM) and cellular protein (2mg/mL) 
over a time period of 60 minutes (section 5.4.3). Samples were processed as outlined in 
sections 5.4.4-5.4.5. Activity measurements were carried out in triplicate.
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5.4.8 TP activity in colon, breast, lung, ovarian and melanoma tumour cell lines.
The cell lines outlined in Table 5.1 were evaluated for TP activity as above. 
Activity measurements were carried out in triplicate with individual cell pellets 
(sections 5A3-5.4.5).
5.4.9 5-FU cytotoxicity in Lung, Breast and Ovarian Cell Lines
5-FU cytotoxicity was measured in lung cell lines including WIL, A549, H125, 
LDAN and SKMES, the breast cell line MCF-7 and the ovarian cell line A2780. 
Cytotoxicity was quantified using the growth inhibition (MTT) assay as described in 
section 2.2.4.2. with a 24 hour drug exposure time. The relationship between 5-FU IC50 
values and TP activity was investigated.
5.4.10 TP activity in colon normal/tumour biopsy tissue
Nine pairs of human normal colon and tumour tissues were evaluated for TP 
activity. Tissues were homogenised in 3mLs of 0.05M Tris/HCl, 0.25M sucrose, pH 7.5. 
Cytosolic fractions were prepared by centrifugation of tissue homogenates at 100,000g 
for 1 hour at 4°C. Supernatants were aliquoted and frozen at -70°C until required. 
Protein concentration was determined using the Bio-Rad assay outlined in section 
2.2.3.3. TP activity was measured under conditions of 5-FU (0.25mM), dR-l-P (2.5mM) 
and cellular protein (0.25mg/mL). Initial evaluation of tissue samples using 2mg/mL 
protein concentration resulted in complete loss of substrate by 15 minutes and therefore 
the protein concentration was adjusted to 0.25mg/mL and the time course reduced to 28 
minutes with 7 minute interval sampling. Samples were processed as described in 
section 5.4.4-5.4.5.
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5.5 Results
5.5.1 Standard Curves
The standard curves for 5-FU and 5-FdUrd are shown in Figure 5.2. These 
curves represent the mean and standard deviation of three separate sets of data. Linearity 
was achieved between 0.05 and lOpg/mL with a limit of detection of 50ng/mL for each 
agent. These values lie well within the parameters of the assay with the range evaluated 
being equivalent to 0.0025-0.5mM for 5-FU and 0.0013-0.27mM for 5-FdUrd. Figure 
5.3 illustrates representative HPLC chromatograms of low (50ng/mL) and high 
(5pg/mL) concentrations for both agents with 50ng/mL being the limit of detection of 
the assay for both agents.
5.5.2 Accuracy
The accuracy with which the extraction procedure (section 5.4.4) purifies 5-FU 
and 5-FdUrd from cell lysate incubation mixtures is shown in Table 5.2. The extraction 
efficiencies for 5-FU are higher than 5-FdUrd at most concentrations evaluated. As can 
be seen efficiency is poorer at concentrations above 2.5mM. This may be due to 
saturation of the extraction columns used to purify the drug from the incubation mixture 
(section 5.4.4). This was resolved by the inclusion of the internal standard. Correction 
for the internal standard resulted in extraction efficiencies greater than 77% at all 
concentrations analysed (Figure 5.4). Mean extraction efficiencies are 71.5 and 60% for 
5-FU and 5-FdUrd respectively and 95.8 and 86.6 respectively when the internal 
standard is included.
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Figure 5.3 Representative chromatograms of 5-FU and 5-FdUrd 
at high and low concentrations. 5-FU and 5-FdUrd were serially 
diluted in HPLC mobile phase to a range of concentrations and 
150|ils was injected onto the HPLC column under the conditions 
described in section 5.4.5. Chromatograms representing 50ng/ml and 
5pg/ml for each drug are illustrated.
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[Drug] (mM) % Extraction Efficiency
5-FU
- Internal Standard +
5-Fdl 
- Internal Si
Jrd
tandard +
0.156 84.9±18.2 116.215.4 53.2110.7 91.116.6
0.3125 77.2±3.2 108.2113.1 60.514.1 88.515.1
0.625 71.1±6.7 92.413.4 58.211.7 95.614.4
1.25 72.9±7.2 85.6+0 67.817.6 77.410
2.5 71.9±0 85.610 68.2+0 84.1115.2
3.75 62.9±12.7 93.719.7 59.5112.2 85.818.7
5.0 59.5113.2 89.210 54.5112.0 83.910
Mean
Extraction
Efficiency
71.5±7.8 95.8±10.9 60.3 ±5.4 86.6±5.4
Table 5.2 Extraction efficiencies for a range of concentrations of 5-FU and 
5FdUrd when combined with cellular protein. Efficiencies were calculated with and 
without inclusion of the internal standard, Iodouracil. Values represent means of 
replicate samples.
5.5.3 Co-efficients o f Variation
The intra- and inter-assay co-efficients of variation for the measurement of TP 
activity in LOVO cells were 10.98% and 23.6% respectively. These measurements were 
taken over 3 days.
5.5.4 Linearity with Cellular Protein Concentration
Increasing concentrations of cellular protein were incubated with a fixed 
concentration of substrate and co-factor and FdUrd formation was quantified by HPLC. 
TP activity increased with protein concentration in a linear fashion in cell lines with low 
and high enzyme activities (r=0.96 and 0.99 for HT-29 and LOVO cells respectively), 
Figure 5.5. Values are means and standard deviations of three individual experiments.
103
2 0 -
15-
1 0 -
a
0.5
♦
HT-29
LOVO
[Protein] (mg/mi)
Figure 5.5 Linearity of TP activity with cellular protein concentration in HT-29 
and LOVO cells. Fixed concentrations of 5-FU (0.5mM) and co-substrate (2.5mM) 
were incubated at 37°C with increasing concentrations of cellular protein, samples 
were removed at 15 minute intervals, extracted and injected onto the HPLC column 
as described in section 5.4.6.4. pmoles of FdUrd produced per minute was plotted 
against protein concentration. TP activity was linear with respect to protein 
concentration up to 2.5mg/ml in HT-29 and LOVO cell lines, (correlation co­
efficients 0.96 and 0.99 respectively).
5.5.5 Linearity with Substrate Concentration
Increasing concentrations of substrate were incubated with a fixed concentration 
of cellular protein and co-factor. LOVO cells were evaluated and TP activity was shown 
to increase with substrate concentration in a linear fashion in cells from 0.13-0.25mM 
however concentrations higher than this appeared to result in saturation of the enzyme 
Figure 5.6. Values are means and standard deviations of three independent experiments.
5.5.6 Linearity with Time
A fixed concentration of substrate (0.5mM), cellular protein (2mg/mL) and co­
factor (2.5mM) were incubated at 37°C and TP activity was measured over one hour in 
HT-29 and LOVO cells. As can be seen in Figure 5.7 the formation of 5-FdUrd is linear 
with respect to time over one hour with a correlation co-efficient (r) of 0.99 for both 
LOVO and HT-29. An incubation time of greater than one hour was not evaluated. 
Since TP activity can be measured in HT-29 (with the lowest measurable activity) over 
this time period a longer incubation would only prolong the time taken to complete the 
assay.
5.5.7 TP Activity in Cell Lines
5.5.7.1 TP activity in Transfected HT-29 cells
Following validation of the enzyme activity assay, TP activity was measured in 
HT-29(TP), HT-29(V) and the parental cells. Activity was also measured in LOVO 
cells. As can be seen in Figure 5.8, TP activity was unchanged in HT-29(V) cells 
compared with HT-29 parental cells with activity of 2.0 pmoles FdUrd formed per 
minute per mg of cellular protein (pmoles/min/mg). HT-29(TP) had approximately 5- 
fold higher TP activity (10.0 pmoles/min/mg) than the controls and LOVO cells had 
approximately a further 2.5-fold increase in activity (25.0 pmoles/min/mg).
105
5.5.7.2 TP Activity in a Range of Tumour Cell lines
TP activity was measured in a range of tumour cell lines including colon (HT- 
29, DLD-1, CACO-2, BE and LOVO) breast,(MCF-7, ZR-75) lung,(WIL, A549, H125, 
LDAN, CALU and SKMES) ovarian (OVCAR, OVIP, POV and A2780) and melanoma 
cells (A375, C32, HS853T, C8161, HS294 and G361), see Table 5.3. As seen in Figure
5.9, within each tumour type (with the exception of ovarian) there is a wide range in TP 
activity with the majority of cell lines having low activity.
5.5.8 5-FU Cytotoxicity in Cell Lines
5-FU cytotoxicity was investigated in a number of cell lines from various tumour 
sources using the MTT assay and representative dose-response curves are illustrated in 
Figure 5.10. The respective 5-FU IC50 values are outlined in Table 5.3. There was 
approximately a 70-fold range in IC50 values obtained, ranging from 1.1 to 75.2pM.
The relationship between 5-FU cytotoxicity and TP activity was investigated by 
plotting 5-FU IC50 versus TP activity. There appeared to be no relationship between 
these two parameters (r=1.28) as shown in Figure 5.11. Two groups of cell lines emerge 
in Figure 5.11. One group with high TP activity the other with low activity, however 
within these two groups there is heterogeneity within the range of 5-FU IC50 values.
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Figure 5.6 Linearity of TP activity with substrate concentration in LOVO cells.
Fixed concentrations of cellular protein (2mg/ml) and co-substrate (2.5mM) were 
incubated with increasing concentrations of 5-FU. Samples were removed at 15 minute 
intervals, extracted and injected onto the HPLC column as described in sections 5.4.3-
5.4.5. TP activity was linear with substrate concentration up to 0.125mM (see inset plot, 
linear regression analysis, TP Activity = 0.06 (Substrate concentration), r=1.0)
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Figure 5.7 Linearity with time. Graph of FdUrd formation with respect to 
time in LOVO cells (r=1.0). 2mg/mL of LOVO cellular protein, 2.5mM 
dR-l-P, 0.5mM 5-FU were incubated at 37°C. Samples were removed at 15 
minute intervals and 5-FdUrd product quantitated. Measurements were 
carried out in triplicate.
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Figure 5.8 TP activity in HT-29 cells transfected with TP compared with the 
parental cells, HT-29, the vector alone controls, HT-29(V) and LOVO cells as a 
positive control. 2mg/mL of cellular protein was incubated with 2.5mM dR-l-P and
0.5mM 5-FU at 37°C. Samples were removed at 15 minute intervals and 5-FdUrd poduct 
was quantified by HPLC. Values are representative of a single experiment. TP activity 
was 2.0, 2.0, 10.2, and 25.0 pmoles/min/mg of protein respectively.
CELL LINE TP ACTIVITY 
(pmoles/min/mg protein)
Colon
HT-29 2.0
HT-29(V) 2.0
DLD-1 2.0
CACO-2 2.7±1.2
BE 3.4±1.2
HT-29(TP) 10.2±3.5
LOVO 25.0±2.4
Breast
MCF-7 7.4±3.8
ZR-75 24.9±9.3
Lung
WIL 0
A549 4.1±0
H125 4.6±0.8
LDAN 4.7±3.1
CALU 7.4±1.2
SKMES 25.7±6.5
Ovary
OVCAR 0
OVIP 1.1±0.7
POV574 44.6±6.7
A2780 3.25±2.1
Melanoma
A375 0.7±0.2
C32 3.3±1.3
HS852T 3.6±0.1
C8161 4.5±1.3
G361 30.7±8.3
Table 5.3 TP activity in colon, breast, lung, ovarian and melanoma cell lines.
Enzyme activity was measured in cell lysate preparations as described in sections 5.4.3-
5.4.5.
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Figure 5.10 Dose response curves of 5-FU cytotoxicity in a range of tumour ceil lines.
Cell lines included five lung lines (A549, H I25, LDAN, SKMES and WIL) and one 
breast, (MCF-7) and one ovarian cell line, (A2780). Cytotoxicity was measured by the 
MTT assay as described in section 2.2.4.2. Values are means ± standard errors of three 
plates, 8 wells per plate. 5-FU IC5o's are outlined in Table 5.3.
Cell Line A549 H125 LDAN SKMES WIL MCF-7 A2780
5-FU
IC 50
31.3
±3.3
38.9
±11.4
48.8
±20.2
75.2
±11.3
10.1
±1.0
1.1
±0.72
3.16
±0.60
Table 5.3 Table of 5-FU IC 5 0  values in tum our cell lines. 5-FU cytotoxicity was 
measured using the MTT assay and dose response curves are outlined in Figure 5.10. 
Values are means and standard deviations of 3 plates.
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Figure 5.11 G raph of TP enzyme activity (nmoles/min/mg protein) versus 5-FU 
IC 5 0 . 12 cell lines were evaluated for a relationship between TP enzyme activity and 
sensitivity to 5-FU; HT-29, DLD-1, CACO-2, BE, LOVO (colon), MCF-7 (breast), 
A2780 (ovarian), SKMES, H I25, LDAN, WIL, and A549 (lung). TP activity was 
measured as described in section 5.4 and 5-FU cytotoxicity was determined using the 
growth inhibition (MTT) assay (section 2.2.4.2). Values are means and standard 
deviations of three determinations of both 5-FU IC50 and TP activity.
5.5.9 TP Activity in Colon Tumour/Normal Biopsy pairs
TP activity was also measured in nine pairs of human colon tumour and normal 
biopsy pairs. In seven out of the nine pairs tested, TP activity was greater in the tumour 
compared to the normal tissue, Figure 5.12. In one pair (no. 7) TP activity was much 
greater in the normal than the tumour. These tissues are from a different source than 
those analysed in chapter 3, Figure 3.2, however the results are very similar. Details
concerning the tumour location and stage of disease are outlined in the table below.
Patient
No.
TP Activity 
(nmoles/min/mg 
protein) 
Normal/Tumour
Tumour
site
Size State of 
Differentiation
Duke's
Stage
1 243.7 206.3 cdlon 5x4 moderate B
2 229.1 757.1 caecum 7x5 moderate C
3 130.0 783.1 caecum 11x7 well B
4 207.9 800.9 caecum 7x5 moderate B
5 316 713.2 sigmoid
colon
5x1.5 well B
6 440 809.1 sigmoid
colon
2x2 moderate A
7 804.2 259.1 ascending
colon
4x3 moderate A
8 229.9 395.6 rectum 8x8 moderate C
9 192.5 260.8 sigmoid
colon
4x4 moderate D
Table 5.4 Patient details for each of the colon tumour/normal biopsy pairs 
analysed. Samples were obtained from Dr Howard L. McLeod of the Department of 
Medicine and Therapeutics at the University of Aberdeen. TP activity was measured in 
both normal colon and tumour tissue and the results are illustrated in Figure 5.12.
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Figure 5.12 Graph of relative TP activity (pmoles/min/mg protein) 
in normal and tum our tissue from 9 biopsy pairs, each represented 
by a single line. Activity measurements were made as described in 
section 5.4, with cellular protein (0.25mg/mL), 5-FU (0.5mM), dR-l-P 
(2.5mM) and 50inM tris-HCl, ImM EDTA. The time course of the 
assay was reduced to 28 minutes, (normally 60 minutes for cell line 
activity measurements). Values are from a single representative 
experiments. Satisfactory repeat measurements were made.
5.6 Discussion
A novel assay was developed for the measurement of TP enzyme activity in 
tumour cell lines. The main purpose of the assay was to determine whether the increase 
in TP protein expression observed in HT-29(TP) cells (Figure 4.3) reflected an increase 
in enzyme activity.
The present method involved assessing the ability of TP to catalyse the 
conversion of 5-FU to 5-FdUrd in the presence of the co-substrate, dR-l-P. Other 
methods used thymine and thymidine as substrates (Gan, 1981 and Freidkin and 
Roberts, 1953) however since 5-FU cytotoxicity is the focus of the present study it was 
thought to be a more appropriate substrate.
TP extracted from tumour cells, catalysed the conversion of 5-FU to 5-FdUrd in 
a linear fashion over one hour allowing a rate of reaction to be measured. No other 
metabolites such as 5-FdUMP were detected by HPLC when compared against 
standards. TP did not appear to catalyse the reverse reaction i.e., the phosphorolysis of 
5-FdUrd to 5-FU, since there was no decrease in the amount of 5-FdUrd after its 
formation throughout the time course analysed. There was no 5-FdUrd formed when 
dR-l-P was absent from the reaction. There was also no spontaneous conversion of 5- 
FU to 5-FdUrd when the enzyme source was absent. Conversion of 5-FU to 5-FdUrd 
was dependent upon enzyme and co-factor.
The activity assay was linear with respect to cellular protein concentration, 
substrate concentration and time when measuring activity in cell lines with both low 
(HT-29) and high (LOVO) activity. Parental HT-29 cells have the lowest measurable TP 
activity.
The intra- and inter-assay variability was 10.98% and 23.6% respectively. The 
summary report of the conference on "Analytical Methods Validation: Bioavailability,
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Bioequivalence and Pharmacokinetic Studies" in 1992 stated that the co-efficient of 
variation should not exceed 15% (Shah, 1992). Using this as a guideline, it would 
therefore appear that the intra-assay variability of the assay is acceptable. The presence 
of the internal standard ensures low variability. Inter-assay variability was, however, 
higher than the normally accepted level (23%).
This assay was more sensitive than immunoblotting. TP protein could not be 
detected in four out of five colon cell lines evaluated (Figure 2.2) however TP activity 
was measured in all five cell lines. Within the wider range of cell lines TP activity was 
undetected in only 2 out of 24 cell lines.
A larger number of samples can be assessed using the present method compared 
to the TLC/radiochemical method described by Gan (1981). Up to 12 cell lines can be 
evaluated in one day using this method, however this does depend on the capacity of the 
equipment necessary to process samples, e.g. vortex evaporator capacity.
The presence of the internal standard Iodouracil proved invaluable. During each 
experiment it is possible to have variable solid-phase extraction efficiencies between 
cell lines (since only two cell lines can be extracted simultaneously) or to lose a fraction 
of the sample due to spillage or breakage of tubes. The inclusion of the internal standard 
resulted in final extraction efficiencies of greater than and 95.8 and 86.6% for 5-FU and 
5-FdUrd respectively (Table 5.2).
This validated and sensitive assay confirmed that HT-29(TP) cells expressed an 
increase in TP protein expression, which was 5-fold greater than controls. Both HT- 
29(V) and HT-29 cells had similar TP activity. The 5-fold increase in activity lead to a 
1.6-fold increase in 5-FU sensitivity. LOVO cells had a further 2.5-fold increase in TP 
activity, which was also observed by Western immunoblotting.
Having shown that transfection could increase TP activity in HT-29 cells, 
enzyme activity was measured in a further 19 cell lines in order to determine how HT-
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29 cells compared with other colon cell lines and also cell lines derived from other 
tumour types. This assay was therefore used for the measurement of TP activity in 24 
cell lines from various tumour types including colon, breast, ovarian, lung and 
melanoma tumours. Activity was heterogeneous within each group of cell lines, Figure
5.9. There was no prominent tumour type, which contained cell lines with high TP 
activity compared with other tumours.
TP activity does appear to reflect TP protein expression in colon cell lines. TP 
protein was not detected in BE, HT-29, CACO-2 and DLD-1 and these cell lines had 
very low TP activity. On the other hand, TP activity was high in LOVO cells in which 
TP protein was easily detected by Western immunoblotting. TP activity correlates with 
protein and mRNA expression in lung cell lines (Heldin, 1993). TP activity was also 
found to be heterogeneous, with a 192-fold range in activities using the 
spectrophotometric method.
The second question addressed was whether increased TP activity measured 
using this sensitive assay correlates with cytotoxicity. TP activity did not correlate with 
sensitivity to 5-FU in colon, lung, breast and ovarian cell lines (r=0.28). For example, in 
the lung cell lines, WIL has no measurable TP activity however this cell line was the 
most sensitive lung cell line to the effects of 5-FU. As can be seen in Figure 5.11 there 
are two distinct groups of cell lines; those with low TP activity and those with high TP 
activity. Within each group there was similar variability in 5-FU IC50, thus confirming 
that TP activity alone does not determine sensitivity to 5-FU and gives some explanation 
as to why a 5-fold increase in TP activity resulted in only a 1.6-fold decrease in 5-FU 
IC50 in HT-29(TP) compared with HT-29(V)cells. Studies in patients with colorectal 
tumours have demonstrated that tumours with the highest TP expression were non­
responders to 5-FU and LCV treatment (Metzger, 1998). Of the patients who responded, 
a broad range of activities was observed.
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In chapter 3 TP protein expression was measured by Western immunoblotting of 
tumour and normal colon pairs from a different source than those used in the present 
study. TP protein expression was elevated in all tumour tissues compared with their 
normal counterparts and this is consistent with other studies as discussed in that chapter. 
In the present study TP activity was measured in another set of tumour and normal colon 
pairs and a similar pattern emerged. In seven out of nine pairs, TP activity was greater in 
the tumour compared with the normal tissue, with a range of 1.35- to 6.02-fold 
elevation. In one of the remaining pairs TP activity was unchanged. In another pair TP 
activity was 3.1-fold greater in the normal tissue compared with the tumour. The general 
trend was however the same for TP activity compared with protein expression for colon 
tumours, i.e, there is an elevation in tumour versus normal tissue. In the study carried 
out by Luccioni et al (1994) TP activity was also elevated in human colon tumour tissue 
compared with normal tissue with a mean increase in activity of 2.3-fold (ranging from
2.1 to 2.9-fold). An elevation in the activity of other enzymes involved in the pyrimidine 
nucleotide pathway such as thymidylate synthase, thymidine kinase, uridine kinase and 
uridine phosphorylase was also found (Luccioni, 1994).
This study has demonstrated that TP protein levels and TP activity are reduced in 
cell lines compared to tumours and therefore many of the tumours from which the cell 
lines were derived may have had higher TP activity which was down-regulated when 
cell lines were established. This brings into question therefore the suitability of colon 
cell lines as models of colon tumours.
5.6.1 Summary
A sensitive enzyme assay has been developed for measuring TP activity (in 
catalysing the formation of 5-FdUrd from 5-FU) which allows the evaluation of up to 12 
cell lines in one day. This assay was used to assess TP activity in HT-29(TP) cells. TP
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activity was shown to be elevated 5-fold when compared with HT-29(V) and HT-29 
thus confirming the success of the transfection experiments. It was also used to measure 
TP activity in a range of tumour cell lines. TP activity was heterogeneous across the 
range of tumour types analysed. TP activity was greatly reduced in cell lines compared 
to tumour tissue and normal colon. As seen with TP protein expression in human colon 
tumour and normal biopsy pairs, section 3.3, Figure 3.2, there is a consistent pattern of 
elevation of TP activity in tumours and this confirms current biochemical data. Most 
importantly, TP activity alone did not determine the sensitivity of the cell lines to 5-FU.
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CHAPTER 6
6. Exploring Potential Rate-limiting Factors in the Activation 
of 5-FU to 5-FdUMP
6.1 Introduction
The human colon carcinoma cell line HT-29(TP) created from HT-29 cells has 
increased TP expression and activity, unaltered growth kinetics and TS expression 
compared with the parental and vector alone control cells. The purpose of creating this 
cell line was to determine the role of increased TP expression on cellular sensitivity to 
5-FU.
HT-29(TP) cells were 1.6-fold more sensitive to 5-FU compared to the vector 
alone control cells, HT-29(V) when assessed using the MTT assays. There was no 
difference in 5-FU cytotoxicity between HT-29(TP) and HT-29 cells. There was no 
notable increase in TS inhibition in HT-29(TP) cells compared with HT-29 and HT- 
29(V) cells when quantitated as the ratio of bound to free enzyme (Figures 4.7 and 4.8). 
The aim of this chapter was to investigate the potential for enhancing this small increase 
in sensitivity to 5-FU in the HT-29(TP) cells. There are a number of factors which 
contribute to 5-FU cytotoxicity, in particular in the direct anabolism of 5-FU to 5- 
FdUMP and subsequent TS inhibition (see Figurel.l). Modulation of these factors was 
evaluated using the MTT assay.
6.1.1 Deoxyribose-1 -Phosphate
TP catalyses the direct deoxyribosyl transfer reaction converting thymine/5-FU 
to thymidine/5-FdUrd in the presence of the co-substrate deoxyribose-1-phosphate (dR- 
l-P). Sub-optimal intracellular concentrations of dR-l-P and deoxyribose donors (e.g. 
thymidine) are thought to limit the activity of TP despite it's increased expression in 
tumours (Breitman, 1964 and Gallo, 1967). Deoxyinosine treatment results in an
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increase in TS inhibition mouse and human sarcoma cell lines (Evans, 1981). This was 
demonstrated in vitro by Schwartz and colleagues who found only a 3-fold increase in 
thymine incorporation in cells in which there was a 12-fold increase in TP enzyme 
activity (Schwartz, 1994). EFN-a treatment caused a 1.8-fold potentiation of 5-FU 
cytotoxicity and the addition of the deoxyribose donor 5-propynyloxy-2’-deoxyuridine 
(PO-Urd) resulted in an overall potentiation of 25-fold. PO-Urd increased thymine 
incorporation, reduced 5-FU IC50 and enhanced TS inhibition. The possibility, therefore, 
that the concentration of the co-substrate for TP, dR-l-P is rate-limiting in HT-29(TP) 
cells was investigated.
6.1.2 Dialysed Serum
The extent to which 5-FU is phosphorylated to 5-FdUrd depends, in part, on the 
concentration of intracellular pyrimidines which compete with 5-FU for the active site 
on TP. Foetal bovine serum, used in the medium for routine culture of cell lines, 
contains low levels of pyrimidines Therefore the possibility that this may be masking 
any increase in TP activity in HT-29(TP) cells was investigated. 5-FU cytotoxicity was 
therefore measured in HT-29, HT-29(V) and HT-29(TP) cells using the MTT assay with 
dialysed serum-containing medium throughout the assay procedure. The sequence of 
dialysed followed by normal serum was also investigated where dialysed serum was 
present in the medium when cells were seeded into 96-well plates and during treatment 
with 5-FU, then during the recovery period following drug treatment, normal serum- 
containing medium was re-introduced. This allowed investigation of the possibility that 
pyrimidines in the medium could reverse TS inhibition following 5-FU treatment.
6.1.3 Leucovorin
TS enzyme catalyses the methylation of dUMP to dTMP and 5,10-CH2THF is 
the essential methyl donor in this reaction (Figure 1.3). High levels of reduced folates
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are necessary for optimal binding between 5-FdUMP and TS. They are also required for 
the stabilisation of the ternary complex and this is a critical determinant of sensitivity to 
5-FU.
Polyglutamated folates are more potent in stabilising TS inhibition than the 
monoglutamated forms. Folates with 3 or 6 glutamate residues are 18- and 200-fold 
more effective, respectively, in stabilisation of the ternary complex than the 
monoglutamated form (Radparvar, 1989; Yin, 1982; Evans, 1981, Moran and Scanlon,
1991). Prolonged exposure is, therefore, necessary to permit accumulation of the more 
potent polyglutamates (Houghton, 1990; Boarman, 1992).
LCV is the exogenous precursor of 5,10-CH2THF. LCV is transported into the 
cell via the reduced folate carrier and subsequently metabolised to other folate 
intermediates which can be polyglutamated, enabling long retention of these reduced 
folates including 5,10-CH2THF in the cell. LCV increases the cytotoxicity of 5-FU in 
vitro (Yin, 1982, Keyomarsi, 1986, Houghton, 1991 and Drake, 1995) in a concentration 
and time-dependent manner. The results of several pre-clinical studies suggest that LCV 
be administered prior to or concurrently with 5-FU to permit metabolism to 
polyglutamates (Nadal, 1988 and 1989).
The apparent limited increase in sensitivity of HT-29(TP) cells to 5-FU 
compared to HT-29(V) cells, may therefore be attributed to sub-optimal concentrations 
of reduced folates necessary for stabilisation and retention of the ternary complex 
formed between TS and 5-FdUMP. Cells were pre-treated with LCV (lOpM) for 24 
hours after which time they were treated with increasing concentrations of 5-FU. A 
delay between LCV and 5-FU was also investigated to allow for folate polyglutamation. 
A 6 hour delay was chosen as a result of TS inhibition studies in MCF-7 and NCI H630 
cells (Drake, 1995). In these studies maximum TS inhibition was achieved when an 
interval of 4 and 18 hours was introduced between 5-FU and LCV treatments.
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6.1.4 Thymidine
TS inhibition has been demonstrated in HT-29, HT-29(V) and HT-29(TP) cells 
by immunoblotting studies (Figures 4.7 and 4.8). Approximately 50% TS inhibition was 
demonstrated at 5-FU ICio and IC50 concentrations, but its contribution to overall 
cytotoxicity was not been assessed. The question of whether TS inhibition is having a 
growth-limiting effect or there are other mechanisms of action responsible for 5-FU 
effect in HT-29 cells remains unresolved.
Exogenous thymidine can have a number of effects on 5-FU cytotoxicity, by 
acting at several sites along its anabolic and catabolic pathways. Firstly, thymidine can 
reverse 5-FU cytotoxicity by releasing cells from dTTP depletion due to TS inhibition 
(Umeda and Heidelberger, 1968). 20 pM thymidine reversed the growth inhibitory 
effects of 5-FU on H630 human adenocarcinoma cells (Chu, 1990). Cell growth was 
restored to 80% of control levels when thymidine was combined with 5-FU and IFN, a 
combination which produced 38% inhibition in the absence of thymidine. Elias and 
Crissman also demonstrated that thymidine blocked the enhanced TS inhibition caused 
by synergy between IFN and 5-FU resulting in an 8-fold increase in 5-FU IC50 (Elias & 
Crissman, 1988).
Secondly, thymidine facilitates increased incorporation of 5-FU into RNA 
resulting in enhanced cytotoxicity (Speigelman, 1980; Kufe and Egan, 1981; Martin, 
1978; 1980, Akazawa, 1986). The mechanism is thought to be competition for TP, thus 
controlling the relative incorporation into RNA and DNA (Figure 1.1). Thirdly, 
thymidine can also be converted to dTTP which acts as a feedback inhibitor of 
ribonucleotide reductase suppressing the production of FdUTP and also competing with 
FdUTP for DNA polymerase (Akayawa, 1986). Fourthly, thymine produced from 
catabolism of thymidine, may compete with 5-FU for DPD the first enzyme in the
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catabolism pathway of 5-FU, resulting in an extension of the half-life of 5-FU. Finally 
as mentioned earlier thymidine can act as a donor of the deoxyribose moiety required for 
TP activity and subsequent 5-FdUMP formation.
Studies were carried out to assess the effects of thymidine on 5-FU cytotoxicity 
in HT-29, HT-29(V) and HT-29(TP) cells. Cells were treated concurrently with 5-FU 
and thymidine (10 and lOOpM). In a separate experiment, cells were treated with 5-FU 
alone and thymidine was introduced into the medium in the recovery period. The aim of 
these experiments was to establish whether TS inhibition was contributing to 5-FU 
cytotoxicity (illustrated by a reversal of 5-FU toxicity) or whether other mechanisms of 
action such as RNA toxicity predominate (illustrated by an augmentation of 5-FU 
effect).
6.2 Materials and Methods
6.2.1 Chemicals and reagents
See section 2.4.2.1. Deoxyinosine was purchased from Aldrich (Poole, UK). Dialysed 
serum, Leucovorin (Folinic acid) and Thymidine were purchased from SIGMA (Poole, 
UK).
6.2.2 Deoxyinosine
6.2.2.1 Method
The MTT assay was used to assess 5-FU cytotoxicity as described in section
2.4.2.2. Cells were treated with 5-FU (2.5x10'7-5x l05M) simultaneously with 
deoxyinosine (150 or 300 (nM). In all experiments one half of each 96 well plate was 
treated with 5-FU alone under normal conditions as a control. Following drug treatment 
cells were allowed to recover for 72 hours (section 2.4.2.2) and assessed for growth 
inhibition.
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6.2.3 Dialysed serum
6.2.3.1 Method
The MTT assay was used to assess 5-FU cytotoxicity as described in section
2.4.2.2. Four experiments were carried out to assess the effects of pyrimidines in the 
growth medium during the growth inhibition assay. Cells were seeded in 96-well -plates 
(500 cells/well) treated with increasing concentrations of 5-FU (2.5xl0'7 to 5xlO"5M), 
and then allowed to recover for 3 days, all in the presence of dialysed serum containing 
medium. Alternatively, cells were seeded and treated with 5-FU in dialysed serum 
containing medium but allowed to recover in normal serum containing medium. In 
addition, the effects of 24 and 72 hour 5-FU exposure were assessed.
6.2.4 Leucovorin
6.2.4.1 Method
The MTT assay was used to assess 5-FU cytotoxicity as described in section
2.4.2.2. Two experiments were carried out to assess the effects of Leucovorin pre­
treatment. In both experiments, cells were pre-treated with LCV (lOpM) for 24 hours. In 
the first experiment, following LCV pre-treatment, cells were subsequently treated with 
5-FU (2.5x10'7-5x10 5M). In the second experiment, cells were incubated in drug-free 
medium for 6 hours prior to 5-FU treatment. In both cases, one half of each 96 well 
plate was treated with 5-FU alone under normal conditions as a control. Following drug 
treatment, cells were allowed to recover for 72 hours in drug-free medium (section 
2.4.2.2) and assessed for growth inhibition.
6.2.5 Thymidine
6.2.5.1 Method
The MTT assay was used to assess 5-FU cytotoxicity as described in section
2.4.2.2. Four experiments were carried out to assess the effects of thymidine on 5-FU
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cytotoxicity. Cells were treated with 5-FU and thymidine (10 or lOOpM) simultaneously 
for 24 hours. Alternatively, cells were treated with 5-FU for 24 hours followed by 
thymidine (10 or lOOpM) for 72 hours. In all experiments one half of each 96 well plate 
was treated with 5-FU alone under normal conditions as a control.
6.3 Results
6.3.1 Deoxyinosine
5-FU cytotoxicity was evaluated in HT-29, HT-29(V) and HT-29(TP) cells in the 
presence of the deoxyribose donor, deoxyinosine. There was no increase in 5-FU 
cytotoxicity in HT-29, HT-29(V) and HT-29(TP) cells treated in the presence of either 
150 or 300pM deoxyinosine (Figure 6.1 and Table 6.1). Deoxyinosine increased the 
resistance of the cells to 5-FU as seen by an increase in 5-FU IC50 compared with 5-FU 
alone. In particular, there was a statistically significant increase in 5-FU IC50 when HT- 
29(TP) cells were treated with 150 and 300p,M deoxyinosine compared with 5-FU alone 
(p<0.01, Students’ t-test).
Cell Line 5-FU Deoxyinosine Deoxyinosine
Alone (150piM) (300pM)
HT-29 20.2±7.5 33.1±13.6 17.9±0.6
n=3 n=3 n=3
HT-29 (V) 9.6±2.5 14.3±10.9 24.8±10
n=3 n=3 n=3
HT-29 (TP) 8.7±1.0 13.9±2.0 19.117.6
n=3 n=3 n=3
Table 6.1 Effect of Deoxyinosine on 5-FU cytotoxicity in HT-29, HT-29(V) and 
HT-29(TP) cells HT-29 cells. Growth inhibition was evaluated using the MTT Assay. 
Cells were seeded in 96-well plates and treated with increasing concentrations of 5-FU 
and a fixed concentration of Deoxyinosine (150 or 300^M) for 24 hours. Within each 
96-well plate, one half was treated with 5-FU alone, no LCV pre-treatment, as a control.
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6.3.2 Dialysed serum
5-FU cytotoxicity under conditions of dialysed serum-containing medium was 
evaluated by the MTT assay. Twenty-four and 72-hour drug exposure times were 
assessed. Dose-response curves are illustrated in Figures 6.2 and 6.3 for dialysed serum 
and dialysed serum followed by normal serum respectively. Associated 5-FU ICso's are 
outlined in Tables 5.2 and 5.3.
There was no increase in 5-FU cytotoxicity in HT-29, HT-29(V) or HT-29(TP) 
cells in the presence of dialysed serum containing medium compared with normal serum 
containing medium. The presence of dialysed serum containing medium appears to 
increase the resistance of the cells to 5-FU (24 and 72 hour exposures). For example, 
there was a statistically significant increase in 5-FU IC50 in HT-29, HT-29(V) and HT- 
29(TP) cells when dialysed serum was present following 72 hour drug treatment 
(p<0.001, Students’ t-test, Table 6.2). When dialysed serum was present in medium 
during drug treatment only, a similar trend of increased resistance to 5-FU was observed 
(Table 6.3).
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Cell Line
5-FU IC50 GiM)
24 hours 72 hours
5-FU Dialysed 5-FU Dialysed
Alone serum Alone serum
HT-29 18.9±1.4 29.4±2.2 3.9±0.5 7.0±0.3
n=3 n=3 n=3 n=3
HT-29 (V) 21.4±2.4 35.7±4.0 3.9±1.6 6.5±0.4
n=3 n=3 n=3 n=3
HT-29 (TP) 21.3±2.3 26.9±2.1 4.5±0.4 6.5±0.3
n=3 n=3 n=3 n=3
Table 6.2 Effect of dialysed serum, present throughout the MTT assay, on 5-FU 
cytotoxicity in HT-29, HT-29 (V) and HT-29 (TP) cells. Growth inhibition was 
measured using the MTT Assay. Dialysed serum present throughout assay. ICso's are 
means and standard errors of 3 plates, 8 wells per plate for each concentration of 5-FU.
Cell Line
5-FU IC50 (mM)
24 hours 72 hours
5-FU Dialysed/Normal 5-FU Dialysed/Normal
Alone serum Alone serum
HT-29 18.9±1.4 21.8±4.3 3.9±0.5 4.6±0.4
n=3 n=3 n=3 n=3
HT-29(V) 21.4±2.4 37.6±5.2 3.9±1.6 6.5±0.6
n=3 n=3 n=3 n=3
HT-29 (TP) 21.3±2.3 24.1±0.2 4.5±0.4 5.2±0.3
n=3 n=3 n=3 n=3
Table 6.3 Effect of dialysed serum followed by normal serum containing medium, 
during an MTT assay, on 5-FU cytotoxicity in HT-29, HT-29(V) and HT-29(TP) 
cells. Growth inhibition was measured using the MTT Assay. Dialysed serum was 
present during seeding of cells and 5-FU treatment. During recovery period normal 
serum-containing medium was used. ICso's are means and standard errors of 3 plates, 8 
wells per plate for each concentration of 5-FU.
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6.3.3 Leucovorin
Pre-treatment of HT-29, HT-29(V) and HT-29(TP) cells with Leucovorin (LCV) 
to expand intracellular pools of reduced folates and increase 5-FU cytotoxicity was 
evaluated. Cells were treated with LCV (lOpM) for 24 hours followed by immediate 5- 
FU treatment for 24 hours or a 6-hour delay before 5-FU treatment.
Pre-treatment with LCV followed by 5-FU treatment did not result in a 
statistically significant difference in 5-FU IC50 (p>0.1, Students’ t-test) in HT-29 cells 
and HT-29(TP) cells compared to 5-FU alone. Similarly, when a 6 hour delay was 
included for folate polyglutamation, there was no significant difference in 5-FU IC50 
(p>0.1, Students’ t-test) compared with 5-FU alone. There was a statistically significant 
decrease (1.4-fold) in 5-FU cytotoxicity in HT-29(V) cells when LCV was administered 
prior to 5-FU without a delay compared with 5-FU alone (p<0.01, Students t-test). This 
was not significant when a 6 hour delay was included (p>0.1, Students t-test).
Cell Line 5-FU IC50 (fiM)
5-FU Alone 5-FU + Leucovorin 
(No delay)
5-FU + Leucovorin 
(6 hour delay)
HT-29 12.2±1.2 12.110.9 14.812.8
HT-29 (V) 19.1±1.8 13.9±0.9 18.6±1.4
HT-29 (TP) 15.8H.9 14.4+2.7 18.317.5
Table 6.4 Effect of Leucovorin pre-treatment on 5-FU cytotoxicity in HT-29, HT- 
29(V) and HT-29(TP). Growth inhibition was evaluated using the MTT Assay. Cells 
were seeded in 96-well plates and treated with Leucovorin (LCV) for 24 hours. 
Following LCV pre-treatment cells were either treated with increasing concentrations of 
5-FU immediately or incubated in drug free medium for 6 hours prior to treatment 5-FU. 
Within each 96-well plate, one half was treated with 5-FU alone, no LCV pre-treatment, 
as a control. ICso's are means and standard errors of three 96-well plates, four wells per 
plate for each 5-FU concentration.
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6.3.4 Thymidine
5-FU cytotoxicity was evaluated in HT-29, HT-29(V) and HT-29(TP) cells in the 
presence of exogenous thymidine (10 or lOOpM). There was no increase in 5-FU IC50 in 
HT-29 and HT-29(TP) cells when treated with thymidine (10 or lOOpM) compared with 
5-FU alone. In particular, there was no statistically significant difference in 5-FU IC50 
when HT-29(TP) cells were treated with 5-FU and thymidine (10 or 100p,M) compared 
with 5-FU alone (p>0.1, Students’ t-test). There was a significant increase (1.4-fold) in 
5-FU IC50 in HT-29(V) cells treated with lOpM thymidine (p<0.05, Students’ t-test) but 
this was not significant following lOOpM thymidine (p>0.1, Students’ t-test). Dose 
response curves are illustrated in Figure 6.5 and associated IC50 values are shown in
Table 6.5.
Cell Line 5-FU IC50 (fiM)
5-FU Alone Thymidine Thymidine
(no thymidine) (lOpM) (lOOpM)
HT-29 7.2±0.1 5.711.0 5.611.1
n=3 n=3 n=3
HT-29(V) 7.8±0.2 11.3±2.7 10.6±4.9
n=3 n=3 n=3
HT-29 (TP) 8.8±0.6 8.011.7 8.810.9
n=3 n=3 n=3
Table 6.5 Effect of thymidine on 5-FU cytotoxicity in HT-29, HT-29(V) and HT- 
29(TP) cells. HT-29 parental cells, HT-29 transfected with TP, HT-29(TP)and HT-29 
transfected with the vector alone were treated with increasing concentrations of 5-FU 
and either 10 or 100p,M thymidine simultaneously for 24 hours. One half of each plate 
was treated with 5-FU alone as a control. Growth inhibition was measured using the 
MTT assay and ICso's are means and standard errors of 3 96-well plates with 4 wells per 
plate.
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6.3.5 5-FU and Thymidine Post-treatment
HT-29, HT-29(V) and HT-29(TP) cells were treated with increasing 
concentrations of 5-FU for 24 hours followed by thymidine (10 or lOOpM) in the 
recovery period. There was no statistically significant difference in 5-FU cytotoxicity 
when HT-29(TP) cells were treated with thymidine following 5-FU treatment (p>0.1, 
Students’ t-test). There is however, a statistically significant increase in 5-FU IC50 in 
HT-29 (1.3-fold) and HT-29(V) cells (2-fold) following lOOpM thymidine post­
treatment compared with 5-FU alone (p<0.01 and p<0.002 respectively, Students’ t- 
test).
Cell Line 5-FU IC50 (fiM)
5-FU Alone
Thymidine
(lOpM)
Thymidine
(lOOpM)
HT-29 5.2±0.5 5.3±0.4 6.7±0.3
HT-29 (V) 7.5±1.2 11.9±5.9 15.3±2.2
HT-29(TP) 5.4±0.5 6.4±0.9 6.1±0.7
Table 6 . 6  Effect of thymidine post-treatment on 5-FU cytotoxicity in HT-29, HT- 
29(V) and HT-29(TP) cells. HT-29 parental cells, HT-29 transfected with TP, HT- 
29(TP)and HT-29 transfected with the vector alone were treated with increasing 
concentrations of 5-FU for 24 hours followed by either 10 or lOOpM thymidine for 72 
hours. On one half of each plate was treated with 5-FU alone as a control. Growth 
inhibition was measured using the MTT assay and ICso's are means and standard errors 
of 3 96-well plates with 4 wells per plate.
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6.4 Discussion
The anabolism of 5-FU to 5-FdUrd and 5-FdUMP and subsequent inhibition of 
TS is influenced by a number of variables. In the present study, an increase in 
expression of the first anabolic enzyme in this pathway, TP, did not increase TS 
inhibition although overall cytotoxicity was increased 1.6-fold in cells transfected with 
TP compared with vector alone controls. Therefore the response of the cells to the 
addition or removal of potentially rate-limiting factors was explored.
Firstly, levels of pyrimidines in the culture medium during cytotoxicity 
experiments do not appear to compete with 5-FU for TP, since on removal no increase 
in cytotoxicity between HT-29, HT-29(V) and HT-29(TP) was observed. Indeed, 
removal of pyrimidines from the cell culture medium during cytotoxicity assays results 
in increased resistance to 5-FU. This may be due to a slowing down of the growth rate 
of the cells as a result of a reduction in nutrients in the culture medium required for 
optimal growth. In retrospect, it would have been better to maintain the cells in dialysed 
serum for 3-4 weeks prior to the cytotoxicity experiments to allow them to become 
accustomed to the change in growth conditions.
Likewise 2'-deoxyinosine (150 and 300[xM) did not enhance 5-FU cytotoxicity in 
HT-29, HT-29(V)or HT-29(TP) cells, indicative that dR-l-P levels are not rate-limiting. 
Interestingly, 2'-deoxyinosine did also increase the resistance of the HT-29(TP) cells to 
5-FU. An explanation for this may be that increased TP and dR-l-P cause an increase in 
the levels of dUrd which, upon further anabolism to dUMP result in competition with 5- 
FdUMP for TS and instability of the ternary complex.
The levels of reduced folates required for stabilisation and retention of the 
ternary complex between 5-FdUMP and TS were also explored. HT-29, HT-29(V) and 
HT-29(TP) cells were pre-treated with LCV (lOpM) in order to expand the intracellular
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concentrations of the reduced folates. 24-hour pre-treatment of cells with LCV did not 
result in greater 5-FU cytotoxicity in HT-29 or HT-29(TP) cells. In addition, when 
further polyglutamation of reduced folates was permitted by a 6-hour interval between 
LCV and 5-FU treatments, 5-FU cytotoxicity remained unaltered. There was a 1.4 fold 
decrease in 5-FU cytotoxicity with LCV treatment compared with 5-FU alone in HT- 
29(V) cells suggesting a minor role for TS inhibition in these cells. This difference is 
not significant when a 6 hour interval is introduced between treatments however. 
Therefore, it would appear that sub-optimal concentrations of reduced folates are not 
limiting TS inhibition and subsequent toxicity in these cell lines. Another possible 
explanation is, however, that the cells were unable to transport LCV intracellularly. Low 
affinity, high capacity folate transport has been demonstrated in Methotrexate-resistant 
cells (Boarman, 1992). Alternatively, the ability of folylpolyglutamate synthetase to 
convert reduced folates to the more potent polyglutamated state may be impaired 
(Romanini, 1991). These factors were not assessed in the current study therefore no firm 
conclusions about the role of these systems in the cytotoxicity of 5-FU in HT-29 cells 
could be made.
If 5-FU toxicity in HT-29 cells results from TS inhibition and dTTP depletion,
then exogenous thymidine should reverse these effects. Examples of complete
protection from 5-FU cytotoxicity by thymidine have been reported (Madoc-Jones, 1968
and Murgo, 1980). In the present study thymidine (10 and lOOpM) was administered
concurrently or following 5-FU treatment. No change in cytotoxicity was observed in
HT-29(TP) cells treated with thymidine and 5-FU compared with 5-FU alone.
Thymidine (lOOpM) post-treatment did however increase 5-FU IC50 values in HT-29
and HT-29(V) cells (1.3-fold and 2-fold respectively) suggesting a minor role for TS
inhibition in these cells. Previous studies demonstrated inhibition of TS in HT-29 cells
by Western immunoblotting (Figures 4.7 and 4.8). The lack of effect in HT-29(TP) cells
140
would indicate that increased TP activity in HT-29(TP) cells may be reversing the 
capacity of thymidine to rescue cells from 5-FU by the phosphorolytic cleavage of 
thymidine to thymine rendering it unavailable to bypass TS inhibition. These results 
indicate that TS inhibition is not, however, the principle mechanism of action of 5-FU in 
these cells and that formation of 5-FdUMP may not be critical.
These data together suggest that, although increased TP expression enhances the 
cytotoxicity of 5-FU 1.6-fold in HT-29(TP) cells compared with HT-29(V), the 
cytotoxicity of 5-FU cannot be further enhanced by the addition of LCV or 
deoxyinosine. In addition, TS inhibition does not appear to be the principle mechanism 
of 5-FU cytotoxicity in HT-29 parental and transfected cells although a minor role was 
apparent. Further experiments would be required to determine whether RNA or DNA 
toxicity or both contribute to 5-FU growth inhibition in these cells.
It is worth noting that, as with the dialysed serum experiments, different results 
may have been obtained in these studies if the cells had been maintained in dialysed 
serum for 3-4 weeks prior to the cytotoxicity experiments. The true effect of exogenous 
leucovorin on 5-FU cytotoxicity may have been masked by the presence of folates in 
normal serum containing medium and exogenous thymidine may have reversed 5-FU 
cytotoxicity.
Cytotoxicity studies in vitro are currently underway in the Department of 
Medical Oncology at the University of Glasgow. Preliminary data has indicated that HT- 
29(TP) cells are more sensitive to 5’-dFUrd than HT-29(V) and HT-29 (ICso’s: 50.82± 
l.llp M ; 93.77±2.21pM; 71.5±13.9pM respectively, data unpublished). Interestingly, 
HT-29(V) cells are more resistant to 5’dFUrd than the parental cells as seen in the 
present study. In addition, xenograft studies in mice will be conducted to assess the 
impact of increased TP on 5-FU and it’s prodrugs in vivo.
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CHAPTER 7
7. General Discussion
7.1.1.1 Modulation o f 5-FU
Despite being the most commonly used anti-cancer agent for the treatment of 
advanced colorectal carcinoma, 5-FU has only modest anticancer effects. In 
combination with biochemical modulators however, such as LCV, the efficacy of 5-FU 
is markedly enhanced both in vitro and clinically (Machover, 1986 and Poon, 1991). 
Nevertheless, no overall improved survival rate has been demonstrated.
Early in vitro studies in mouse and human cell lines demonstrated that the 
uptake of 5-FU through the plasma membrane is not rate-limiting in it’s cytotoxic action 
(Laskin, 1979). Rather, the intracellular metabolism of 5-FU is responsible for the 
varied sensitivities of the cell lines to 5-FU. In particular, the activities of the activating 
enzymes TP, UP and ORTPase were consistently higher in the more sensitive cell lines. 
Similarly, a human ovarian cell line resistant to 5-FU (PE04) had reduced TP activity 
compared with cells derived from the same tumour prior to the onset of resistance (Chu, 
1990). In addition, drug-induced resistance to 5-FU is associated with lower activities of 
both activating enzymes TP and UP, in L I210 leukemia and Ehrlich ascites carcinoma 
cells (Reichard, 1959).
Recombinant human interferons synergistically enhance the cytotoxic effects of 
5-FU in vitro, however clinical trials in patients with colorectal cancer have been 
contradictory and in some cases IFN-a treatment has resulted in greater toxicity and 
sometimes death compared with 5-FU alone (Corfu-A Study Group, 1995). Studies in 
vitro demonstrated that IFN-a caused an increase in the activity of the 5-FU anabolic 
enzyme TP and increased levels of the cytotoxic nucleotide 5-FdUMP which inhibits TS 
(Schwartz, 1992).
142
Aims
The aims of this thesis, which were set out at the beginning of the project, have 
largely been achieved. The aims were as follows:
1. To characterise a panel of colon adenocarcinoma cell lines with respect to growth 
kinetics, TP and TS protein expression and intrinsic sensitivity to 5-FU.
2. To evaluate TP protein expression in human colon tumour and normal biopsy tissues.
3. To transfect human colon carcinomas cells in vitro with the gene for TP and assess 
its contribution alone to 5-FU toxicity.
4. To develop a method for the measurement of TP enzyme activity in cell lines and 
tissues.
The results of this thesis have contributed towards a greater understanding of the 
role of TP in colon adenocarcinoma cell lines and biopsy tissues and also towards the 
future application of a gene-directed approach to it's treatment.
Colon Adenocarcinoma Cell Lines
Five colon adenocarcinoma cell lines (HT-29, BE, CACO-2, DLD-1 and LOVO) 
were evaluated for TP protein expression by Western immunoblotting and enzyme 
activity was measured using the assay described in Chapter 5. TP protein was detected 
in the LOVO cell line only. Similar results were obtained when TP activity was 
measured in these cell lines. TP activity was measurable in all the colon cell lines. HT- 
29, BE, CACO-2 and DLD-1 cells had similar low activity (2-2.4 pmoles/min/mg) and 
LOVO cells had the highest activity (25.0 pmoles/min/mg).
The sensitivity of the colon cell lines to 5-FU was measured using the MTT and 
clonogenic assays and a 3.3 and 4.1-fold range in 5-FU IC50 was demonstrated 
respectively. The two assays were found to correlate (r=0.88) and the MTT assay alone 
was used in all subsequent cytotoxicity experiments.
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TP activity and protein expression did not appear to correlate with 5-FU 
cytotoxicity. LOVO cells with the highest TP activity and expression were not the most 
sensitive cell line to 5-FU whereas HT-29 and CACO-2 cells with low TP activity and 
no measured TP protein were the most sensitive. This was confirmed when TP activity 
and 5-FU sensitivity was evaluated in a number of cell lines from other tumour sources. 
TP activity alone did not determine the sensitivity of cell lines to 5-FU (r=0.28).
TS protein was detected in all 5 colon cell lines with a 5.9-fold range in 
expression. The sensitivity of the cell lines to 5-FU correlated with TS expression 
(r=0.87) confirming a role for this enzyme as a target for 5-FU in cell lines. These 
findings are consistent with other reports where TS levels were higher in 5-FU 
insensitive than sensitive colon and breast cell lines (Johnston, 1992) and in 5 human 
gastrointestinal tumour cell lines where TS activity directly correlated with 5-FdUrd 
cytotoxicity (Washtein, 1981). In addition, the role of TS in vitro translates to the clinic 
where colorectal and gastric tumours with a low mean TS protein level demonstrate an 
improved response to treatment with 5-FU/LV-based treatment than those with a high 
mean TS level (Johnston, 1995).
Colon Biopsy Tissues
TP expression and activity were also assessed in colon tumours and adjacent 
non-neoplastic regions to assess the relative levels of TP and to determine the relevance 
of the colon cell lines as a model for human tumours. TP protein expression was 
elevated in colon tumour tissues compared with their normal colon counterparts as was 
TP enzyme activity. This agrees with current literature where TP expression is elevated 
in tumours of the stomach, colon, ovary and breast compared to normal regions of the 
same tissue (Zimmerman, 1964; Yoshimura, 1990; Luccioni, 1994; Pauly, 1977 and 
Fox, 1997).
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Interestingly, TP levels were higher in tissue samples than cell lines, suggesting 
down regulation of activity in vitro possibly as a result of a decreased requirement for 
the angiogenic activity of TP in cells in culture. Another explanation may be that the 
tumour biopsy samples comprised stroma and inflammatory infiltrate as well as tumour 
cells and that inflammatory cells such as macrophages have high TP activity (Fox, 
1996).
TP protein expression/activity was heterogeneous in tumours as demonstrated by 
a 6-fold range in expression and a 4-fold range in activity. Heterogeneity of 
expression/activity of TP in tumours may explain why only a proportion of patients 
respond to treatment with 5-FU. As a result, increased expression of TP in tumours 
through the delivery of the TP gene sequence may overcome this lack of sensitivity. 
This theory was investigated first in vitro using DNA transfection studies in colon cell 
lines.
TP expression correlates with metastasis in colon and gastric cancers 
(Takebayashi and Maeda, 1996), with angiogenesis in breast and NSCLC (Toi, 1995, 
Moghadam, 1995 and Koukourakis, 1997) with poorer survival in gastric cancer 
(Maeda, 1996), poorer prognosis in colon, gastric and NSCLC (Takebayashi, 1995, 
Maeda, 1996 and Koukourakis, 1997) and malignancy in bladder and colon cancer. 
Increased TP expression in tumours therefore confers a more aggressive phenotype. This 
suggests that a transient expression vector rather than a stable expression vector should 
be used clinically to elevate TP levels, prior to treatment with 5-FU, to lower the risk of 
promoting tumour growth.
TP Transfection Studies in HT-29 cells
HT-29 cells with no detectable TP protein and low TP activity, were transfected 
with TP cDNA and a vector alone control. TP protein was detected in HT-29(TP) cells. 
TP activity was 5-fold greater in HT-29(TP) cells than both HT-29 and HT-29(V) cells.
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There was no change in the growth kinetics of the transfected cells and basal levels of 
TS expression were also unchanged.
Evaluation of the transfected cells with respect to their sensitivity to 5-FU, 
demonstrated that HT-29(TP) cells were more sensitive to 5-FU than the HT-29(V) cells 
(1.6-fold reduction in 5-FU IC50) however there was no difference in sensitivity when 
compared with the parental cells. Therefore, the vector alone controls were more 
resistant to 5-FU than the parental cells, despite having similar basal levels of TS 
enzyme and unchanged growth kinetics. This suggests that transfection alone (without 
the TP cDNA) may have caused genetic alterations in the cells resulting in increased 
resistance to 5-FU. Transfection with the TP cDNA included in the DNA vector may 
have sensitised the cells, returning them to a similar level to that of the parental cells.
In addition to assessing growth inhibition by the MTT assay in the transfected 
cells, the levels of TS ternary complex formed were assessed following treatment of 
cells with 5-FU at IC10 (lOpM) and IC50 (50pM) concentrations for 1 and 24 hours. 
There was no apparent change in the ratio of bound to free TS enzyme in HT-29(TP) 
compared with HT-29(V) cells and the parental cells. This experiment was carried out 
only once and therefore no firm conclusions could be drawn concerning differences 
between cell lines. With both 5 and lOpM treatment however, a similar pattern did 
emerge after 1 and 24 hours. If TS inhibition is the principle mechanism of cytotoxicity 
of 5-FU in these cells then a small increase in cytotoxicity (1.6-fold) might not be 
identifiable using this assay at the time points and drug concentrations used in this 
experiment. Further studies with a wider time course and a range of 5-FU concentrations 
may provide further information regarding the extent of TS inhibition.
Following treatment with 5-FU, total TS expression was 2-3 fold higher in HT- 
29(V) than the parental cells. The apparent greater induction of TS may play a role in
the increased resistance to 5-FU compared with the parental cells.
146
TS inhibition remained unchanged despite an elevation in total TS levels at 24 
hours in HT-29(V) and HT-29(TP) cells. This would suggest that adequate intracellular 
concentrations of 5-FdUMP and reduced folates are present to inhibit TS in the 
transfected cells. This was confirmed when exogenous LCV (lOpM) did not enhance the 
cytotoxicity of 5-FU in HT-29, HT-29(V) and HT-29(TP) cells. In the same way, an 
increase in the levels of cofactor for TP by the addition of 2'deoxyinosine did not 
enhance cytotoxicity suggesting that dR-l-P levels are not limiting the activity of TP 
and hence the cytotoxicity of 5-FU.
In the present study, thymidine was administered to cells concurrently with 5-FU 
or post-5-FU treatment. Only a small change in 5-FU cytotoxicity was observed (1.3-2- 
fold) in HT-29 and HT-29(V) cells suggesting a minor role for TS inhibition in the 
overall cytotoxicity of 5-FU. There was no change however, in the cytotoxicity of 5-FU 
in HT-29(TP) cells following thymidine treatment. This suggests that the phosphorolytic 
activity of TP is reducing the availability of thymidine necessary to reverse TS 
inhibition or compete with 5-FdUrd for incorporation into DNA.
It may be more appropriate to maintain the cells in dialysed serum-containing 
medium prior to cytotoxicity experiments with modulators such as Leucovorin and 
thymidine since the presence of folates and pyrimidines in the medium may mask the 
effects of these agents on 5-FU cytotoxicity.
TS inhibition leads to depletion of thymidylate (dTMP), a precursor of one of the 
4 deoxyribonucleotides (dTTP) necessary for DNA synthesis. As a result of dTTP 
depletion, FdUTP and dUTP become incorporated into DNA in its place (Yin, 1991, 
Lonn, 1988). Enzymes such as dUTPase and uracil-DNA glycosylase are responsible for 
excising these nucleotides from DNA (Ingraham, 1980 and Mauro, 1993) and resistance 
has been shown to be attributable to increased activities of these enzymes and a 
significant decrease in the level of 5-FU metabolites in DNA (Chu, 1990). The intrinsic
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activity of these enzymes was not evaluated in the present study and may explain the 
lack of effect of increased TP on 5-FU cytotoxicity seen in HT-29(TP) cells.
The activity of TK, the enzyme responsible for the conversion of 5FdUrd to 5- 
FdUMP was not measured in the present study. Therefore a possible explanation for the 
lack of effect of increased TP levels on 5-FU cytotoxicity could be that there is 
insufficient TK enzyme to deal with the increased formation of 5FdUrd. TK activity 
could be measured using the activity assay outlined in Chapter 5. This would involve 
using FdUrd as the substrate and ATP as the cofactor in place of 5-FU and dR-l-P. The 
formation of FdUMP could be detected by HPLC. This would provide further 
information relating to the anabolic pathway which leads to inhibition of TS by FdUMP.
The in vitro data for HT-29 cells are not necessarily representative of the in vivo 
situation however. In HT-29(TP) cells, TS inhibition is not critical for 5-FU 
cytotoxicity. TS protein and mRNA expression do however, predict for response to 5- 
FU/LCV-based chemotherapy in patients with colorectal and gastric cancer (Johnston, 
1995). In addition, resistance to 5-FU-based therapy can be a result of acute induction of 
TS protein as well as stable amplification of TS-specific genes (Washtein, 1984, Berger, 
1987, Clark, 1987 and Johnston, 1992).
Following commencement of the present study, Schwartz carried out similar 
transfections in HT-29 cells using the pCMV-TP-Neo vector (Schwartz, 1995). A number 
of clones with a range of TP activities were reported (1.8-5.4 fold greater than parental 
cells) which possessed greater sensitivity to 5-FU than the parental cells and a more 
significant effect on 5-FU cytotoxicity was demonstrated than in the present study. The 
clone with 5-fold greater TP activity resulted in a 19-fold reduction in 5-FU IC50 .
Comparison of both studies revealed that different drug exposure times and 
methods for assessing 5-FU cytotoxicity were used. However, it would be expected that
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a similar relative difference between transfected and control cells would be obtained 
despite the differences in methodology.
One possible explanation for the difference in results obtained could be however 
that the transfected cells in the present study were pooled rather than cloned. Pooled 
transfectants should more closely reflect the heterogeneity of TP in tumours. The 
resultant heterogeneity of expression of TP may be masking any increase in 5-FU 
cytotoxicity in these cells. This was investigated by immunohistochemical analysis of 
paraffin-embedded cell pellets with the TP antibody (data not shown). LOVO cells were 
used as a positive control since they have approximately 3-fold greater TP activity than 
HT-29(TP) cells and 12-fold greater activity than the parental cells. The intensity of 
staining in LOVO cells however was very low and there was no visible difference 
between LOVO and HT-29 or HT-29(TP) cells. It was impossible to evaluate 
heterogeneity of expression using this method.
A number of other studies have investigated the effects of increased TP 
expression by DNA transfection. Many have been unable to repeat the work of Schwartz 
and colleagues. MCF-7 breast carcinoma cells with 100-fold greater TP activity 
following DNA transfection showed no difference in their sensitivity to 5-FU than the 
parental cells (Patterson, 1995). This level of TP activity may not have enhanced 5-FU 
cytotoxicity since the mechanism of action of 5-FU in these cells has been shown to be 
incorporation into RNA (Kufe and Major, 1981). Haraguchi et al (1993) transfected KB 
epidermoid cells with TP and demonstrated unaltered sensitivity to 5-FU. A recent study 
where lung carcinoma cells were transfected with TP resulted in a clone with 50-fold 
greater TP activity and 5-FU IC50 was decreased 8-fold (Kato, 1997).
Another study looking at the effects of IFN-a on a panel of colon
adenocarcinomas (including HT-29), reported that IFN-a increased the activity of TP in
6 out of 8 cell lines, HT-29 cells being one of them (Tevaearai, 1992). An enhancement
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of 5-FU cytotoxicity was observed in only one of the 6 cell lines where increased TP 
activity was observed. There was no increase in the sensitivity of HT-29 cells to 5-FU.
In some of the above studies thymidine mediated reversal of 5-FU cytotoxicity 
was evaluated. In many cases, where a difference in 5-FU cytotoxicity was observed, 
thymidine reversed cytotoxicity implicating TS inhibition as the principle mechanism of 
5-FU cytotoxicity (in the others this was not assessed). The data therefore varies from 
one cell line to another, both with IFN-a treatment and DNA transfection as methods of 
increasing TP activity. This emphasises that different cell lines utilise different pathways 
of 5-FU effect and that the results reported by Schwartz and colleagues do not represent 
a trend observed in all colon cancer cell lines. Therefore, in many of the in vitro studies 
TP activity was not critical for the cytotoxicity of 5-FU. This was further demonstrated 
in the present study where no correlation could be made between TP activity and 5-FU 
IC50 in a range of tumour cell lines. TP activity was heterogeneous within each tumour 
type. Two groups of cell lines emerged with high and low TP activity. Within each 
group 5-FU cytotoxicity was heterogeneous.
The IFN-a studies carried out by Schwartz were conclusive however, in that 
IFN-a caused an induction of TP, increased levels of 5-FdUMP, with no difference in 
incorporation of 5-FU into DNA and RNA and no difference in UP activity (Schwartz,
1992). Tevaearai and colleagues could not repeat these results in HT-29 cells and this 
apparent discrepancy may be answered by examining the time course of IFN-a induced 
changes in TP activity (Tevaearai, 1992) or may suggest that TP is not critical in the 
HT-29 cells used in this study.
It would appear that cells in which 5-FU utilises this pathway of effect (5-FU to
5-FdUMP via 5FdUrd) will respond to treatment with IFN-a or DNA transfection with
the TP gene and those cell lines in which other mechanisms and pathways predominate,
an increase in TP activity (even 100-fold) will have no impact. This could be confirmed
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by first screening cell lines with thymidine to demonstrate reversal of TS inhibition and 
the importance of this pathway in the activation of 5-FU to 5-FdUMP. Following this, 
transfection studies with pCMV-TP-Neo could be conducted to evaluate whether an 
increase in TP activity would further enhance the TS inhibition already known to be 
critical.
RNA Toxicity
As was discussed in the Introduction, two other known targets of 5-FU exist, 
namely RNA and DNA. FUTP competes with UTP for RNA polymerase. Incorporation 
of FUTP leads to RNA dysfunction. Incorporation of 5-FU in RNA has been 
demonstrated in HT-29 (Greenhalgh, 1990). Pre-treatment with thymidine (0.5mM) 
resulted in an increase in 5-FU cytotoxicity (Greenhalgh, 1990). It is thought that 
thymidine does so by causing an accumulation of thymidine triphosphate (dTTP) which 
then results in feedback inhibition of ribonucleotide reductase. The high levels of dTTP 
are also believed to repress the anabolic conversion of 5-FU into deoxy-derivatives thus 
preserving it for entry into RNA (Speigelman, 1980). It was evident however that 
thymidine did not enhance 5-FU cytotoxicity by increasing incorporation into RNA in 
HT-29, HT-29(V) and HT-29(TP) cells. Pre-treatment with thymidine was not evaluated 
however and may have revealed a role for RNA-directed cytotoxicity.
DNA toxicity
The deoxynucleotides FdUTP/dUTP compete with dTTP for DNA polymerase. 
Incorporation of FdUTP into DNA results in inhibition of chain elongation and altered 
DNA stability causing DNA single- and double-strand breaks as a result of attempts to 
excise fraudulent nucleotides and repair the DNA. Under normal circumstances dUTP 
levels are virtually undetectable since dUTPase efficiently hydrolyses dUTP to dUMP 
thereby making uracil misincorporation into DNA an unlikely event (Brynoff, 1978 and 
Grafstrom, 1978). Following inhibition of TS and subsequent dTTP depletion the ratio
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of dUTP/dTTP is increased, more uracil may become incorporated into DNA generating 
areas of continuous DNA excision/repair and strand breaks (Goulian 1986).
FdUrd treatment of HT-29 cells resulted in DNA damage in the form of single 
and double strand breaks (Canman, 1993). Sensitivity to 5FdUrd was related to the level 
of DNA damage. The appearance of single strand breaks preceded that of double-strand 
breaks consistent with the 5-FU misincorporation/misrepair mechanism which is 
expected to yield a larger number of single strand breaks prior to the formation of 
double strand breaks.
The role of these mechanisms of 5-FU cytotoxicity was not evaluated in the 
present study. It is therefore feasible that 5-FU utilises either of these pathways as it's 
mechanism of cytotoxicity in HT-29 cells.
Downstream Events
Despite numerous attempts to modulate the activity of 5-FU and other anti­
cancer agents, few studies have addressed the genetic factors, which may control 
resistance to DNA damaging agents. The p53 gene product, known as "the guardian of 
the genome" (Lane, 1992) plays a vital role in the nature of cellular response to DNA 
damage. Following exposure of cells to DNA damaging agents such as 5-FU, expression 
of and stability of p53 is induced and either arrest in the Gi phase of the cell cycle 
(allowing repair of DNA damage to occur) or programmed cell death/apoptosis occurs. 
Normal p53 function can become disrupted by mutation of the gene causing cells to 
continue proliferating despite DNA damage and leading to further genetic instability. 
Apoptosis is also regulated by other genes e.g. bcl-2 and bax. bcl-2 is a repressor of 
programmed cell death and bax homodimerises or heterodimerises with bcl-2 and 
counters the death repressor activity of bcl-2 (Oltvai, 1993). The ratio of Bcl-2 to bax is 
thought to determine the susceptibility to death following an apoptotic stimulus. When
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bcl-2 is in excess, cells are protected however, when bax is in excess the bax 
homodimers dominate and cells are susceptible to apoptosis.
Inada and colleagues reported that apoptosis of gastric and colon tumour 
xenografts was related to 5-FU cytotoxicity (Inada, 1997). Following treatment with 5- 
FU, TS inhibition was followed by an accumulation of cells in S-phase (due to 
inhibition of DNA synthesis) and this was followed by apoptotic death (Inada, 1997). 
HT-29 cells have a mutated p53 gene which may explain in part the resistance of these 
cells to 5-FU. Mutant p53 results in a continuation of cell proliferation following DNA 
damage and resistance to 5-FU.
The concept that increased expression of a single enzyme involved in the 
anabolism of 5-FU would sensitise HT-29 cells to 5-FU may appear in retrospect to be a 
naive one. Studies in patients with colorectal tumours have confirmed that TP 
expression alone does not confer increased sensitivity to 5-FU (Metzger, 1998). The 
cytotoxicity of 5-FU is dependent on many factors e.g. the levels of anabolic enzymes, 
the levels of co-factors and co-substrates for these enzymes (e.g. dR-l-P, RIP or 5,10- 
CH2THF), mutations occurring in genes encoding target enzymes resulting in reduced 
affinity of the associated substrate, levels of DNA and RNA repair enzymes, not to 
mention the multiple routes of anabolism and subsequent sites of action which differ 
from one tumour to another.
Despite disappointing results with respect to the cytotoxicity of 5-FU, a greater 
effect may be seen with 5-FU pro-drugs such as 5’-dFUrd and Tegafur which require 
activation by TP. Preliminary cytoxicity experiments have indicated an increase in 
sensitivity of HT-29(TP) cells to 5’-dFUrd and this will be further investigated using 
xenograft studies. The application of a TP as a candidate gene for gene- 
directed/fluoropyrimidine pro-drug therapy is therefore promising as a means of
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improving the current lack of effective treatment for colon cancer and requires further 
investigation.
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